

METHODS, KITS AND APPARATUS FOR EXPANDING A POPULATION OF CELLS

CROSS-REFERENCE TO RELATED APPLICATIONS

5

[0001] The present invention claims the benefit of priority to US provisional patent application 61/980,506 “Methods, Kits And Apparatus For Expanding A Population Of Cells ” filed with the US Patent and Trademark Office on 16 April 2014, the contents of which is hereby incorporated by reference in its entirety for all purposes.

10

FIELD OF THE INVENTION

[0002] The present invention relates to the expansion (proliferation) of a population of cells such as a population of lymphocytes. The invention in general provides novel methods and reagents for the expansion (proliferation) of cell populations that require binding of a receptor binding molecule (such as a first agent as described herein) to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells. The invention employs a multimerization reagent that has immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells. This primary activation signal may as such be sufficient to activate the cells to expand/proliferate. This first agent can either be bound reversibly or also irreversibly to the multimerization reagent. The multimerization reagent may have immobilized thereon (bound thereto) also a second agent that stimulates an accessory molecule on the surface of the cells. The second agent, when binding to the accessory molecule on the surface on the surface of the cells, may thereby stimulate the activated cells to expand. Also this second agent can either be bound reversibly or also irreversibly to the multimerization reagent. The multimerization agent may either be immobilized on a solid support or soluble. In one aspect, the method disclosed herein is a serial expansion of a population of cells in which a complete population of lymphocytes is stimulated/expanded, the reagents necessary for the expansion are then removed by chromatography on a suitable stationary phase and the expanded/stimulated cells are optionally transfected with e.g. a T cell receptor or a chimeric antigen receptor (CAR) and subjected to a second stimulation expansion with a different stimulatory molecule that binds to the introduced T cell receptor or the chimeric antigen receptor. The invention also relates to an apparatus for the expansion of the selected cell population.

BACKGROUND OF THE INVENTION

[0003] The development of techniques for propagating T cell populations *in vitro* has been crucial to many of the advances in the understanding of T cell recognition of antigen and T cell activation. The development of culture methods for the generation of human antigen-specific T cell clones has been useful in defining antigens expressed by pathogens and tumors that are recognized by T cells to establish methods of immunotherapy to treat a variety of human diseases. Antigen-specific T cells can be expanded *in vitro* for use in adoptive cellular immunotherapy or cancer therapy in which infusions of such T cells have been shown to have anti-tumor reactivity in a tumor-bearing host. In addition, adoptive immunotherapy has also been used to treat viral infections in immunocompromised individuals.

[0004] A method of expanding human T cells *in vitro* in the absence of exogenous growth factor and accessory cells that has been established in the recent years is described in US Patent 6,352,694 B1 and European Patent EP 0 700 430 B1. Disclosed in these patents is an *in vitro* method for inducing a population of T cells to proliferate. The method comprises contacting a population of T cells with a solid phase surface having directly immobilized thereon: (a) a first agent which provides a primary activation signal to the T cells, thereby activating the T cells; and (b) a second agent which stimulates an accessory molecule on the surface of the T cells, thereby stimulating the activated T cells. The binding of the first agent and the second agent to the T cells induces the T cells to proliferate/to expand. The preferred first agent described in US Patent 6,352,694 B1 and European Patent EP 0 700 430 B1 is a monoclonal anti-CD3 antibody which binds to the TCR/CD3 (TCR = T Cell Receptor) complex and thereby stimulates the TCR/CD3 complex-associated signal in the T cells. The preferred second agent according to these two patents is a monoclonal anti-CD28 antibody which binds the accessory molecule CD28 that is present on T cells. Binding of this second agent to the CD28 accessory molecule provides the necessary co-stimulus that is necessary for expansion/proliferation of activated T cells. Meanwhile, Dynabeads® CD3/CD28 (Invitrogen) are commercially available for T cell expansion. Dynabeads® CD3/CD28 CTS™ are uniform, 4.5 µm superparamagnetic, sterile, non-pyrogenic polystyrene beads coated with a mixture of affinity purified monoclonal antibodies against the CD3 and CD28 cell surface molecules on human T cells.

[0005] However, such magnetic beads are, for example, difficult to integrate into a method to expand cells under conditions required for clinical trials or therapeutic purposes

since it has to be made sure that these magnetic beads are completely removed before administering the expanded T cells to a patient. Thus, the present invention aims to provide an alternative method for expanding cell populations such as regulatory T cells or central memory T-cells for research, diagnostic and especially therapeutic purposes. Ideally, this new method should also be compatible with integration into an automatized process which can be used for rapid and easy expansion of the desired cells population for therapeutic applications.

[0006] This object is solved by the subject matter of the independent claims, inter alia the methods, kits, arrangements and apparatuses as recited in the independent claims.

SUMMARY OF THE INVENTION

[0007] The present invention provides methods, kits, arrangements, and apparatus for the *in vitro* expansion of a desired cell population, having a receptor molecule on its surface which can provide upon binding of a suitable agent a primary activation signal to the population of cells and thereby activating the population of cells for expansion (proliferation). Thus, the methods of the invention are also used for inducing a population of cells to proliferate.

[0008] According to a first aspect, the invention provides an *in vitro*-method of expanding a population of cells, comprising contacting a sample comprising the population of cells with a multimerization reagent,

wherein the multimerization reagent has reversibly immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells;

wherein the multimerisation reagent comprises at least one binding site Z1 for the reversible binding of the first agent,

wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to the binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1, and

wherein the first agent binds to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells and thereby activating the cells.

[0009] According to a second aspect the invention provides an *in vitro*-method of expanding a population of cells, comprising contacting a sample comprising the population of cells with a multimerization reagent,

wherein the multimerization reagent is in a soluble form and has immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells;

wherein the multimerisation reagent comprises at least one binding site Z1 for the binding of the first agent,

wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of binding to the binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the bond formed between the binding partner C1 and the binding site Z1, and

wherein the first agent binds to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells and thereby activating the cells.

[0010] According to a third aspect the invention provides a reagent kit for expanding a population of cells, the kit comprising

(i) a multimerization reagent,

wherein the multimerisation reagent comprises at least one binding site Z for the reversible binding of a first agent,

(ii) a first agent that binds to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells and thereby activating the cells,

wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to a binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1, and

(iii) a second agent that stimulates an accessory molecule on the surface of the cells,

wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is able of reversibly binding to a binding site Z2 of the multimerization reagent, wherein the second agent is bound to the multimerization reagent via the bond formed between the binding partner C2 and the binding site Z2,

wherein the second agent binds to the accessory molecule on the surface on the surface of the cells, thereby stimulating the activated cells.

[0011] According to a fourth aspect the invention provides a reagent kit for expanding a population of cells, the kit comprising

(i) a multimerization reagent,

wherein the multimerisation reagent is in soluble form and comprises at least one binding site Z for the reversible binding of a first agent,

(ii) a first agent that binds to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells and thereby activating the cells,

wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of binding to a binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1.

[0012] According to a fifth aspect the invention provides an *in vitro*-method of serially expanding a population of lymphocytes, wherein the population of lymphocytes comprises T cells, the method comprising

contacting a sample comprising the T cell comprising population of lymphocytes with a multimerization reagent,

wherein the multimerization reagent is in a soluble form and has reversibly immobilized thereon (i) a first agent that provides a primary activation signal to the T cells and (ii) a second agent which stimulates an accessory molecule on the surface of the T cells,

wherein the multimerisation reagent comprises at least one binding site Z1 for the reversible binding of the first agent,

wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to the binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1,

wherein the multimerisation reagent comprises at least one binding site Z2 for the reversible binding of the second agent,

wherein the second agent comprises at least one binding partner C2, wherein the binding partner C2 is able of reversibly binding to the binding site Z2 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C2 and the binding site Z2,

wherein the first agent binds to a receptor molecule on the surface of the T cells, thereby providing a primary activation signal to the cells and thereby activating the T cells,

wherein the second agent binds to the accessory molecule on the surface of the T cells,

thereby stimulating the activated cells, the first agent and the second agent thereby together inducing the T cells to expand.

[0013] According to a sixth aspect the invention provides an arrangement of a bioreactor and a stationary phase for chromatography,

5 wherein the bioreactor is suitable for the expansion of cells,

 wherein the stationary phase is suitable for cell separation and removal of reagents, the stationary phase being a gel filtration matrix and/or affinity chromatography matrix, wherein the gel filtration and/or affinity chromatography matrix comprises an affinity reagent, wherein the affinity reagent comprises a binding site Z1 specifically binding to a binding partner C1
10 comprised in a first agent and/or the affinity reagent comprises a binding site Z2 specifically binding to a binding partner C2 comprised in a second agent, thereby being suitable of immobilizing on the stationary phase the first agent and/or the second agent, the first binding partner C1 and/or the free second binding partner C2,

 wherein the bioreactor and the stationary phase are fluidly connected.

15 [0014] According to a seventh aspect the invention provides an apparatus for purification and expansion of a population of cells, the apparatus comprising at least one arrangement of a bioreactor and a stationary phase for chromatography according to the sixth aspect.

 [0015] According to an eight aspect, the invention provides a multimerization reagent capable of expanding a population of cells,

20 wherein the multimerisation reagent is in soluble form and comprises at least one binding site Z1 for the reversible binding of a first agent that provides a primary activation signal to the cells,

 wherein the multimerization reagent has reversibly immobilized thereon (bound thereto) said first agent that provides a primary activation signal to the cells;

25 wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to the at least one binding site Z1 of the multimerization reagent,

 wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1,

[0016] According to a ninth aspect, the invention provides a composition capable of expanding a population of cells, the composition comprising

(i) a first multimerization reagent,

wherein the first multimerisation reagent is in soluble form and comprises at least one binding site Z1 for the reversible binding of a first agent that provides a primary activation signal to the cells,

wherein the first multimerization reagent has reversibly immobilized thereon (bound thereto) said first agent that provides a primary activation signal to the cells;

wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to the at least one binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1, and

(ii) a second multimerization reagent,

wherein the second multimerization reagent is in soluble form and comprises at least one binding site Z2 for the reversible binding of a second agent that stimulates an accessory molecule on the surface of the cells,

wherein the multimerization reagent has reversibly immobilized thereon (bound thereto) said second agent that stimulates an accessory molecule on the surface of the cells,

wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is able of binding to the at least one binding site Z2 of the multimerization reagent, wherein the second agent is bound to the multimerization reagent via the bond formed between the binding partner C2 and the binding site Z2.

DESCRIPTION OF THE DRAWINGS

[0017] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings. The figures illustrate embodiments of methods of the invention. Without wishing to

be bound by theory, the figures include conclusions with regard to the underlying expansion mechanism. The conclusions are given for illustrative purposes only and merely serve in allowing a visualization of the expansion method is achievable on a molecular level.

[0018] **Figure 1** depicts an embodiment of an *in vitro*-method of expanding of
5 expanding a population of cells that has a cell surface receptor the binding of which by a first agent can provide an activation signal for the cells to expand.

[0019] As shown in **Fig. 1a** a sample that comprises the population of cells (2) that carry a surface receptor molecule (30) is contacted with a multimerization reagent (4). The population of cells (2) is in mixture with other cell populations (22) that lack the surface
10 receptor molecule (30). The multimerization reagent (4) has reversibly immobilized thereon (bound thereto) a first agent (6) that provides a primary activation signal to the cells. The multimerization reagent (4) comprises at least one binding site Z1 (42) for the reversible binding of the first agent (6) and the first agent (6) comprises at least one binding partner C1 (6a), wherein the binding partner C1 (6a) is able of reversibly binding to the binding site Z1
15 (44) of the multimerization reagent. Thus, for immobilization, the first agent (6) is bound to the multimerization reagent (4) via the reversible bond formed between the binding partner C1 (6a) and the binding site Z1 (42). In the example shown in **Fig. 1** the multimerization reagent (4) has a second binding site Z2 (44) which is not used in this example. The multimerization reagent (4) is itself immobilized on a solid support (10) such as a magnetic bead, a polymeric
20 bead of a surface of a cell culture plate or reactor. The population of cells (2) can, for example be, a lymphocyte cell population such as a population of B cells that can be activated via the CD40 receptor (see, for example, Carpenter et al, *Journal of Translational Medicine* 2009, 7:93 "Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation). In this case, the cell surface
25 molecule (30) is CD40 and the first reagent (6) can be any CD40 binding molecule that provides the desired activation signal, for example, the monoclonal antibody CP-870,893 or an antibody binding fragment thereof such as a monovalent Fab fragment. The binding partner C1 of the first agent (6) may, for example, be any affinity peptide that is fused or conjugated to, for example, the C-terminus of one the two polypeptide chains (heavy or light chain) of the
30 antibody molecule. The binding partner C1 (6a) may, for example, be a streptavidin-binding peptide such as the peptide Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 01), also known as the "Strep-tag®") that is described in US patent 5,506,121, for example, or streptavidin binding peptides having a sequential arrangement of two or more individual binding modules

as described in International Patent Publication WO 02/077018 or US patent 7,981,632. When using a streptavidin binding peptide as binding partner C1, the multimerization reagent (4) be any streptavidin mutein to which the streptavidin peptide (= first binding partner C1 (6a)) reversibly binds via its (biotin) binding sites Z1 (42) schematically shown in Fig. 1. Such a multimerization reagent may be a streptavidin mutein (analog) that comprises the amino acid sequence Val⁴⁴-Thr⁴⁵-Ala⁴⁶-Arg⁴⁷ (SEQ ID NO: 02) at sequence positions 44 to 47 of wild type streptavidin or a streptavidin mutein (analog) that comprises the amino acid sequence Ile⁴⁴-Gly⁴⁵-Ala⁴⁶-Arg⁴⁷ (SEQ ID NO: 03) at sequence positions 44 to 47 of wild type streptavidin, both of which are described in US patent 6,103,493, for example, and are commercially available under the trademark Strep-Tactin®. In the Example of **Fig. 1**, the multimerization reagent (4) might further include multimeric calmodulin or glutathione-S-transferase, both of which form reversible bonds with calmodulin binding peptides or glutathione. Thus, the binding site Z2 (44) can be formed by calmodulin or glutathione-S-transferase. Such a protein conjugate of for example, calmodulin with a streptavidin mutein can be made by standard protein chemistry, for example, by using bifunctional linkers.

[0020] As shown in **Fig. 1b**, after contacting the cell population (2) with the multimerisation reagent (4) and usually incubating the cell population with the multimerization reagent (4), the population of cells (2) forms complexes/is bound to the multimerization agent via the first agent (6). The first agent binds specifically to the cell surface receptor molecule such as CD40 in this Example and provides the activation signal for cell expansion, of for example B cells. The other cell populations (22) contained in the initial sample that lack the specific cell surface molecule (30) do not bind to the multimerization reagent. In this respect, it is noted that the cell population (2) usually has multiple copies of the cell surface molecule (30) on its surface and binding of these multiple copies is typically needed for activation. Thus, the multimerization agent (4) provide typically more than one binding site Z1 so that multiple first agents (6) can be reversibly bound to achieve “multimerization” of the first agent, meaning to present the first agent in a sufficient density to the population of cells (2) (not shown in the scheme of Fig.1). In this respect, it is noted that a multimerization agent as used herein can as such have multiple binding sites Z1, for example, a streptavidin mutein (being a homo-tetramer) in its native state has four such binding sites Z1. It is however also possible that the multimerization reagent is based on a compound that has as such only one binding site Z1 for the reversible binding of a binding partner C1. Such an example is multimeric calmodulin. Calmodulin as such has only one binding site for calmodulin binding peptides. However, calmodulin can be biotinylated and then reacted with streptavidin-

oligomers (see also below), thereby providing a multimerization reagent in which multiple calmodulin molecules are presented in high density on a “scaffold”, thereby providing multimeric calmodulin.

[0021] As shown in **Fig.1c**, after incubation (which is usually carried out over a period of time suitable to achieve expansion of the desired cell population) the binding between the binding partner C1 (6a) of the first agent (6) and the binding site Z1 of the multimerization reagent (4) is disrupted by disrupting the respective reversible bond. The disruption may be achieved by adding a competitor to the incubation/reaction mixture containing the population of cells (2) being bound to the multimerization reagent. For competitive disruption (which can be understood as being a competitive elution) of the reversible bond between the binding partner C1 (6a) of the first agent and the binding site Z1 (22) of the multimerization reagent, the incubation mixture/population of cells can be contacted with a free first binding partner C1 (20) or an analog of said first binding partner C that is capable of disrupting the bond between the first binding partner C1 (6a) and the binding site Z1 (22). In the example of the binding partner C1 being a streptavidin binding peptide that binds to biotin binding site of streptavidin, the first free partner C1 (20) may be the corresponding free streptavidin binding peptide or an analogue that binds competitively. Such an analogue can, for example, be biotin or a biotin derivate such as desthiobiotin.

[0022] As shown in **Fig. 1d**, addition of the first free partner (20) or the analogue thereof results in displacement of the binding partner C1 (6a) from the multimerization reagent (4) and thus, since the binding partner C1 is comprised in the first agent (6), displacement of the first agent (6) from the multimerization reagent (4). This displacement of the first agent (6) in turn results in a dissociation of the first agent (6) from the cell surface receptor (30), in particular if the binding affinity of the bond between the first agent and the cell surface receptor (30) has a dissociation constant (K_d) in the range of 10^{-2} M to 10^{-13} M and is thus also reversible. Due to this dissociation, the stimulation of the cell population (2) is also terminated. Thus, the present invention provides the advantage that the time period of the stimulation or expansion of the cell population can be exactly controlled and thus also the functional status of the cell population can be closely controlled. In this context, it is noted that the binding affinity of antibody molecules towards their antigen, including for example, a cell surface receptor molecule such as CD40 in this Example, is usually in the affinity range of the K_d of 10^{-7} M to 10^{-13} M. Thus, conventional monoclonal antibodies can be used as first agent (and also of course second agent as explained below) in the present invention. In order to avoid any

unwanted avidity effects that lead to a stronger binding, monoclonal antibodies can also be used in form of their monovalent antibody fragments such as Fab-fragments or single chain Fv fragments.

[0023] In addition, due to the dissociation of the first agent from the cell surface molecule (30), the present invention has the added advantage that the stimulated cell population is free of stimulating agents at the end of the stimulation period and that all other reagents used in the method, namely the first agent (6) as well as the free first partner (20) of the binding partner C1 or the analogue thereof can be easily removed from the stimulated cell population (2) via a “removal cartridge” described in International patent application WO 2013/124474 while the multimerization reagent (4) being immobilized on a solid support such as a bioreactor surface or a magnetic bead is being held back. Thus, reverting to the removal of the free agent (6) and the free first partner (20), in accordance with the description of the “removal cartridge” in WO 2013/124474 (see with reference to Fig. 4 thereof, for example), the elution sample obtained in **Fig. 1d** here can be loaded onto the second chromatography column of WO 2013/124474. This chromatography column has a suitable stationary phase that is both an affinity chromatography matrix and, at the same time, can act as gel permeation matrix. This affinity chromatography matrix has an affinity reagent immobilized thereon. The affinity reagent may, in the case of the current Example, for instance, be streptavidin, a streptavidin mutein, avidin, an avidin mutein or a mixture thereof. The first agent (6), the free first partner (20) of the binding partner C1 (which is also called “competition reagent” herein) bind to the affinity reagent, thereby being immobilized on the chromatography matrix. As a result the elution sample containing the isolated and expanded cell population (2) is being depleted of the first agent (6) and the competition reagent (20). The expanded cell population (2), being freed of any reactants, is now in a condition for further use, for example, for diagnostic applications (for example, further FACSTM sorting) or for any cell based therapeutic application.

[0024] **Fig.2** shows a further embodiment of an expansion method of the invention. As shown in **Fig. 2a** a sample comprises a population of cells (2) that carry two specific cell surface molecules (30) and (32). The cell surface molecule (30) is involved in a primary activation signal to the cell population, while the cell surface molecule (32) is an accessory molecule on the cell surface that is involved in providing a stimulus to the cells. The population of cells may, for example, be a T cell population in which the cell surface molecule (30) is a TCR/CD3 complex and the cell surface molecule (32) is the accessory molecule

CD28. Binding of both the TCR/CD3 complex as the primary activation signal and CD28 as co-stimulant are necessary for expansion/proliferation of T cells. The population of T cells (2) is in mixture with other cell populations (22) that lack the surface receptor molecules (30) and (32). Also in this embodiment, the cell population (2) is contacted with a multimerization reagent (4). The multimerization reagent (4) has reversibly immobilized thereon (bound thereto) a first agent (6) that provides a primary activation signal to the cells. In addition, the multimerization agent has reversibly immobilized thereon (bound thereto) a second agent (8) that stimulates CD28 as accessory molecule on the surface of the cells.

[0025] The multimerization reagent (4) comprises at least one binding site Z1 (42) for the reversible binding of the first agent (6) and the first agent (6) comprises at least one binding partner C1 (6a), wherein the binding partner C1 (6a) is able of reversibly binding to the binding site Z1 (44) of the multimerization reagent. Thus, for immobilization, the first agent (6) is bound to the multimerization reagent (4) via the reversible bond formed between the binding partner C1 (6a) and the binding site Z1 (42). In addition, in the Example illustrated in **Fig. 2**, the second agent (8) comprises a binding partner C2 (8a), wherein the binding partner C2 is able of being reversibly bound to a binding site Z2 (44) of the multimerization reagent (4). The second agent (8) is bound to the multimerization reagent (4) via the reversible bond formed between the binding partner C2 (8a) and the binding site Z2 (44). In this Example, the first agent (6) might be a monoclonal anti-CD3-antibody or an antigen binding fragment thereof such as a Fab fragment. The second agent (8) might be a monoclonal anti-CD28 antibody or an antigen binding fragment thereof such as Fab fragment. The first binding partner (6a) might be a streptavidin binding peptide (6a) that is fused or conjugated to the anti-CD3 antibody or the anti-CD3 antibody fragment. The second binding partner (8a) might be calmodulin binding peptide that is also conjugated or fused to the CD28 antibody or the CD28 binding antibody fragment. In this context, it is noted that monoclonal antibodies against, for example, CD3 or CD28 are well-known (see, for example, US Patent 6,352,694 B or European Patent EP 0 700 430 B1 discussed above) and are commercially available from numerous suppliers such as Santa Cruz Biotechnology (Santa Cruz, CA, USA), Life Technologies, (Carlsbad, CA, USA), BD Biosciences (San Jose, CA, USA), Biolegend (San Diego, CA, USA) or Miltenyi Biotec (Bergisch Gladbach, Germany) to name only a few. Accordingly, such monoclonal antibodies can be used as first and second agent and can, for example, be chemically coupled (conjugated) with a binding partner C1 or C2. Alternatively, it is also possible to either clone the genes of the variable domains from the hydridoma cell line or use

an antibody of which the amino acid sequence is known and produce a respective antibody fragment such as a Fab fragment or a Fv recombinantly. When using such an approach as described herein in the Example section for both the hybridoma cell line OKT3 (ATCC[®] CRL-8001[™], described in US Patent 4,361,549) that produces a monoclonal anti-CD3 antibody) and the anti-CD28 antibody 28.3 described by Vanhove et al, BLOOD, 15 July 2003, Vol. 102, No. 2, pages 564-570 and GenBank accession number AF451974.1, the binding partners C1 and C2 are conveniently provided by the respective expression vector used for the recombinant production so that the antibody fragment carries the binding partner C1 or C2 as a fusion peptide as the C-terminus of either the light or the heavy chain (In this context, the amino acid sequence of the variable domain of the heavy chain and of the variable domain of the light chain of the antibody OKT3 that are described in Arakawa et al J. Biochem. 120, 657-662 (1996) are shown for illustration purposes as SEQ ID NOS 17 and 18 and in the accompanying Sequence Listings, while the amino acid sequence of the variable domain of the anti-CD28 antibody 28.3 described by Vanhove et al, supra, is shown as SEQ ID NOS 19 (VH) and 20 (VL) in the accompanying Sequence Listings). Also this methodology of cloning the variable domains of an antibody molecule and recombinantly producing a respective antibody fragment is well known to the person skilled in the art, see for example, Skerra, A. (1994) A general vector, pASK84, for cloning, bacterial production, and single-step purification of antibody Fab fragments. *Gene* 141, 79-84, or Skerra, A. (1993) Bacterial expression of immunoglobulin fragments. *Curr Opin Immunol.* 5, 256-562). Finally, it is also possible to generate antibody molecules of artificial binding molecules with antibody like properties against a given target such as CD3 or CD28 as in the Example of **Fig. 2** by well-known evolutive methods such as phage display (reviewed, e.g., in Kay, B.K. et al. (1996) *Phage Display of Peptides and Proteins – A Laboratory Manual*, 1st Ed., Academic Press, New York NY; Lowman, H.B. (1997) *Annu. Rev. Biophys. Biomol. Struct.* 26, 401–424, or Rodi, D.J., and Makowski, L. (1999) *Curr. Opin. Biotechnol.* 10, 87–93), ribosome display (reviewed in Amstutz, P. et al. (2001) *Curr. Opin. Biotechnol.* 12, 400-405) or mRNA display as reported in Wilson, D.S. et al. (2001) *Proc. Natl. Acad. Sci. USA* 98, 3750-3755.

[0026] In the case of the Example shown in **Fig. 2**, the multimerization reagent (4) has two different binding sites Z1 (42) and Z2 (44). With the binding partner C1 (6a) being a streptavidin binding peptide, the binding site Z1 (42) of the multimerization reagent (4) is provided by a suitable streptavidin mutein to which the streptavidin peptide (6a) reversibly binds. Since the binding C2 is a calmodulin binding peptide, the binding site Z2 (44) of the

multimerization reagent (4) is provided by multimeric calmodulin. The multimerization reagent (4) can be a single molecule, for example a conjugate of multimeric calmodulin with streptavidin (this alternative would be usually used in case of a soluble multimerization) or can also consist of two independent molecules. The latter option is preferred when the multimerization reagent (44) is immobilized on a solid support as shown in **Fig.2** In this case, a mixture of a streptavidin mutein and calmodulin can be coated (immobilized) on the solid support, for example, in a 1:1 molar ratio with respect to the binding sites Z1 and Z2. In this context, it is noted that, due to the immobilisation of calmodulin on the surface of the solid support, there is no need to prepare multimeric calmodulin as explained above but immobilization of the calmodulin on the surface is sufficient to present calmodulin (that, as mentioned above, has only a single binding site for calmodulin binding peptides, in a sufficiently high density to ensure binding of the cell population (2). For example, in this case, a bivalent antibody fragment that has two binding sites against CD28 or an intact antibody that has per se two identical binding sites could be used as second reagent (8).

[0027] As shown in **Fig. 2b**, after contacting the T cell population (2) with the multimerisation reagent (4) and usually incubating the cell population with the multimerization reagent (4), the population of T cells (2) forms complexes/is bound to the multimerization agent via the first agent (6) and the second agent (8). The first agent (6) and the second agent (8) bind specifically to the TCR/CD3 complex and the accessory molecule CD28, thereby inducing the T cells to proliferate/expand.

[0028] As shown in **Fig. 2c**, after incubation (which is usually carried out over a period of time suitable to achieve expansion of the desired cell population) the binding between the binding partner C1 (6a) of the first agent (6) and the binding site Z1 of the multimerization reagent (4) is disrupted by disrupting the respective reversible bond. Likewise, the binding between the binding partner C2 (8a) of the second agent (8) and the binding site Z2 of the multimerization reagent (4) is disrupted by disrupting the respective reversible bond. The reversible bond between the binding partner C1 (6a) of the first agent (6) and the binding site Z1 can be disrupted by biotin (which acts as an analogue (20) of the free first partner) while the reversible bond between the binding partner C2 (8a) of the first agent (8) and the binding site Z2 can be disrupted by the addition of a metal chelator (calcium chelator) such as EDTA or EGTA (that acts an analogue (20) of the free second partner) since the binding of calmodulin to calmodulin binding peptides is calcium ion (Ca^{2+}) dependent). This of course means that the contacting of the cell population (2) is carried out in a Ca^{2+} containing buffer.

[0029] As shown in **Fig. 2d**, addition of the analogue (20) of the first free partner and the second free partner, respectively results in displacement of the binding partners C1 (6a) and C2 (8a) from the multimerization reagent (4) and thus in displacement of the first agent (6) and the second agent (8) from the multimerization reagent (4). This displacement of the first agent (6) and second agent (8) in turn results in a dissociation of the first agent (6) and the second agent (8) from the TCR/CD3 complex and the accessory molecule CD28, thereby terminating the stimulation/expansion of the cell population (2). Thus, as said above, the present invention provides the advantage that the time period of the stimulation or expansion of a T cell population can be exactly controlled and therefore also the functional status of the population of T cells can be closely controlled. After the elution of the cells as illustrated in **Fig. 1d**, the first agent (6), the second reagent (8) as well as the analogue (20) of free first partner of the binding partner C1 and the second free partner of the binding partner C2 can be easily removed from the stimulated cell population (2) via a "removal cartridge" described in International patent application WO 2013/124474. In addition, and importantly, in case the initial sample was a population of lymphocytes, for example, in form of PMBCs obtained from a Ficoll gradient, the T cell population (2) is now available for serial expansion as defined here. Since the expanded cell population (e.g. by an initial stimulation via CD3/CD28) can be transfected during expansion e.g. with a T cell receptor (TCR) or a chimeric antigen receptor (CAR, also known as artificial T cell receptor), the genetically modified cells can then be liberated from the initial stimulus and subsequently be stimulated with a second type of stimulus e.g. via the de novo introduced receptor. These second stimuli may comprise an antigenic stimulus in form of a peptide/MHC molecule, the cognate (cross-linking) ligand of the genetically introduced receptor (e.g. natural ligand of a CAR) or any ligand (such as an antibody) that directly binds within the framework of the new receptor (e.g. by recognizing constant regions within the receptor). Thus, the T cell population obtained from this serial expansion can be used for adoptive cell transfer.

[0030] **Fig. 3** shows a further embodiment of an expansion method of the invention. Also the sample used in this Example comprises a population of T cells (2) that carry two specific cell surface molecules (30) and (32), with the cell surface molecule (30) being a TCR/CD3 complex and the cell surface molecule (32) being the accessory molecule CD28. In **Fig. 3a** the population of T cells (2) is shown after being contacted with a multimerization reagent (4). Also in this Example, the multimerization reagent (4) has reversibly immobilized thereon (bound thereto) as first agent (6) an anti-CD3 antibody or an antigen binding fragment thereof that provides a primary activation signal to the T cells and as second agent (8) an anti-CD28

antibody or an antigen binding fragment thereof that stimulates CD28 as accessory molecule.

[0031] The multimerization reagent (4) shown in the Example of **Fig. 3** comprises only one type binding site Z1 (42) for the reversible binding of both the first agent (6) and the second agent (8). Both the first agent (6) and the second agent (8) comprise at least one binding partner C1 (6a, 8a), wherein both the binding partner C1 (6a) and the binding partner (8a) are able of reversibly binding to the binding site Z1 (44) of the multimerization reagent. Thus, for immobilization, the first agent (6) and the second agent (8), respectively are bound to the multimerization reagent (4) via the reversible bond formed between the binding partner C1 (6a) and the binding partner C2 and the binding site Z1 (42). The binding partners C1 and C2 can either be different or identical. For example, the binding partner C1 can be a streptavidin binding peptide of the sequences Trp-Ser-His-Pro-Gln-Phe-Glu-Lys ((SEQ ID NO: 01), the “Strep-tag®”) while the binding partner C2 can be the streptavidin binding peptide of the sequence Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer)₃-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys ((SEQ ID NO: 04), also known as “di-tag3”) or of the sequence Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer)₂-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys ((SEQ ID NO: 05), also known as “the di-tag2”), described by Junttila et al., *Proteomics* 5 (2005), 1199-1203 or US Patent 7,981,632). All these streptavidin binding peptides bind to the same binding site, namely the biotin binding site of streptavidin. If one or more of such streptavidin binding peptides is used as binding partners C1 and C2, the multimerization reagent (4) is a streptavidin mutein. As shown in **Fig. 3**, a soluble multimerization reagent (4) is used. In the case of a streptavidin mutein, this soluble multimerization reagent may, for example, be an oligomer or a polymer of streptavidin or avidin or of any mutein (analog) of streptavidin or avidin. The oligomer may comprise three or more monomers of streptavidin, avidin or a mutein thereof. The oligomer or polymer may be crosslinked by a polysaccharide. Such oligomers or polymers of streptavidin or of avidin or of muteins of streptavidin or of avidin can in a first step be prepared by the introduction of carboxyl residues into a polysaccharide, e. g. dextran, essentially as described in “Noguchi, A., Takahashi, T., Yamaguchi, T., Kitamura, K., Takakura, Y., Hashida, M. & Sezaki, H. (1992). Preparation and properties of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C dextran conjugate. *Bioconjugate Chemistry* 3,132-137”. In a second step, streptavidin or avidin or muteins thereof are coupled via primary amino groups of internal lysine residue and/or the free N-terminus to the carboxyl groups in the dextran backbone using conventional carbodiimide chemistry. Alternatively, cross-linked oligomers or polymers of streptavidin or avidin or of any muten of streptavidin or avidin may also be obtained by crosslinking via

bifunctional linkers such as glutardialdehyde or by other methods described in the literature.

[0032] Using as binding partners C1 and C2, moieties that bind to the same binding site (42) of the multimerization agent has the advantage that, as shown in **Fig. 3b**, the same free partner (of the first binding partner C1 and also of the second binding partner C2) or analogue thereof can be used to terminate the expansion of the population of T cells (2) and to release this population of T cells (2) from the multimerization agent. In the Example of **Fig. 3**, an analogue of the first and second partner C1 and C2 such as biotin or a biotin derivate (iminobiotin or desthiobiotin) can be conveniently used for the termination of the expansion and the elution of the population of T cells (2).

[0033] As shown in **Fig. 3c**, after the elution of the cells as illustrated in **Fig. 1d**, the first agent (6), the second reagent (8) as well as biotin as the analogue (20) of free first partner of the binding partner C1 and the second free partner of the binding partner C2 can be easily removed from the stimulated cell population (2) via a “removal cartridge” described in International patent application WO 2013/124474. In addition, the embodiment of using a soluble multimerization reagent (4) has the further advantage of being able to avoid any solid support such as magnetic beads. This means there is no risk of contamination of the activated T cells by such magnetic beads. This also means that a process that is compliant with GMP standards can be much easier established compared to the known method such as the use of Dynabeads® in which additional measures have to be taken to ensure that the final expanded T cell population is free of magnetic beads. Furthermore, the use of a soluble multimerisation agent makes it much easier to remove the same from the activated cell population (T cells, B cells or also natural killer cells) since the cells can be simple sedimented by centrifugation and the supernatant including the soluble multimerization agent can be discarded. Alternatively, the soluble multimerization agent can be removed from the expanded cell population in a gel permeations matrix of the removal cartridge of International patent application WO 2013/124474. Since no solid phase (e.g. magnetic beads) are present, the present invention also provides for an automated closed system for expansion of the cells that can be integrated into known cell expansion systems such as the Xuri Cell Expansion System W25 and WAVE Bioreactor 2/10 System, available from GE Healthcare (Little Chalfont, Buckinghamshire, United Kingdom) or the Quantum® Cell Expansion System, available from TerumoBCT Inc. (Lakewood, CO, USA).

[0034] **Fig. 4** shows the results of an experiment in which CD3⁺ T responder cells were proliferated after being stimulated *in vitro* with α CD3 and α CD28 Fab fragments that were

reversibly immobilized on beads coated with the streptavidin mutein Strep-tactin®. **Fig. 4A** in a histogram showing size-distribution (forward scatter) of stimulated cells, **Fig. 4B** depicts histograms representing the degree of proliferation according to the number of cells per cell division that are indicated on top of **Fig. 4B** (0 represents undivided cells; 5 represents cells that have gone through at least 5 divisions), and **Fig. 4C** shows a picture of the culture dish after 4 days of stimulation.

[0035] **Fig. 5** shows the results of the differential intracellular calcium mobilization in Jurkat cells that are either labelled with the α CD3 antibody OKT3 or with Fab fragments of OKT3 being multimerized with Strep-tactin® (also referred to as Fab multimers herein). **Fig. 5A:** Jurkat cells were loaded with the calcium-sensitive dye Indo-1-AM and calcium release was triggered by injection of either α CD3 mAb (black squares) or α CD3 OKT3 Fab multimers (derived from the parental cell line OKT3) with or without prior D-biotin disruption (dark grey triangles and light grey circles respectively) compared to injection of PBS (inverted white triangles). Application of ionomycin served as positive control. Time-resolved changes in intracellular Ca^{2+} concentration were monitored by flow-cytometry based on the change in FL6/FL7 ratio. **Fig. 5B:** Indo-1-AM-labeled Jurkat cells were activated by different α CD3 stimuli as described in Fig 4a; OKT3: upper graph and α CD3 Fab-multimer: middle graph) followed by subsequent ($t=140\text{s}$) D-biotin mediated disruption of α CD3 Fab-multimer signaling. Injection of PBS (lower graph) and ionomycin served as negative or positive control. Data are representative of three different experiments.

[0036] **Fig. 6** shows the result of the reversible staining of cells by anti CD3 OKT3 Fab-multimers. Freshly isolated PBMCs were stained with either a monoclonal antibody (left dot plot, parental clone for the Fab-multimers) or cognate PE-labeled Fab-multimers and analyzed either before (second left column) or after treatment with D-biotin (middle column). Remaining Fab monomers were then detected after subsequent washing steps using fresh PE-labeled Strep-Tactin® (second right column). Secondary Fab-multimer staining of reversibly stained cells served as control (right column). Only live ($\text{PI}^{\text{negative}}$) cells are shown. Numbers in dot plots indicate the percentage of cells within gates.

[0037] **Fig. 7** shows the isolation of cells by reversible binding of anti-CD28 Fab fragments multimerized with *Strep*-Tactin® labeled with phycoerythrine as a fluorescent label. CD28⁺ cells were selected/isolation by Fab-multimer magnetic cell selection from freshly isolated PMBCs as described in International Patent Application WO2013/011011. Before selection cells were control stained with either the cognate fluorescent α CD28-multimers (left

dot plot) or with an antibody directed against the immunoglobulin kappa light chain (second left dot plot, α -Ig kappa mAb). After selection, cells were treated with D-biotin and subsequently washed to remove magnetic beads and Fab-monomers. Liberated CD28⁺ cells were subsequently (re-)stained either with CD28 Fab-multimers (second right dot plot) or with the α -Ig kappa mAb (right dot plot) to detect potentially remaining Fab-monomers. Only live (PI^{negative}) CD3⁺ cells are shown. Numbers in dot plots indicate the percentage of cells within gates.

[0038] **Fig. 8** shows the results of an experiment in which CD3⁺ T responder cells were proliferated after being stimulated *in vitro* with reversible α CD3/ α CD28 Fab fragments that were reversibly immobilized on soluble oligomeric Strep-tactin® acting a soluble multimerization reagent. For the experiments the results of which are shown in **Fig. 8**, 300.000 CD3⁺ responder T cells (Tresp) were labeled with 2 μ M Carboxyfluorescein succinimidyl ester (CFSE) and stimulated with varying amounts of a preparation of soluble Streptactin oligomers on which a combination of α CD3 Fab fragment and α CD28 Fab both carrying a Strep-tag as streptavidin binding peptide at the heavy chain were immobilized. (“1x” corresponds to 3 μ g multimerized Strep-tactin functionalized with 0.5 μ g α CD3- and 0.5 μ g α CD28 Fab; numbers indicate fold amount of “1x”). Tresp cells either left unstimulated or were stimulated with blank Strep-tactin multimers (no Fab) served as negative control. Tresp cells were seeded in duplicates in 48-well plates along with 300.000 CD3 negative autologous feeder cells (irradiated with 30Gy) in 1ml cell culture medium supplemented with 20U/ml interleukin 2 (IL-2). Cells were incubated at 37°C without media exchange and proliferation was analyzed according to CFSE dilution after 5 days by FACS analysis (**Fig. 8B**). **Fig. 8A** shows size distribution of cells after 5 days in culture. Histograms show live CD3⁺ cells, while **Fig. 8C** shows cells after culture that were liberated by stimulation reagents after treated with 1mM D-biotin and washed. The dissociation and removal of monomeric Fab fragments was analyzed by restaining with Strep-Tactin® labeled with phycoerythrine (ST-PE) as a fluorescent label and a representative histogram is shown. **Fig. 8D** shows the absolute number of live (trypan blue negative) cells after 5 days was counted using a Neubauer counting chamber and plotted against the respective stimulation condition. Median cell numbers are shown in **Fig. 8D**; error bars indicate standard deviation (SD). **Fig. 8E** shows a picture of the culture dish after 5 days of stimulation.

[0039] **Fig. 9** depicts an illustration of the serial expansion method of the present invention (**Fig. 9a**) while **Fig. 9b** briefly describes some features and advantages of the serial

expansion.

[0040] Fig. 10 shows an arrangement of the invention that can be used together with the expansion methods of the invention. This arrangement (100) includes a bioreactor (50), a first “removal cartridge” (70) and a second “removal cartridge” (90). The bioreactor (50) is fluidly connected to the first removable cartridge (70), and the first removal cartridge is fluidly connected to the second removal cartridge (90). This arrangement (100) can be part of a device for automated cell expansion and purification as described here.

[0041] In the bioreactor (50) an expansion method as described herein is carried out, for example an expansion method illustrated in Fig. 3 that makes use of a soluble multimerization reagent. In this case, after termination of the activation/expansion of the cell population (2) by addition of a competitor (20) (free partner of the binding partner C1 or an analogue thereof) the reaction mixtures that is released from the bioreactor contains the expanded population of cells (2), the first agent (6), the second agent (8) as well as the soluble multimerization reagent (4). In this example, the first agent (6) is a CD3 binding antibody fragment that includes a streptavidin binding peptide as binding partner C1, the second agent (8) is a CD28 binding antibody fragment that includes a streptavidin binding peptide as binding partner C1 and the competitor (20) (free analogue of the binding partner C1) is biotin. This reaction mixture is applied on the first removal cartridge (70). This first removal cartridge (70) is a removal cartridge as described in International patent application WO 2013/124474 that includes a chromatography column with a suitable stationary phase. The stationary phase can serve both an affinity chromatography matrix and, at the same time, can act as gel permeation matrix. This affinity chromatography matrix has an affinity reagent immobilized thereon. The affinity reagent may, in the case of the current Example, for instance, be streptavidin, a streptavidin mutein, avidin, an avidin mutein or a mixture thereof. Thus, the first agent (6) and the second agent (8) bind to the affinity reagent via their streptavidin binding peptide. Also biotin as the competitor (20) binds to the affinity reagent. Thus, these three reagents are all being immobilized on the chromatography matrix of the first removal cartridge while the expanded cell population (2) and the soluble multimerization reagent (4) pass through the stationary phase. This “flow through” is then applied onto the second removal cartridge (90). Also this second removal cartridge (90) comprises a stationary phase. This stationary phase comprises a second affinity reagent thereon which is able to bind to the binding site Z1 (42) of the multimerization reagent (4). This affinity reagent may for example be biotin that is covalently bound to the stationary phase. Such a stationary phase may, for example, be d-biotin

SepharoseTM obtainable from Affiland S.A. (Ans-Liege, Belgium). Thus, the soluble multimerization reagent (4) will be bound (retained) on the stationary phase of the second removal cartridge (90) while the expanded population of cells (2) passes through the stationary phase and is being freed of any reactants. The population of cells (2) is now in a condition for any further use, for example, for diagnostic applications (for example, further FACSTM sorting) or for any cell based therapeutic application. It is noted here that it is of course also possible to change the order of the first "removal cartridge" (70) and the second "removal cartridge" (90) in an arrangement (100), such that bioreactor (50) is (directly) fluidly connected to the second removable cartridge (90), and the first removal cartridge (70) is arranged after and fluidly connected to the second removal cartridge (90). In this arrangement the multimerization reagent (4) will first be removed from the population of cells (2) and subsequently the first agent (6), the second (8) and e.g. the competitor (20) are removed. Such an arrangement is also encompassed in the present invention and can also be part of a device for automated cell expansion and purification as described here.

[0042] Fig. 11 shows a further embodiment of an arrangement of the invention that can be used together with the expansion methods of the invention. This arrangement (110) includes a bioreactor (50), a first "removal cartridge" (70) and a second "removal cartridge" (90). The bioreactor (50) is fluidly connected to the first removable cartridge (70), and the first removal cartridge is fluidly connected to the second removal cartridge (90). In addition, the second removal cartridge (110) is fluidly connected to the bioreactor (50). This arrangement (110) can also be part of a device for automated cell expansion and purification as described here. When used, for example, together with an expansion method that employs a soluble multimerization reagent (4), a purified expanded population of cells (2) is obtained as eluate of the second removal cartridge (90). Since the removal cartridge (90) is fluidly connected to the bioreactor (50), the population of cells (2) can be transferred back into the bioreactor (50), for example, to serial clonal expansion as described here, by transfecting the population of cells, for example, with the gene of an T cell receptor and subsequent further (second) expansion using an expansion method of the invention.

[0043] Fig. 12 shows a further embodiment of an arrangement of the invention that can be used together with the expansion methods of the invention. This arrangement (120) includes a bioreactor (50), a first "removal cartridge" (70) and a second "removal cartridge" (90). The bioreactor (50) is fluidly connected to the first removable cartridge (70), and the first removal cartridge is fluidly connected to the second removal cartridge (90). Similar to the embodiment

shown in Fig. 11, the second removal cartridge (110) is fluidly connected to the bioreactor (50). However, a “selection cartridge” (92) as described in International patent application WO 2013/124474 is arranged in between the second removal cartridge (90) and the bioreactor (50). Thus, a subpopulation of cells (2a) that is comprised in the population of cells (2) can be selected/enriched via this “selection cartridge” (92) as described in WO 2013/124474. This subpopulation of cells (2a) can either be transferred into the bioreactor (50), for example, to undergo serial expansion as described here. Alternatively (not shown), this subpopulation of cells (2a) can be used for cell based therapy. It is again noted here that the use of a soluble multimerization reagent as described here allows the design of automated cell purification and expansion devices which are functionally closed and thus not prone to contamination. In addition, since soluble multimerization reagent avoids the need for solid phase materials such as magnetic beads, such cell purification devices can be designed as continuous flow devices.

[0044] Fig. 13 shows the expansion kinetics of proliferation of purified CD4⁺ and CD8⁺ T responder cells (Tresp) that were stimulated *in vitro* either with α CD3/ α CD28 Fab fragments or with α CD3/ α CD28/ α CD8 that were reversibly immobilized on two kinds of a soluble oligomeric Strep-tactin® mutein acting as soluble multimerization reagent. The first kind of oligomeric Strep-tactin® was the fraction of the oligomeric streptavidin mutein ($n \geq 3$) obtained in Example 5 (also referred herein as “conventional Streptactin® backbone”, illustrated by the triangle symbol with the tip down in Fig. 13), the second kind of this oligomeric streptavidin mutein used as soluble multimerization reagent was an oligomer that was obtained by reacting the soluble oligomeric streptavidin mutein with biotinylated human serum albumin (HSA) This HSA based soluble multimerization reagent is also referred herein as “large Streptactin® backbone). In the experiments of Fig. 13 the expansion was carried out without medium exchange. The results for the CD4⁺ T responder cells are shown in **Fig. 13A**, the results for the CD8⁺ T responder cells are shown in **Fig. 13B**. In this context, it is noted that the experimentally used soluble multimerization reagents that were functionalized by reversibly binding first agents, and optionally second and third agents are referred to in the Figures as “Streptamer® multimers”

[0045] Fig. 14 shows the expansion kinetics of proliferation of purified CD4⁺ and CD8⁺ T responder cells (Tresp) that were stimulated *in vitro* with α CD3/ α CD28 Fab fragments that were reversibly immobilized fragments that were reversibly immobilized with two kinds of soluble oligomeric Strep-tactin® acting as soluble multimerization reagent. The first kind of oligomeric Strep-tactin® was the fraction of the oligomeric streptavidin mutein ($n \geq 3$)

obtained in Example 5 (also referred herein as “conventional Streptactin® backbone”, illustrated by the triangle symbol with the tip on top in Fig. 14), the second kind of this oligomeric streptavidin mutein used as soluble multimerization reagent was the HSA based soluble multimerization agent, the above-mentioned “large Streptactin® backbone”). In the experiments of Fig. 14 the expansion was carried out with medium exchange. The results for the CD4⁺ T responder cells are shown in **Fig. 14A**, the results for the CD8⁺ T responder cells are shown in **Fig. 14B**.

[0046] **Fig. 15** shows the combined data from the results obtained in Figs 13 and 14 for the expansion kinetics of proliferation of purified CD4⁺ and CD8⁺ T responder cells, with **Fig. 15A** depicting the results for CD4⁺ T cells and **Fig. 15B** depicting the results for the CD8⁺ T cells. Straight lines are used for the culturing with medium exchange on day 3, while dashed lines depict the values obtained for the degree of expansion without media exchange on day 3. The data shown in Fig. 15 are normalized on the input cell number. Only data for the Tresp stimulated with the oligomeric streptavidin mutein ($n \geq 3$), the Tresp stimulated with the commercially available Dynabeads (positive control) and the unstimulated T cells (negative control) are shown but no data on the multimerization reagent with the “large Streptactin® backbone”.

[0047] **Fig. 16** shows early cluster formation of T cells after activation of purified CD4⁺ and CD8⁺ T responder cells stimulated *in vitro* with α CD3/ α CD28 Fab fragments that were reversibly immobilized on the soluble oligomeric streptavidin mutein ($n \geq 3$) described in Example 5. **Fig. 16A** depicts the results for CD4⁺ T cells and **Fig. 16B** depicts the results for the CD8⁺ T cells. Data for the Tresp stimulated with the soluble multimerization reagent (the oligomeric streptavidin mutein), the Tresp stimulated with the commercially available Dynabeads (positive control) and the unstimulated T cells (negative control) are shown.

[0048] **Fig. 17** shows the expansion kinetics and phenotype of CD3⁺ central memory T cells (T_{cm}) (CD3⁺CD62L⁺CD45RA⁺-T_{cm}) polyclonally stimulated *in vitro* with α CD3/ α CD28 Fab fragments that were reversibly immobilized on the soluble oligomeric streptavidin mutein (with $n \geq 3$) described in Example 5. The graphs shown in Fig. 17 represent the degree of proliferation according to the number of cells harvested per time point, with **Fig. 17A** showing the proliferation in only IL-2 supplemented media and in **Fig. 17B** showing the proliferation in IL-2 and IL-15 supplemented media. **Fig. 17C** shows a flow-cytometric analysis of CD62L and CD127 surface expression after 14 days of culture in these variable cytokine milieus.

[0049] **Fig. 18** shows the kinetics of selective antigen-specific (Ag-specific) expansion out of a bulk population of purified CD3+CD62L+CD45RA- Tcm responder cells that were stimulated *in vitro* with both a peptide:MHC molecule complex (that acts as first agent that provides a primary activation signal to the cells) and α CD28 Fab fragment (that acts as second agent that binds the accessory molecule on the surface of the cells) and unstimulated T cells (negative control) are shown. Both, the complex of antigen-specific peptide with the MHC molecule and the α CD28 Fab fragment were reversibly immobilized on the same soluble oligomeric streptavidin mutein (with $n \geq 3$) described in Example 5. The peptide used for the antigen-specific expansion in Fig. 18A was the peptide CRVLCCYVL (SEQ ID NO: 06), amino acids 309–317 of the immediate-early 1 protein restricted by the HLA-C702 MHC molecule (described in Ameres et al, PLOS Pathogens, May 2013, vol. 9, issue 5, e1003383) representing an HLA-C7/IE-1 epitope that is specific for cytomegalovirus (CMV). The MHC I molecule that presents the peptide carries at its C-terminus of the heavy chain the streptavidin binding peptide (SAWSHPQFEK(GGGS)₂GGSAWSHPQFEK (SEQ ID NO: 07), that is commercially available as “Twin-Strep-tag®” from IBA GmbH, Göttingen, Germany). **Fig. 18A** shows exemplary flow-cytometric analysis for the fraction of the Ag-specific cells that were proliferated using the peptide:MHC-I complex specific for this HLA-C7/IE-1 epitope as first agent that provides a primary activation signal to the cells reversibly immobilized on the soluble oligomeric streptavidin mutein. The graphs in **Fig. 18B** to **Fig. 18E** illustrates the expansion kinetics of further Ag-specificities according to the number of specific peptide:MHCI multimer-positive cells harvested per time point in analogy to Fig. 18A using distinct complexes of an antigen-specific peptide with the MHC I molecule as first agent that provides a primary activation signal to the cells reversibly immobilized on the soluble oligomeric streptavidin mutein. In more detail, **Fig. 18B** shows the expansion of Ag-specific cells that were expanded using the peptide:MHC-I complex specific for the pp65 epitope of CMV (amino acids 341-350 (QYDPVAALF, (SEQ ID NO: 08)) restricted by HLA-A2402), **Fig. 18C** shows the expansion of Ag-specific cells that were expanded using another peptide:MHC-I complex specific for the pp65 epitope of CMV (amino acids 265-274 RIPHERNGFTV, (SEQ ID NO: 09)) restricted by HLA-B702), **Fig. 18D** shows the expansion of Ag-specific cells that were proliferated using the peptide:MHC-I complex specific for the hexon 5 epitope of adenovirus (amino acids 114-124 (CPYSGTAYNSL, (SEQ ID NO: 10)) restricted by HLA-B702), **Fig. 18E** shows the expansion of Ag-specific cells that were proliferated using the peptide:MHC-I complex specific for the HLA-B7/IE-1₃₀₉₋₃₁₇ epitope of CMV (exemplary FACS data see above Fig. 18A). All peptide:MHC molecules bearing the

Twin Strep®-Tag are commercially available from IbaGmbH. In this context, the amino acid sequences of the HLA-A*2402, HLA-B*0702 and HLA-C*0702 molecules that carry the “Twin-Strep-tag®” as their C-terminus are shown as SEQ ID NO: 21, 22 and 23 in the accompanying Sequence Listings, while the amino acid sequence of the β_2 microglobulin (which forms together with the α chain, that means the HLA encoded molecules the respective MHC I molecule) is shown as SEQ ID NO: 24 in the accompanying Sequence Listing. In addition, **Fig.18F** show exemplary flow-cytometric analysis of CD62L and CD127 surface expression after 14 days of culture for HLA-B7/Hexon5₁₁₄₋₁₂₄ stimulated/expanded cells from Fig. 18D.

[0050] **Fig. 19** shows the kinetics of selective Ag-specific expansion out of purified CD3+CD62L+CD45RA-Tcm responder cells that were stimulated *in vitro* with a) antigen specific peptide MHC I complexes and b) α CD28 Fab fragments that were reversibly immobilized as first and second agent on soluble oligomeric streptavidin muteins. For this purpose 500.000 CD3+CD62L+CD45RA- responder Tcm cells (Tresp) were stimulated Ag-specifically using 3 μ l of a preparation of Streptactin multimerization reagent functionalized with 0.5 μ g peptide:MHC class I complexes equipped with a streptavidin binding peptide (the specific peptide represents amino acids 114-124 (CPYSGTAYNSL, SEQ ID NO: 10) of the Hexon 5 protein of the adenovirus restricted by HLA-B0702, see above) and 0.5 μ g α CD28 Fab. As an alternative, 4.5 μ l of a preparation of Streptactin multimerization reagent loaded with 0.5 μ g this peptide:MHC class I complex, 0.5 μ g α CD8 Fab and 0.5 μ g α CD28 Fab. For comparison, polyclonal stimulation was performed, using 3 μ l of a preparation of Streptactin multimerization reagent (1mg/ml) either loaded with a combination of 0.5 μ g α CD3 Fab and 0.5 μ g α CD28 Fab. Again as the alternative stimulation condition described above, 4.5 μ l of a preparation of Streptactin multimers loaded with 0.5 μ g α CD3 Fab, 0.5 μ g α CD8 Fab and 0.5 μ g α CD28 Fab was used. Untreated (unstimulated) Tresp cells served as negative control and Tresp cells stimulated polyclonal with Dynabeads as positive control. Tresp cells were seeded in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2 and 5ng/ml IL-15. Cells were incubated at 37°C with media exchange every 3 days and cell count was analyzed after 7 and 14 days. The photographs shown in **Fig. 19** represent the degree of cluster formation on day 5 for Ag-specific stimulation as exemplified for the HLA-B7/Hexon 5 epitope of adenovirus.

[0051] **Fig. 20** shows the yield and phenotype of expansion of purified CD8+ T responder cells stimulated *in vitro* with α CD3/ α CD28 Fab fragments that were reversibly

immobilized on two kinds of soluble oligomeric Strep-tactin® acting as a soluble multimerization reagent. The first kind of oligomeric Strep-tactin® was the fraction of the oligomeric streptavidin mutein (nmericobtained in Example 5 (conventional backbone), the second kind of this oligomeric streptavidin mutein used as soluble multimerization reagent was the soluble oligomer described above and referred herein as “large” Streptactin® backbone. In these experiments, the fraction of the oligomeric conventional streptavidin mutein ($n \geq 3$) was also used as a multimerization reagent that were either functionalized with single Fab fragments (third bar in Fig. 20A and Fig. 20B) or with a combination of α CD3 and α CD28 Fab-fragments. Furthermore to the combined stimulation with α CD3/ α CD28 Fab fragments, also an additional α CD8 Fab fragment (commercially available from IBA GmbH, Göttingen, Germany) was immobilized in order to test whether it is possible to preferentially stimulate a specific T cell subpopulation. **Fig. 20A** shows a graph of bars that represent the degree of proliferation according to the number of cells harvested at day 6 compared to the negative controls (unstimulated purified CD8+ T responder cells) and normalized to the positive control (purified CD8+ T responder stimulated with commercially available Dynabeads (beads on which α CD3 and α CD28 monoclonal antibodies are irreversible immobilized). **Fig. 20B** shows flow-cytometric analysis of the surface expression of CD8 and the T cell surface molecule CD45RO (that is indicative of T cell proliferation and activation) after cell culture. The various stimulating conditions were compared using one-way ANOVA and no significant difference (n.s.) was detected.

[0052] **Fig. 21** shows the yield and phenotype for the expansion of purified CD8+ T responder cells stimulated *in vitro* with α CD3/ α CD28 Fab fragments that were reversibly immobilized on soluble oligomeric Strep-tactin® acting as a soluble multimerization reagent that were either functionalized with single Fab fragments or with a combination of Fab-fragments (as already described above). In these experiments, the CD8+ T responder cells were stimulated with the soluble multimerization reagent (the soluble oligomeric Strep-tactin® (1mg/ml) of Example 5) which was functionalized with varying amounts of α CD3 and α CD28 Fab fragments, optionally together with the α CD8 Fab fragment described above. The term „1x“ corresponds to 1.5 μ g multimerized Streptactin functionalized with 0.5 μ g α CD3 Fab fragment alone and 1.5 μ g multimerized Streptactin functionalized with 0.5 μ g α CD28 Fab alone), or 3 μ l of a preparation of oligomeric Streptactin loaded with 0.5 μ g α CD3 Fab fragment and 0.5 μ g α CD28 Fab, or 4.5 μ l of a preparation of Streptactin multimers loaded with 0.5 μ g strep-tagged α CD3, 0.5 μ g strep-tagged α CD8 and 0.5 μ g strep-tagged α CD28 Fab. Accordingly, the term „2x“ corresponds to 3.0 μ g multimerized Streptactin functionalized with

1µg αCD3 Fab fragment alone and 3.0 µg multimerized Streptactin functionalized with 1µg αCD28 Fab alone, meaning that twice the amount of immobilized αCD3 Fab fragment was used. Untreated Tresp cells served as negative control and purified CD8+ T responder stimulated with commercially available Dynabeads (beads on which αCD3 and αCD28 monoclonal antibodies are irreversible immobilized) as positive control. **Fig. 21A** shows a graphs in which the bars represent the degree of proliferation according to the number of cells harvested at day 5 compared to the negative controls and normalized to the positive control. **Fig. 21B** shows FACS analysis of CD8 and CD45RO surface expression after cell culture.

[0053] Fig. 22 shows the activation of intracellular signaling cascades of transduced Jurkat cells that have been modified to express an αCD19 chimeric antigen receptor (CAR), and that were stimulated using the oligomeric Strep-tactin® of Example 5 as soluble multimerization reagent. The specificity of a CAR is typically derived from a scFv region assembled from the antigen-binding region of a monoclonal antibody (mAb) that specifically binds a target/tumor associated antigen such as CD19 and links it to T cell specific signaling (described in Hudecek et al, Clin Cancer Res. 2013 June 15; 19(12): 3153–3164. In the experiments the extracellular domain (ECD) of CD19, which contains the natural ligand of the αCD19 CAR as well as the polyclonal αIgG F(ab)₂ fragment that recognizes the IgG4 spacer (donkey-anti-human F(ab)₂ is commercially available from Jackson Immuno Research) within the αCD19-CAR were also used in this experiment as first agent that provides a primary activation signal to the Jurkat cells. The reversibly immobilization to the soluble oligomeric streptavidin mutein was provided by the streptavidin peptide SAWSHPQFEK(GGGS)₂GGSAWSHPQFEK (SEQ ID NO: 07) that was fused to the C-terminus of the ECD of CD19 or by the biotinylated (Fab)₂ fragment of the αIgG (since the streptavidin mutein “m2” binds biotin with reduced affinity, this binding is reversible and can for example be displaced by addition of an excess of free biotin). In the control experiment of **Fig. 22A** 300.000 CD3+ Jurkat responder cells (Jresp) were stimulated with varying amounts of a mixture of preparations of oligomeric Streptactin (1mg/ml) that was functionalized with the αCD3 Fab and the αCD28 Fab („x1“ corresponds to 3µg multimerized Streptactin functionalized with 0.5µg αCD3- and 0.5µg αCD28 Fab – polyclonal Streptamer multimer). In the experiment of **Fig. 22B** 3µl of a preparation of the oligomeric Streptactin was functionalized with 0.5µg (x1) or 1µg (x2) of the extracellular domain (ECD) of CD19 or with 3µl of a preparation of the oligomeric Streptactin loaded with 0.5µg (x1) or 1µg (x2) αIgG that recognizes the IgG4 spacer (which are both CAR-specific Streptamer® multimers). Jresp stimulated with Dynabeads (beads on which αCD3 and αCD28 monoclonal antibodies are

irreversible immobilized) or PMA and ionomycin served as positive controls. Jresp cells were seeded in 1.5ml Eppendorf tubes in 200µl cell culture medium supplemented with 30U/ml IL-2. Cells were incubated at 37°C and put on ice and lysed after 0 min to 20min of stimulation.

[0054] Fig. 23 shows the expansion of purified CD3⁺ T responder cells stimulated *in vitro* with αCD3/αCD28 Fab fragments that were reversibly immobilized on the soluble oligomeric Strep-tactin® of Example 5 that served a soluble multimerization reagent. In one experiment, in addition to αCD3/αCD28 Fab fragments, also an αCD8 Fab fragment commercially available from IBA GmbH, Göttingen, Germany (catalogue number 6-8000-203) was immobilized on the soluble oligomer of the streptavidin mutein in order to test whether it is possible to preferentially stimulate *in vitro* the CD8⁺ T cell subpopulation within the bulk CD3⁺ culture with a multimerization reagent of the invention having reversibly immobilized thereon also an αCD8 Fab fragment. In more detail, 500.000 purified CD3⁺ responder T cells (Tresp) were stimulated with 3µl of a preparation of oligomeric Streptavidin (1mg/ml) loaded with a combination of 0.5µg of the αCD3 and 0.5µg of the αCD28 Fab. As an alternative approach, 4.5µl of the Streptactin oligomer were loaded with 0.5µg αCD3, 0.5µg αCD8 Fab and 0.5µg αCD28 Fab described above. Unstimulated Tresp cells served as negative control and Tresp stimulated with Dynabeads (beads on which αCD3 and αCD28 monoclonal antibodies are irreversible immobilized) served as positive control.

[0055] Fig. 24 depicts exemplary strategies for the generation of oligomeric streptavidin muteins that can be used as soluble multimerization reagent of the invention. Fig. 24A shows that in a first step, the streptavidin mutein “m2” (SA_{m2}) that comprises the amino acid sequence Ile⁴⁴-Gly⁴⁵-Ala⁴⁶-Arg⁴⁷ (SEQ ID NO: 03) at sequence positions 44 to 47 of wild type streptavidin is used for generation of oligomeric streptavidin muteins having a “conventional backbone”. In a second step, oligomeric soluble streptavidin muteins having a “large backbone” can be generated by either by coupling of streptavidin mutein with biotinylated carrier protein such as human serum albumin (HSA) or by coupling the streptavidin muteins with synthetic carriers such as PEG. Fig. 24B: Biotinylation of human serum albumin (HSA).

DETAILED DESCRIPTION OF THE INVENTION

[0056] The present invention provides methods, kits and an apparatus for expanding a population of cells or for inducing a population of T cells to proliferate.

[0057] The term “population of cells” as used herein encompasses all cells which can be expanded by binding to a cell surface receptor a first agent that provides a primary activation

signal to the cells. It is also possible that for expansion of the population of cells, binding of second agent to a second cell surface receptor (accessory molecule) might be needed to produce a co-stimulatory signal required for expansion of the cells. In some embodiments the cell population may be a population of lymphocytes including, but not limited a population of

5 B cells, a population of T cells or a population of natural killer cells. Illustrative examples of cell populations are B cells carrying CD40 or CD137 (both cell population can be proliferated upon binding of only a first agent that provides an activation signal, for example 4-1BB ligand; or an α CD40 antibody molecule or an α CD137 antibody molecule (see for example Zhang et al., 2010, J Immunol, 184:787-795)). Other illustrative examples for agents (either first or

10 second) that may be used for the expansion of B cells are agents that bind to IgG, CD19, CD28 or CD14, for example α CD19, α IgG, α CD28, or α CD14 antibody molecules. It is also envisioned that first or second agents for the expansion of B cell may comprise ligands for toll like receptors or interleukins, such as IL-21 (see for example Dienz O, et al. 2009. J. Exp. Med. 206:69). It is noted that lipopolysaccharide dependent activation of B cells is also

15 encompassed in the present invention, as a lipopolysaccharide can also be used as first agent and can be equipped with a binding partner C1 as used herein. Other illustrative examples of suitable cell populations include T cell population that expand after being activated by binding of a first agent to TCR/CD3 and binding of a second agent to an accessory molecule on the T cell such as CD28. In this case, the first agent stimulates a TCR/CD3 complex-associated

20 signal in the T cells and the second agent provides a secondary stimulus by binding CD28 as accessory molecule. Agents that can be used for the expansion of T cells may also include interleukins, such as IL-2, IL-7, IL-15, or IL-21 (see for example Cornish et al. 2006, Blood. 108(2):600-8, Bazdar and Sieg, 2007, Journal of Virology, 2007, 81(22):12670-12674, Battalia et al, 2013, Immunology, 139(1):109-120). Other illustrative examples for agents that may be

25 used for the expansion of T cells are agents that bind to CD8, CD45 or CD90, such as α CD8, α CD45 or α CD90 antibodies. Illustrative examples of T cell population including antigen-specific T cells, T helper cells, cytotoxic T cells, memory T cell (an illustrative example of memory T-cells are CD62L⁺CD8⁺ specific central memory T cells) or regulatory T cells (an illustrative example of Treg are CD4⁺CD25⁺CD45RA⁺ Treg cells). The term "T cell

30 (population)" as used herein also includes T cells that comprise a chimeric antigen receptor (CAR) that is also known as artificial T cell receptors or chimeric T cell receptors. Thus, a T cell population that comprises a chimeric antigen receptor can also be expanded using the methods, reagents and devices of the present invention. See in this respect also Example 15 in which Jurkat cells that express a chimeric CD19 specific antigen receptor (CAR) were

stimulated using a soluble multimerization reagent of the present invention. Another illustrative example of a suitable cell population includes natural killer cells (NK cells), which may for example be expanded with agents that bind to CD16 or CD56, such as for example α CD16 or α CD56 antibodies. In illustrative example for such an α CD16 antibody is the antibody 3G8 with a VH sequence set forth in SEQ ID NO: 25 and a VL sequence set forth in SEQ ID NO: 26 (see for example Hoshino et al, Blood. 1991 Dec 15;78(12):3232-40.). Another agent that may be used for expansion of NK cells may be IL-15 (see for example Vitale et al. 2002. The Anatomical Record. 266:87-92). Yet another illustrative example of a suitable cell population includes monocytes, which may for instance be expanded using an agent that binds to CD14, such as an α CD14 antibody molecule. The cell population can be of any mammalian origin, including but not limited to human, rabbit, guinea pig, squirrel, hamster, cat, dog, lemur, goat, pig, horse, rhesus monkey, macaque, or a chimpanzee.

[0058] Thus, in line with the above, this invention pertains to methods for selectively inducing *ex vivo* expansion of a population of cells such as B cells, T cells or natural killer cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells. In addition, the proliferation of these cells such as B cells or T cells can be induced without the need for antigen, thus providing an expanded cell population such as a T cell population which is polyclonal with respect to antigen reactivity. The methods disclosed herein may provide for sustained proliferation of a selected population of T cells such as CD4⁺ or CD8⁺ T cells over an extended period of time to yield a multi-fold increase in the number of these cells relative to the original T cell population. In general, in case of a (clonal) expansion of a lymphocyte population as described herein, all progeny may share the same antigen specificity as the cell population that was selected for expansion.

[0059] Also in line with the above, provided by this invention are methods for expanding a population of antigen specific T cells. To produce a population of antigen specific T cells, T cells are contacted with an antigen in a form suitable to trigger a primary activation signal in the T cell, i.e., the antigen is presented to the T cell such that a signal is triggered in the T cell through the TCR/CD3 complex. For example, the antigen can be presented to the T cell by an antigen presenting cell in conjunction with an MHC molecule. An antigen presenting cell, such as a B cell, macrophage, monocyte, dendritic cell, Langerhans cell, or other cell which can present antigen to a T cell, can be incubated with the T cell in the presence of the antigen (e.g., a soluble antigen) such that the antigen presenting cell presents the antigen to the T cell. Alternatively, a cell expressing an antigen of interest can be incubated with the T cell. For

example, a tumor cell expressing tumor-associated antigens can be incubated with a T cell together to induce a tumor-specific response. Similarly, a cell infected with a pathogen, e.g., a virus, which presents antigens of the pathogen can be incubated with a T cell. Following antigen specific activation of a population of T cells, the cells can be expanded in accordance with the methods of the invention. For example, after antigen specificity has been established, T cells can be expanded by culture with an anti-CD3 antibody (used as first agent) and an anti-CD28 antibody (used as second agent) according to the methods described herein. In another embodiment, the first agent can be an MHC I: peptide complex, which binds to an antigen specific T cell population. In such an embodiment, any antigen specific peptide that is known and that can be complexed with the respective MHC I molecule can be used. See in this respect Examples 11 and 12 in which selective Antigen-specific expansion of Tcm responder cells out of bulk CD3⁺ central memory T cells was exemplified for four different antigen-specific cells. Alternatively, it is also possible to use as first agent the natural ligand of a receptor that triggers of cell expansion. See in this respect Example 15 in which the extracellular domain of CD19 caused the activation of intracellular signaling cascades of transduced Jurkat cells that were modified to express chimeric CD19 binding antigen receptor (CAR).

[0060] The sample of the cell population can be from any suitable source, typically all sample of a body tissue or a body fluid such as blood. In the latter case, the sample might for example, be a population of peripheral blood mononucleated cells (PBMC) that can be obtained by standard isolation methods such a ficoll gradient of blood cells. The cell population to be expanded can however also be in purified form and might have been isolated using an reversible cell staining/isolation technology as described patent in US patent 7,776,562, US patent 8,298,782, International Patent application WO02/054065 or International Patent Application WO2013/011011. Alternatively, the population of cells can also be obtained by cell sorting via negative magnetic immunoadherence as described in US Patent 6,352,694 B1 or European Patent EP 0 700 430 B1. If an isolation method described here is used in basic research, the sample might be cells of *in vitro* cell culture experiments. The sample will typically have been prepared in form of a fluid, such as a solution or dispersion.

[0061] In line with the above, in one embodiment the invention provides an *in vitro*-method of expanding a population of cells, comprising contacting a sample comprising a population of cells with a multimerization reagent. The multimerization reagent has reversibly

immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells, wherein the multimerisation reagent comprising at least one binding site Z1 for the reversible binding of the first agent. The first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to the binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1. The first agent binds to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells and thereby activating the cells.

[0062] In another embodiment, the invention provides a method, wherein the multimerization agent has reversibly immobilized thereon (bound thereto) a second agent that stimulates an accessory molecule on the surface of the cells. The second agent comprises a binding partner C2, wherein the binding partner C2 is able of being reversibly bound to a binding site Z2 of the multimerization reagent, wherein the second agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C2 and the binding site Z2. The second agent binds to the accessory molecule on the surface on the surface of the cells, thereby stimulating the activated cells. In this embodiment the first agent may stimulate a TCR/CD3 complex-associated signal in the T cells and may be a binding agent that specifically binds CD3. In this embodiment the accessory molecule on the T cell may be CD28 and the second agent that binds the accessory molecule is a binding reagent that specifically binds CD28. In this case, the first agent that specifically binds CD3 may be selected from the group consisting of an anti-CD3-antibody, a divalent antibody fragment of an anti-CD3 antibody, a monovalent antibody fragment of an anti-CD3-antibody, and a proteinaceous CD3 binding molecule with antibody-like binding properties. Also the second agent that specifically binds CD28 may be selected from the group consisting of an anti-CD28-antibody, a divalent antibody fragment of an anti-CD28 antibody, a monovalent antibody fragment of an anti-CD28-antibody, and a proteinaceous CD28 binding molecule with antibody-like binding properties. The divalent antibody fragment may be an (Fab)₂'-fragment, or a divalent single-chain Fv fragment while the monovalent antibody fragment may be selected from the group consisting of a Fab fragment, a Fv fragment, and a single-chain Fv fragment (scFv). A proteinaceous CD3 or CD28 binding molecule with antibody-like binding properties may be an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, a protein based on the ankyrin scaffold, a protein based on the crystalline scaffold, an adnectin, and an avimer.

[0063] In general the first and the second agent that is used in the present invention may, for instance be, an antibody, a fragment thereof and a proteinaceous binding molecule with antibody-like functions. Examples of (recombinant) antibody fragments are Fab fragments, Fv fragments, single-chain Fv fragments (scFv), a divalent antibody fragment such as an (Fab)₂'-fragment, diabodies, triabodies (Iliades, P., et al., *FEBS Lett* (1997) 409, 437-441), decabodies (Stone, E., et al., *Journal of Immunological Methods* (2007) 318, 88-94) and other domain antibodies (Holt, L.J., et al., *Trends Biotechnol.* (2003), 21, 11, 484-490). In some embodiments one or more binding sites of the first or second agent may be a bivalent proteinaceous artificial binding molecule such as a dimeric lipocalin mutein that is also known as "duocalin". In some embodiments the receptor binding reagent may have a single second binding site, i.e., it may be monovalent. Examples of monovalent first or second agents include, but are not limited to, a monovalent antibody fragment, a proteinaceous binding molecule with antibody-like binding properties or an MHC molecule. Examples of monovalent antibody fragments include, but are not limited to a Fab fragment, a Fv fragment, and a single-chain Fv fragment (scFv), including a divalent single-chain Fv fragment.

[0064] As mentioned above, an example of a proteinaceous binding molecule with antibody-like functions is a mutein based on a polypeptide of the lipocalin family (see for example, WO 03/029462, Beste et al., *Proc. Natl. Acad. Sci. U.S.A.* (1999) 96, 1898-1903). Lipocalins, such as the bilin binding protein, the human neutrophil gelatinase-associated lipocalin, human Apolipoprotein D or human tear lipocalin possess natural ligand-binding sites that can be modified so that they bind a given target. Further examples of a proteinaceous binding molecule with antibody-like binding properties that can be used as a receptor binding reagent that specifically binds to the receptor molecule include, but are not limited to, the so-called glubodies (see e.g. international patent application WO 96/23879), proteins based on the ankyrin scaffold (Mosavi, L.K., et al., *Protein Science* (2004) 13, 6, 1435-1448) or crystalline scaffold (e.g. international patent application WO 01/04144) the proteins described in Skerra, *J. Mol. Recognit.* (2000) 13, 167-187, AdNectins, tetranectins and avimers. Avimers, including multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains, contain so called A-domains that occur as strings of multiple domains in several cell surface receptors (Silverman, J., et al., *Nature Biotechnology* (2005) 23, 1556-1561). Adnectins, derived from a domain of human fibronectin, contain three loops that can be engineered for immunoglobulin-like binding to targets (Gill, D.S. & Damle, N.K., *Current Opinion in Biotechnology* (2006) 17, 653-658). Tetranectins, derived from the respective human homotrimeric protein, likewise contain loop regions in a C-type lectin domain that can be

engineered for desired binding (ibid.). Peptoids, which can act as protein ligands, are oligo(N-alkyl) glycines that differ from peptides in that the side chain is connected to the amide nitrogen rather than the α carbon atom. Peptoids are typically resistant to proteases and other modifying enzymes and can have a much higher cell permeability than peptides (see e.g. Kwon, Y.-U., and Kodadek, T., *J. Am. Chem. Soc.* (2007) 129, 1508-1509). Yet further examples of suitable proteinaceous binding molecules are an EGF-like domain, a Kringle-domain, a fibronectin type I domain, a fibronectin type II domain, a fibronectin type III domain, a PAN domain, a Gla domain, a SRCR domain, a Kunitz/Bovine pancreatic trypsin Inhibitor domain, tendamistat, a Kazal-type serine protease inhibitor domain, a Trefoil (P-type) domain, a von Willebrand factor type C domain, an Anaphylatoxin-like domain, a CUB domain, a thyroglobulin type I repeat, LDL-receptor class A domain, a Sushi domain, a Link domain, a Thrombospondin type I domain, an immunoglobulin domain or a an immunoglobulin-like domain (for example, domain antibodies or camel heavy chain antibodies), a C-type lectin domain, a MAM domain, a von Willebrand factor type A domain, a Somatomedin B domain, a WAP-type four disulfide core domain, a F5/8 type C domain, a Hemopexin domain, an SH2 domain, an SH3 domain, a Laminin-type EGF-like domain, a C2 domain, "Kappabodies" (cf. Ill. et al., *Protein Eng* (1997) 10, 949-57, a so called "minibody" (Martin et al., *EMBO J* (1994) 13, 5303-5309), a diabody (cf. Holliger et al., *PNAS USA* (1993)90, 6444-6448), a so called "Janusis" (cf. Traunecker et al., *EMBO J* (1991) 10, 3655-3659, or Traunecker et al., *Int J Cancer* (1992) Suppl 7, 51-52), a nanobody, a microbody, an affilin, an affibody, a knottin, ubiquitin, a zinc-finger protein, an autofluorescent protein or a leucine-rich repeat protein. An example of a nucleic acid molecule with antibody-like functions is an aptamer. An aptamer folds into a defined three-dimensional motif and shows high affinity for a given target structure.

[0065] Turning now the multimerization reagent, the binding sites Z1 and Z2 of the multimerization agent can be identical (see also the Example of Fig. 3). In this case, a single multimerization agent may be used.

[0066] In the embodiment that a reversibly bond first and, optionally second agent is used, the multimerization reagent may be immobilized on a solid surface. Any solid surface (support) can be used for the immobilization of the multimerization reagent. Illustrative examples of solid surfaces on which the multimerization reagent can be immobilized include a magnetic bead, a polymeric bead, a cell culture plate, a microtiter plate, a membrane, or a hollow fiber. Hollow fibers are, for example, used as bioreactor in the Quantum® Cell

Expansion System, available from TerumoBCT Inc. (Lakewood, CO, USA). The multimerization reagent is usually covalently attached to the solid support, however, non-covalent interactions can also be used for immobilization, for example on plastic substrates, if wanted. As also explained in more detail below, the multimerization reagent can, for example, be a streptavidin or avidin mutein that reversibly binds a streptavidin binding peptide. Such streptavidin muteins can be covalently attached to any surface, for example, resin (beads) used for chromatography purification and are commercially available in such form from IBA GmbH, Göttingen, for example, as *Strep-Tactin*® Sepharose, *Strep-Tactin*® Superflow®, *Strep-Tactin*® Superflow® high capacity or *Strep-Tactin*® MacroPrep®. Other illustrative examples multimerization reagents that are readily commercially available are immobilized metal affinity chromatography (IMAC) resins such as the TALON® resins (Westburg, Leusden, The Netherlands) that can be used for the reversible immobilization of oligohistidine tagged (his-tagged) proteins in general, meaning here, for the reversible binding of a first or a second agent that carries as first binding partner C1 or second binding partner C2 an oligohistidine tag such as an penta- or hexa-histidine tag. Other examples of multimerization reagents are calmodulin sepharose available from GE Life Sciences which can be used together with a first or second agent that comprises a calmodulin binding peptide as binding partner C1 or C2 or sepharose, to which glutathion is coupled. In the case, the binding partner C1 or C2 is glutathion-S-transferase.

[0067] In other embodiments of the method of the invention the multimerization reagent can be in a soluble form. In principle, the same multimerization agents can be used as in the case of a multimerization reagent that is immobilized on a solid support. The multimerization reagent in soluble form, can for example, be a streptavidin mutein oligomer, a calmodulin oligomer, a compound (oligomer) that provides least two chelating groups K, wherein the at least two chelating groups are capable of binding to a transition metal ion, thereby rendering moiety A capable of binding to an oligohistidine affinity tag, multimeric glutathione-S-transferase, or a biotinylated carrier protein.

[0068] As explained above, the first and second agent has, in addition to the binding site that is able to bind the respective cell surface receptor molecule, a binding partner C1 or C2 (which will be referred to as "binding partner C" in the following for the ease of reference). This binding partner C is able to bind to a binding site Z of the multimerization reagent (Z means either binding site Z1 or binding site Z2 of the multimerization reagent) C. The non-covalent bond that is formed between the binding partner C that is included in the first or

second agent and the binding site(s) Z of the multimerization reagent may be of any desired strength and affinity, as long as it is disruptable or reversible under the conditions under which the method of the invention is performed. The dissociation constant (K_D) of the binding between the binding partner C that is included in the receptor binding reagent and the binding site Z of the multimerization reagent may have a value in the range from about 10^{-2} M to about 10^{-13} M. Thus, this reversible bond can, for example, have a K_D from about 10^{-2} M to about 10^{-13} M, or from about 10^{-3} M to about 10^{-12} M or from about 10^{-4} M to about 10^{-11} M, or from about 10^{-5} M to about 10^{-10} M. The K_D of this bond as well as the K_D , k_{off} and k_{on} rate of the bond formed between the binding site B of the receptor binding reagent and the receptor molecule can be determined by any suitable means, for example, by fluorescence titration, equilibrium dialysis or surface plasmon resonance. The receptor molecule binding reagent may include at least one, including two, three or more, second binding partners C and the affinity reagent may include at least two, such as three, four, five, six, seven, eight or more binding sites for the binding partner that is included in the receptor molecule binding reagent. As described in US patent 7,776,562, US patent 8,298,782 or International Patent application WO 2002/054065 any combination of a binding partner C and an affinity agent with one or more corresponding binding sites Z can be chosen, as long as the binding partner C and the binding site Z of the affinity agent are able to reversibly bind or multimerize in a (multivalent) complex, which typically goes along with an avidity effect.

[0069] The binding partner included in the first or second agent may be an oligopeptide, a polypeptide, a protein, a nucleic acid, a lipid, a saccharide, an oligosaccharide, or a polysaccharide. Such a binding partner has a higher affinity to the binding site of the multimerization reagent than to other matter. Examples of a respective binding partner include, but are not limited to, an immunoglobulin molecule, a fragment thereof and a proteinaceous binding molecule with antibody-like functions.

[0070] In some embodiments the binding partner C that is included in the first or second agent includes biotin and the affinity reagent includes a streptavidin analogue or an avidin analogue that reversibly binds to biotin.

[0071] In some embodiments the binding partner C that is included in the first or second agent includes a biotin analogue that reversibly binds to streptavidin or avidin, and the affinity reagent includes streptavidin, avidin, a streptavidin analogue or an avidin analogue that reversibly binds to the respective biotin analogue.

[0072] In some further embodiments the binding partner C that is included in the first or second agent includes a streptavidin or avidin binding peptide and the affinity reagent includes streptavidin, avidin, a streptavidin analogue or an avidin analogue that reversibly binds to the respective streptavidin or avidin binding peptide.

5 [0073] In some embodiments the binding partner that is included in the first or second agent may include a streptavidin-binding peptide Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 01) and the affinity reagent may include a streptavidin mutein (analogue) that comprise the amino acid sequence Val⁴⁴-Thr⁴⁵-Ala⁴⁶-Arg⁴⁷ (SEQ ID NO: 02) at sequence positions 44 to 47 of wild type streptavidin or the streptavidin mutein (analogue) that comprises the amino
10 acid sequence Ile⁴⁴-Gly⁴⁵-Ala⁴⁶-Arg⁴⁷ (SEQ ID NO: 03) at sequence positions 44 to 47 of wild type streptavidin, both of which are described in US patent 6,103,493, for example, and are commercially available under the trademark Strep-Tactin®. The streptavidin binding peptides might, for example, be single peptides such as the “Strep-tag®” described in US patent 5,506,121, for example, or streptavidin binding peptides having a sequential arrangement of
15 two or more individual binding modules as described in International Patent Publication WO 02/077018 or US patent 7,981,632.

[0074] In some embodiment the binding partner C of the first or second agent includes a moiety known to the skilled artisan as an affinity tag. In such an embodiment the affinity reagent includes a corresponding binding partner, for example, an antibody or an antibody
20 fragment, known to bind to the affinity tag. As a few illustrative examples of known affinity tags, the binding partner that is included in the first or second agent may include an oligohistidine, an immunoglobulin domain, maltose-binding protein, glutathione-S-transferase (GST), chitin binding protein (CBP) or thioredoxin, calmodulin binding peptide (CBP), FLAG'-peptide, the HA-tag (sequence: Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala, (SEQ ID NO: 11)), the VSV-G-tag (sequence: Tyr-Thr-Asp-Ile-Glu-Met-Asn-Arg-Leu-Gly-Lys, (SEQ
25 ID NO: 12)), the HSV-tag (sequence: Gln-Pro-Glu-Leu-Ala-Pro-Glu-Asp-Pro-Glu-Asp, (SEQ ID NO: 13)), the T7 epitope (Ala-Ser-Met-Thr-Gly-Gly-Gln-Gln-Met-Gly, (SEQ ID NO: 14)), maltose binding protein (MBP), the HSV epitope of the sequence Gln-Pro-Glu-Leu-Ala-Pro-Glu-Asp-Pro-Glu-Asp (SEQ ID NO: 13) of herpes simplex virus glycoprotein D, the “myc”
30 epitope of the transcription factor c-myc of the sequence Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu (SEQ ID NO: 15), the V5-tag (sequence: Gly-Lys-Pro-Ile-Pro-Asn-Pro-Leu-Leu-Gly-Leu-Asp-Ser-Thr, SEQ ID NO: 16), or glutathione-S-transferase (GST). In such an embodiment the complex formed between the one or more binding sites of the multimerisation

reagent, in this case an antibody or antibody fragment, and the antigen can be disrupted competitively by adding the free antigen, i.e. the free peptide (epitope tag) or the free protein (such as MBP or CBP). The affinity tag might also be an oligonucleotide tag. Such an oligonucleotide tag may, for instance, be used to hybridize to an oligonucleotide with a complementary sequence, linked to or included in the affinity reagent.

[0075] In some embodiments the binding between the binding partner C that is included in the first or second agent and one or more binding sites of the multimerization reagent occurs in the presence of a divalent, a trivalent or a tetravalent cation. In this regard in some embodiments the multimerization reagent includes a divalent, a trivalent or a tetravalent cation, typically held, e.g. complexed, by means of a suitable chelator. The binding partner that is included in the receptor binding reagent may in such an embodiment include a moiety that includes, e.g. complexes, a divalent, a trivalent or a tetravalent cation. Examples of a respective metal chelator, include, but are not limited to, ethylenediamine, ethylenediaminetetraacetic acid (EDTA), ethylene glycol tetraacetic acid (EGTA), diethylenetriaminepentaacetic acid (DTPA), N,N-bis(carboxymethyl)glycine (also called nitrilotriacetic acid, NTA), or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA). As an example, EDTA forms a complex with most monovalent, divalent, trivalent and tetravalent metal ions, such as e.g. calcium (Ca^{2+}), manganese (Mn^{2+}), copper (Cu^{2+}), iron (Fe^{2+}), cobalt (Co^{3+}) and zirconium (Zr^{4+}), while BAPTA is specific for Ca^{2+} . As an illustrative example, a standard method used in the art is the formation of a complex between an oligohistidine tag and copper (Cu^{2+}), nickel (Ni^{2+}), cobalt (Co^{2+}), or zinc (Zn^{2+}) ions, which are presented by means of the chelator nitrilotriacetic acid (NTA).

[0076] In some embodiments the binding partner C that is included in the first or second agent includes a calmodulin binding peptide and the affinity reagent includes multimeric calmodulin as described in US Patent 5,985,658 or as described herein with reference to Figure 2, for example. In some embodiments the binding partner C that is included in the first or second agent includes a FLAG peptide and the affinity reagent includes an antibody that binds to the FLAG peptide, e.g. the FLAG peptide, which binds to the monoclonal antibody 4E11 as described in US Patent 4,851,341. In one embodiment the binding partner C that is included in the first or second agent includes an oligohistidine tag and the affinity reagent includes an antibody or a transition metal ion binding the oligohistidine tag. The disruption of all these binding complexes may be accomplished by metal ion chelation, e.g. calcium chelation, for instance by adding EDTA or EGTA (supra). Calmodulin, antibodies such as 4E11 or chelated

metal ions or free chelators may be multimerized by conventional methods, e.g. by biotinylation and complexation with streptavidin or avidin or multimers thereof or by the introduction of carboxyl residues into a polysaccharide, e.g. dextran, essentially as described in Noguchi, A, et al. *Bioconjugate Chemistry* (1992) 3, 132-137 in a first step and linking calmodulin or antibodies or chelated metal ions or free chelators via primary amino groups to the carboxyl groups in the polysaccharide, e.g. dextran, backbone using conventional carbodiimide chemistry in a second step. In such embodiments the binding between the binding partner C that is included in the first or second agent and the one or more binding sites Z of the multimerization reagent can be disrupted by metal ion chelation. The metal chelation may, for example, be accomplished by addition of EGTA or EDTA.

[0077] In some embodiments, in particular, if the multimerization reagent is in soluble form and is based on streptavidin or avidin, it is an oligomer or a polymer of streptavidin or avidin or of any mutein (analogue) of streptavidin or avidin. The binding site Z is the natural biotin binding of avidin or streptavidin. The respective oligomer or polymer may be crosslinked by a polysaccharide. In one embodiment oligomers or polymers of streptavidin or of avidin or of muteins (analogs) of streptavidin or of avidin are prepared by the introduction of carboxyl residues into a polysaccharide, e. g. dextran, essentially as described in Noguchi, A, et al., *Bioconjugate Chemistry* (1992) 3,132-137 in a first step. Then streptavidin or avidin or analogues thereof may be linked via primary amino groups of internal lysine residue and/or the free N-terminus to the carboxyl groups in the dextran backbone using conventional carbodiimide chemistry in a second step. In addition, cross-linked oligomers or polymers of streptavidin or avidin or of any mutein (analogue) of streptavidin or avidin may also be obtained by crosslinking individual streptavidin or avidin molecules (the tetrameric homodimer of streptavidin or avidin is referred herein as an "individual molecule" or smallest building block of a respective oligomer or polymer) via bifunctional molecules, serving as a linker, such as glutardialdehyde or by other methods described in the art. It is, for example, possible to generate oligomers of streptavidin muteins by introducing, in a first step, thiol groups into the streptavidin mutein (this can, for example, be done by reaction the streptavidin mutein 2-iminothiolan (Trauts reagent) and by activating, in a separate reaction amino groups available in the streptavidin mutein. This activation of amino groups can be achieved by reaction of the streptavidin mutein with a commercially available heterobifunctional crosslinkers such as sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo SMCC) or Succinimidyl-6-[(β -maleimidopropionamido)hexanoate (SMPH). In a second step, the two reaction products so obtained are mixed together, leading to the reaction of the

thiol groups contained in the one batch of modified streptavidin mutein with the activated (by maleimid functions) amino acids of the other batch of modified streptavidin mutein. By this reaction, multimers/oligomers of the streptavidin mutein are formed. These oligomers can have any suitable number of "individual molecule" or streptavidin building block" higher than 3 and the oligomerization degree can be varied according to the reaction condition (see Fig. 24). After reacting these two batches of the modified streptavidin mutein, the oligomeric soluble multimerization reagent is typically isolated via size exclusion chromatography and any desired fraction can be used as multimerization reagent. Typically, the oligomers do not have (and do not need to have) a single molecular weight but they usually observe a statistical weight distribution such as Gaussian distribution. Any oligomer with more than three streptavidin homotetramers (building blocks; $n \geq 3$) can be used as soluble multimerization reagent. The oligomers might have, for example from 3 to 25 streptavidin mutein homotetramers. With a molecular weight of about 50 kDa for streptavidin muteins such as the mutein "m1" or "m2" described in more detail below, these soluble oligomers have a molecular weight from about 150 kDa to about 1250 kDa. Since each streptavidin molecule/mutein has four biotin binding sites such a multimerization reagent provides 12 to 100 binding sites Z1 (and Z2) as described herein.

[0078] In accordance with the above disclosure, in addition to such oligomeric multimerization reagents that only contain cross-linked streptavidin homotetramers, it is possible to react tetrameric streptavidin muteins to a carrier to obtain multimerization reagents that are used in the present invention. In addition to the above described reaction with a polysaccharide, it is also possible to use physiologically or pharmaceutically acceptable proteins such as serum albumin (for example human serum albumin (HSA) or bovine serum albumin (BSA) as carrier protein. In such a case, the streptavidin mutein (either as individual homo-tetramer or also in the form of oligomers with $n \geq 3$) can be coupled to the carrier protein via non-covalent interaction. For this purpose, biotinylated BSA (which is commercially available from various suppliers such as ThermoFisher Scientific, Sigma Aldrich or Vectorlabs, to name only a few) can be reacted with the streptavidin mutein. When so doing, some of the streptavidin oligomers will non-covalently bind via one or more biotin binding sites (Z1, Z2) to the biotinylated carrier protein, leaving the majority of the binding sites (Z1, Z2) of the oligomer available for binding the agents such as the first agent and optionally the second agent and any further agent as described herein. Thus, by such an approach a soluble multimerization reagent with a multitude of binding sites Z1 can be conveniently prepared (see Fig. 24). Alternatively, a streptavidin mutein (either as individual homo-tetramer or also in the

form of oligomers with $n \geq 3$) can be covalently coupled to a synthetic carrier such as a polyethylene glycol (PEG) molecule. Any suitable PEG molecule can be used for this purpose, as long as the PEG molecule and the respective multimerization reagent is soluble. Typically, PEG molecule up to a molecular weight of 1000 Da are all soluble in water or culture media that may be used in the present invention. Such PEG based multimerization reagent can be easily prepared using commercially available activated PEG molecules (for example, PEG-NHS derivatives available from NOF North America Corporation, Irvine, California, USA, or activated PEG derivatives available from Creative PEGWorks, Chapel Hills, North Carolina, USA) with amino groups of the streptavidin mutein.

[0079] Under streptavidin or wild-type streptavidin (wt-streptavidin), the amino acid sequence disclosed by Argarana et al., Nucleic Acids Res. 14 (1986) 1871-1882 is referred to. Streptavidin muteins are polypeptides which are distinguished from the sequence of wild-type streptavidin by one or more amino acid substitutions, deletions or additions and which retain the binding properties of wt-streptavidin. Streptavidin-like polypeptides and streptavidin muteins are polypeptides which essentially are immunologically equivalent to wild-type streptavidin and are in particular capable of binding biotin, biotin derivative or biotin analogues with the same or different affinity as wt-streptavidin. Streptavidin-like polypeptides or streptavidin muteins may contain amino acids which are not part of wild-type streptavidin or they may include only a part of wild-type streptavidin. Streptavidin-like polypeptides are also polypeptides which are not identical to wild-type streptavidin, since the host does not have the enzymes which are required in order to transform the host-produced polypeptide into the structure of wild-type streptavidin. The term "streptavidin" also includes streptavidin tetramers and streptavidin dimers, in particular streptavidin homotetramers, streptavidin homodimers, streptavidin heterotetramers and streptavidin heterodimers. Each subunit normally has a binding site for biotin or biotin analogues or for streptavidin-binding peptides. Examples of streptavidins or streptavidin muteins are mentioned, for example, in WO 86/02077, DE 19641876 A1, US 6,022,951, WO 98/40396 or WO 96/24606.

[0080] In a preferred embodiment, streptavidin muteins that are used as multimerization reagent are those streptavidin muteins which are described in US Patent 6,103,493 and also in DE 196 41 876.3. These streptavidin muteins have at least one mutation within the region of amino acid positions 44 to 53, based on the amino acid sequence of wild-type streptavidin. Preference is given to muteins of a minimal streptavidin, which start N-terminally in the region of amino acids 10 to 16 of wild-type streptavidin and end C-terminally in the region of amino

acids 133 to 142 of wild-type streptavidin. Examples of such preferred streptavidin muteins have a hydrophobic aliphatic amino acid instead of Glu at position 44, any amino acid at position 45, a hydrophobic aliphatic amino acid at position 46 or/and a basic amino acid instead of Val at position 47. The streptavidin mutein may be a mutein that comprises the amino acid sequence Val⁴⁴-Thr⁴⁵-Ala⁴⁶-Arg⁴⁷ (SEQ ID NO: 02) at sequence positions 44 to 47 or the streptavidin mutein (analog) that comprises the amino acid sequence Ile⁴⁴-Gly⁴⁵-Ala⁴⁶-Arg⁴⁷ (SEQ ID NO: 03) at sequence positions 44 to 47 of wild type streptavidin., Such muteins are described in US patent 6,103,493, for example, and are commercially available from IBA GmbH in the form of mutein “m1” and mutein “m2” under the trademark Strep-Tactin®.

[0081] A method according to the present invention may in some embodiments be used to deplete a sample of reagents that have previously been used in cell expansion. The first or second agent and the respective free partner (the competition agent) may, for instance, be present included in the eluate of an expansion method as described above. Using a method according to the invention such reagents may be at least essentially, including entirely removed from a sample, e.g. from a cell population. As an illustrative example, a first or second agent as defined above may be depleted from a sample to levels that are below the detection limit of e.g. FACS or Western Blot. A competition reagent (free first or second binding partner or analogue thereof) may have been used in order to terminate and control the expansion and release the cell population from the multimerization agent. This competition reagent may have a binding site that is capable of specifically binding to the binding site Z of the affinity reagent in a “removal cartridge” of WO 2013/124474. In such an embodiment the respective method of the invention may also serve in depleting the first and second agent and the competition reagent, including removing the same.

[0082] A method according to the present invention may be carried out at any temperature at which the viability of the cell population is at least essentially uncompromised. When reference is made herein to conditions that are at least essentially not harmful, not detrimental or at least essentially not compromising viability, conditions are referred to, under which the percentage of the population of cells that are to be expanded with full viability, is at least 70 %, including at least 75 %, at least 80 %, at least 85 %, at least 90 %, at least 92 %, at least 95 %, at least 97 %, at least 98 %, at least 99 % or at least 99.5 %. In some embodiments a method according to the invention is carried out at a temperature of about 20 °C or higher. Depending on the cell population to be expanded a suitable temperature range may for instance be from about 20 °C to about 45 °C, including from about 25 °C to about 40

°C, or from about 32 °C to 37 °C. In some embodiments a method according to the invention is carried out at a constant temperature value, or at a selected temperature value $\pm$ about 5 °C, $\pm$ about 4 °C, $\pm$ about 3 °C, $\pm$ about 2 °C, $\pm$ about 1 °C or $\pm$ about 0.5 °C. The person skilled in the art is able to empirically determine a suitable temperature, taking into account the nature of the cells and the expansion conditions. Typically human cells are expanded at a temperature such as 37 °C.

[0083] In a further embodiment, the invention provides an *in vitro*-method of expanding a population of cells, comprising contacting a sample comprising a population of cells with a multimerization reagent, wherein the multimerization reagent is in a soluble form and has immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells. The multimerization reagent comprises at least one binding site Z1 for the binding of the first agent, wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of binding to the binding site Z1 of the multimerization reagent. The first agent is bound to the multimerization reagent via the bond formed between the binding partner C1 and the binding site Z1, and the first agent binds to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells and thereby activating the cells. It is expressly noted here that when a soluble multimerization agent is used, the bond between the binding part C1 and the binding site Z1 does not need to be reversible.

[0084] In an embodiment of this second the multimerization agent has immobilized thereon (bound thereto) a second agent that stimulates an accessory molecule on the surface of the cells, wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is able of being bound to a binding site Z2 of the multimerization reagent. The second agent is bound to the multimerization reagent via the bond formed between the binding partner C2 and the binding site Z2, wherein the second agent binds to the accessory molecule on the surface on the surface of the cells, thereby stimulating the activated cells.

[0085] In one embodiment of this second method, the bond formed between the binding partner C1 and the binding site Z1 may be irreversible and/or also the bond formed between the binding partner C2 and the binding site Z2 may be irreversible.

[0086] In a different embodiment of this second method, the bond formed between the binding partner C1 and the binding site Z1 may be reversible. Also the bond formed between the binding partner C2 and the binding site Z2 may be reversible. In this case, the dissociation

constant (K_d) for the reversible binding between said binding site Z1 and said binding partner C1 and/or for the reversible binding between said binding site Z2 and said binding partner C2 may be in the range of 10^{-2} M to 10^{-13} M.

[0087] In this second method that is based on a soluble multimerization reagent, the first and second reagent as well as the multimerization reagent and all other reagents and cell populations can otherwise be used in the same manner as disclosed above for the method that makes use of reversible between the first or second agent and the multimerization reagent.

[0088] The invention further provides a reagent kit for expanding a population of cells, the kit comprising

(i) a multimerization reagent, wherein the multimerization reagent comprises at least one binding site Z for the reversible binding of a first agent,

(ii) a first agent that binds to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells and thereby activating the cells, wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to a binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1, and

(iii) a second agent that stimulates an accessory molecule on the surface of the cells, wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is able of reversibly binding to a binding site Z2 of the multimerization reagent, wherein the second agent is bound to the multimerization reagent via the bond formed between the binding partner C2 and the binding site Z2, wherein the second agent binds to the accessory molecule on the surface on the surface of the cells, thereby stimulating the activated cells.

[0089] The invention also provides a reagent kit for expanding a population of cells, the kit comprising

(i) a multimerization reagent, wherein the multimerization reagent is in soluble form and comprises at least one binding site Z for the reversible binding of a first agent,

(ii) a first agent that binds to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells and thereby activating the cells, wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of binding to

a binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1.

5 [0090] This second reagent kit may further comprises (iii) a second agent that stimulates an accessory molecule on the surface of the cells, wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is able of binding to a binding site Z2 of the multimerization reagent, wherein the second agent is bound to the multimerization reagent via the bond formed between the binding partner C2 and the binding site Z2.

10 [0091] A kit as disclosed herein is in particular used when the population of cells is a lymphocyte population.

[0092] In accordance with the disclosure above, the invention also provides novel multimerization reagents and novel composition comprising multimerization reagents that are capable of expanding a population of cells. Such a multimerization reagent that is capable of expanding a population of cells is a multimerisation reagent that is in soluble form and
15 comprises at least one binding site Z1 for the reversible binding of a first agent that provides a primary activation signal to the cells, wherein the multimerization reagent has reversibly immobilized thereon (bound thereto) said first agent that provides a primary activation signal to the cells; wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to the at least one binding site Z1 of the
20 multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1. It should be noted here that such a multimerization agent can have immobilized thereon any of the first agent that are described herein.

[0093] A multimerization reagent of the invention may further comprise at least one
25 binding site Z2 for the reversible binding of a second agent that stimulates an accessory molecule on the surface of the cells, wherein the multimerization reagent has reversibly immobilized thereon (bound thereto) the second agent that stimulates an accessory molecule on the surface of the cells, wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is able of binding to the at least one binding site Z2 of the
30 multimerization reagent. In this embodiment the second agent is bound to the multimerization reagent via the bond formed between the binding partner C2 and the binding site Z2.

[0094] Also in line with the disclosure given above, such a multimerization reagent is

capable of expanding a lymphocyte population or a subpopulation contained in the lymphocyte population. The lymphocyte population to be expanded may any suitable population, for example, a B cell population, a T cell population, or a natural killer cell population. The T-cell population may be an antigen-specific T cell population, a T helper cell population, a cytotoxic T cell, a memory T cell, a regulatory T cell, or a natural killer T cell population. Accordingly, in such embodiments of the multimerization reagent the first agent is able to stimulate a TCR/CD3 complex-associated signal in the T cells. The first agent present in the multimerization reagent may thus be binding reagent that specifically binds CD3, while the second agent that binds the accessory molecule may be a binding agent that specifically binds CD28 or CD137.

[0095] In embodiments of the multimerization reagent the first agent that specifically binds CD3 may be an anti-CD3-antibody, a divalent antibody fragment of an anti-CD3 antibody, a monovalent antibody fragment of an anti-CD3-antibody, and/or a proteinaceous CD3 binding molecule with antibody-like binding properties. In these embodiments, the second agent that specifically binds CD28 or CD137 may be an anti-CD28-antibody, a divalent antibody fragment of an anti-CD28 antibody, a monovalent antibody fragment of an anti-CD28-antibody, a proteinaceous CD28 binding molecule with antibody-like binding properties, an anti-CD137-antibody, a divalent antibody fragment of an anti-CD137 antibody, a monovalent antibody fragment of an anti-CD137-antibody, a proteinaceous CD137 binding molecule with antibody-like binding properties, 4-1BB ligand, and any mixture thereof. Thus, a multimerization reagent of the invention can generally have immobilized thereon one kind of first agent and a mixture of second agents, for example, an anti-CD3 antibody as first agent and for example, an anti-CD28 antibody and 4-1BB ligand as (joint) second agents.

[0096] If the multimerization reagent is to be used for the expansion of B cells, the first agent immobilized on the multimerization reagent may be a binding reagent that specifically binds CD40 or CD137. In accordance with the disclosure given herein, in such embodiments the first binding reagent that specifically binds CD40 or CD137 may be selected from an anti-CD40-antibody, a divalent antibody fragment of an anti-CD40 antibody, a monovalent antibody fragment of an anti-CD40-antibody, and a proteinaceous CD40 binding molecule with antibody-like binding properties or an anti-CD137-antibody, a divalent antibody fragment of an anti-CD137 antibody, a monovalent antibody fragment of an anti-CD137-antibody, a proteinaceous CD137 binding molecule with antibody-like binding properties, and CD40 ligand (CD154).

[0097] Also in accordance with the general disclosure of the present invention, in the multimerization reagent as described herein the binding sites Z1 and Z2 of the multimerization reagent can be identical. As described above, such a multimerization reagent may comprises an oligomer or a polymer of streptavidin, an oligomer or a polymer of avidin, an oligomer or a polymer of an analog of streptavidin that reversibly binds biotin, an oligomer or a polymer of an analog avidin that reversibly bind biotin, a reagent that comprises at least two chelating groups K, wherein the at least two chelating groups are capable of binding to a transition metal ion, thereby rendering the reagent capable of binding to an oligohistidine affinity tag, multimeric glutathione-S-transferase, multimeric calmodulin and a biotinylated carrier protein.

[0098] A novel composition provided herein that is capable of expanding a population of cells may comprise

(i) a first multimerization reagent, wherein the first multimerisation reagent is in soluble form and comprises at least one binding site Z1 for the reversible binding of a first agent that provides a primary activation signal to the cells, wherein the first multimerization reagent has reversibly immobilized thereon (bound thereto) said first agent that provides a primary activation signal to the cells, wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to the at least one binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1, and

(ii) a second multimerization reagent, wherein the second multimerization reagent is in soluble form and comprises at least one binding site Z2 for the reversible binding of a second agent that stimulates an accessory molecule on the surface of the cells, wherein the multimerization reagent has reversibly immobilized thereon (bound thereto) said second agent that stimulates an accessory molecule on the surface of the cells, wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is able of binding to the at least one binding site Z2 of the multimerization reagent, wherein the second agent is bound to the multimerization reagent via the bond formed between the binding partner C2 and the binding site Z2.

[0099] Such a novel composition is, for example, the reaction mixture used in Example 13, in which two separate multimerization reagents were functionalized either with an α CD3 Fab fragment alone or an α CD28 Fab fragment alone. It is noted in this context, that such a

composition was shown in Example 13 to have the same expansion efficiency as a single multimerization reagent on which both the first agent and the second agent are jointly immobilized. Thus, the combined use of two or more multimerization reagents being functionalized individually with only one type of reagent (for example, one first or one second agent) is functionally equivalent to using for the expansion one joint multimerization reagent which has immobilized thereon both a first agent and a second agent. In this context, it is also noted that a multimerization reagent of the present invention be functionalized with as many agents (for example, one, two, three, four or even more agents) that are intended to be used for the expansion of a selected cell population. A third or fourth agent may, for example, for example provide a stimulus for the expansion of a desired subpopulation of cells. See in this context, for instance, Example 13 in which a soluble multimerization reagents was reversibly functionalized with three reagents, namely a α CD3 Fab fragment as first reagent, a α CD28 Fab fragment as second reagent and a α CD8 Fab fragment as third reagent to enrich the subpopulation of CD8⁺ T cells in a sample of a population of CD3⁺ T cells (lymphocyte). By using such a combinations of agents that can all be reversibly immobilized on the same multimerization reagent, the present invention allows for the possibility to preferentially expand or selectively enrich any desired cell (sub)population from an sample that, for example, comprises a variety of different subpopulations. In this context, it is noted that it however also possible to use for this purpose use three different multimerization reagents, for example, a first multimerization reagent that is functionalized with only a α CD3 Fab fragment, a second multimerisation reagent that is functionalized with a α CD28 Fab fragment and a third multimerization reagent that is functionalized with a α CD8 Fab fragment. Likewise, it is possible to use only two different multimerization reagents, a first multimerization reagent that is functionalized with only a α CD3 Fab fragment and a second multimerisation reagent that is functionalized with both a α CD28 Fab fragment and a α CD8 Fab fragment. Accordingly, the present invention allows to design any kind of wanted expansion reagent in a modular fashion.

[00100] The invention also provides an *in vitro*-method of serially expanding a population of lymphocytes, wherein the population of lymphocytes comprises T cells. This method comprises

contacting a sample comprising the T cell comprising population of lymphocytes with a multimerization reagent,

wherein the multimerization reagent is in a soluble form and has reversibly immobilized

thereon (i) a first agent that provides a primary activation signal to the T cells and (ii) a second agent which stimulates an accessory molecule on the surface of the T cells,

wherein the multimerization reagent comprises at least one binding site Z1 for the reversible binding of the first agent,

5 wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to the binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1,

wherein the multimerization reagent comprises at least one binding site Z2 for the reversible
10 binding of the second agent,

wherein the second agent comprises at least one binding partner C2, wherein the binding partner C2 is able of reversibly binding to the binding site Z2 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C2 and the binding site Z2,

15 wherein the first agent binds to a receptor molecule on the surface of the T cells, thereby providing a primary activation signal to the cells and thereby activating the T cells,

wherein the second agent binds to the accessory molecule on the surface of the T cells, thereby stimulating the activated cells, the first agent and the second agent thereby together inducing the T cells to expand.

20 **[00101]** In this method contacting the sample that contains the population of lymphocytes that in turn contains the T cell population with the soluble multimerization reagent that has immobilized thereon the first and second agent results in specific binding of T cells to the multimerization reagent.

[00102] The contacting of the sample comprising the T cell comprising population of
25 lymphocytes with the multimerization reagent can be carried out in a bioreactor such as a hollow-fiber bioreactor (e.g. hollow fiber bioreactor of the Quantum® cell expansion system) or a plastic bag bioreactor (e.g. Cellbag® used in Xuri Cell Expansion System W25 from GE Healthcare).

[00103] This method further comprises contacting the population of lymphocytes
30 (reaction mixture containing the T cells bound to the multimerization reagent via the first agent

and the second agent) with (i) a free first binding partner C1 or an analogue thereof capable of disrupting the bond between the first binding partner C1 and the binding site Z1 and (ii) a free second binding partner C2 or an analogue thereof, capable of disrupting the bond between the second binding partner C2 and the binding site Z2. By so doing the reversible bond between said binding partner C1 of the first agent and said binding sites Z1 as well as the reversible bond between said binding partner C2 of the second agent and said binding site Z2 of said multimerization reagent is disrupted, thereby releasing in an eluate the T cells bound to the multimerization reagent via the first agent and the second agent and stopping the expansion of the T cells.

[00104] In this method the eluate (the reaction mixture in which the expansion reaction has been terminated by addition of the free first partner(s) or analogue(s) thereof) that contains the expanded T cell population may be exposed to chromatography on a suitable (first) stationary phase. The (first) stationary phase may be a gel filtration matrix and/or an affinity chromatography matrix as described in International patent application WO 2013/124474. This gel filtration and/or affinity chromatography matrix comprises an affinity reagent, wherein the affinity reagent comprises a binding site Z1 and/or Z2 specifically binding to the binding partner C1 and/or C2 comprised in the first agent or the second agent. By so doing the first agent, the second agent, the first binding partner C1 and/or the free second binding partner C2 are immobilized on the stationary phase. In this method, the first stationary phase is fluidly connected to the bioreactor.

[00105] In one of the embodiments of this serial expansion the binding sites Z1 and Z2 of the multimerization agent are identical. In addition, a single multimerization agent may be used. When a soluble multimerization agent is used, the T cell population (or the expanded cell population in general) is separated from the soluble multimerization reagent. The separation/removal might be carried out using a second stationary phase. For this purpose, a mixture comprising the T cells and the soluble multimerization reagent are exposed, before or after being applied onto the first stationary phase described above, to chromatography on a suitable second stationary phase. This secondary stationary phase may be a gel filtration matrix and/or affinity chromatography matrix, wherein the gel filtration and/or affinity chromatography matrix comprises an affinity reagent. The affinity reagent comprised on the chromatography resin include a binding partner D that (specifically) binds to the binding site Z1 and/or binding site Z2, if present, of the multimerization reagent, thereby immobilizing the multimerization reagent on the stationary phase. If a streptavidin based multimerization agent

is used and both first and second agents have a streptavidin binding peptide as binding partner C1 or C2, the binding partner D that is comprised in the affinity reagent of this second stationary phase can be biotin. The soluble oligomer of streptavidin or of a streptavidin mutein that is used as multimerization reagent then binds to the biotin that is usually covalently
5 coupled to a chromatography matrix such as biotin-sepharoseTM that is commercially available.

[00106] In this method of serial expansion the first agent may stimulates a TCR/CD3 complex-associated signal in the T cells and the first agent may thus be a binding reagent that specifically binds CD3. In addition, the accessory molecule on the T cell may be CD28. In this case the second agent that binds the accessory molecule is a binding reagent that specifically
10 binds CD28.

[00107] In this method of serial expansion, the T cells may be transfected either during or after expansion e.g. with a T cell receptor (TCR) or a chimeric antigen receptor (CAR, also known as artificial T cell receptor). This transfection for the introduction of the gene of the desired receptor can be carried out with any suitable retroviral vector, for example. The
15 genetically modified cell population can then be liberated from the initial stimulus (the CD3/CD28 stimulus, for example) and subsequently be stimulated with a second type of stimulus e.g. via the de novo introduced receptor). This second type of stimulus may comprise an antigenic stimulus in form of a peptide/MHC molecule, the cognate (cross-linking) ligand of the genetically introduced receptor (e.g. natural ligand of a CAR) or any ligand (such as an
20 antibody) that directly binds within the framework of the new receptor (e.g. by recognizing constant regions within the receptor). Cf. in this respect, Cheadle et al, "Chimeric antigen receptors for T-cell based therapy" Methods Mol Biol. 2012; 907:645-66 or Barrett et al., Chimeric Antigen Receptor Therapy for Cancer Annual Review of Medicine Vol. 65: 333-347 (2014).

25 [00108] In this method, the population of lymphocytes that comprises T cells can be a population of peripheral blood mononucleated cells (PBMC) or a population of enriched or purified T cells. The population of lymphocytes may, for example, be derived from whole blood, or from a non-mobilized apheresis product or a frozen tissue preparation.

[00109] In this method of serial expansion that is based on a soluble multimerization
30 reagent, the first and second reagent as well as the multimerization reagent and all other reagents and cell populations can otherwise be used in the same manner as disclosed above for the method that makes use of reversible between the first or second agent and the

multimerization reagent.

[00110] The invention is further directed to an arrangement of a bioreactor and a first stationary phase for chromatography. The bioreactor is suitable for the expansion of cells, and the stationary phase is suitable for cell separation and removal of reagents. The first stationary phase is a gel filtration matrix and/or affinity chromatography matrix, wherein the gel filtration and/or affinity chromatography matrix comprises an affinity reagent, wherein the affinity reagent comprises a binding site Z1 specifically binding to a binding partner C1 comprised in a first agent and/or the affinity reagent comprises a binding site Z2 specifically binding to a binding partner C2 comprised in a second agent. The first stationary phase is thereby being suitable of immobilizing thereon the first agent and/or the second agent, the first binding partner C1 and/or the free second binding partner C2. In addition the bioreactor and the stationary phase are fluidly connected. This arrangement can be used in the serial expansion as explained above and can be integrated into known cell expansion systems such as the Quantum® cell expansion system) or the Xuri Cell Expansion System W25.

[00111] In this arrangement the first stationary phase is either comprised in a chromatography column or is a planar stationary phase. The arrangement may further comprises a second stationary phase which is fluidly connected to the first stationary phase. The secondary stationary phase may be a gel filtration matrix and/or affinity chromatography matrix, wherein the gel filtration and/or affinity chromatography matrix comprises an affinity reagent. This affinity reagent may comprise a binding partner D that (specifically) binds to the binding site Z1 of the multimerization reagent, thereby being suitable of immobilizing the multimerization reagent on the stationary phase.

[00112] The invention is further directed to an apparatus for purification and expansion of a population of cells, the apparatus comprising at least one arrangement of a bioreactor and a first stationary phase or a second stationary phase for chromatography as defined above.

[00113] The apparatus may further comprise a plurality of arrangements of a bioreactor and a stationary phase being fluidly connected in series.

[00114] The apparatus may comprise a sample inlet being fluidly connected to the bioreactor of the arrangement of a bioreactor and the stationary phase for chromatography. The apparatus may also comprise a sample outlet for purified and expanded target cells, the sample outlet being fluidly connected to the stationary phase of the last of the at least one arrangement of a bioreactor and the stationary phase for chromatography.

[00115] Finally, the apparatus may be designed as a functionally closed system.

[00116] As one of ordinary skill in the art will readily appreciate from the disclosure of the present invention, other compositions of matter, means, uses, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve
5 substantially the same result as the corresponding exemplary embodiments described herein may likewise be utilized according to the present invention.

Experimental Examples

Example 1: Stimulation/expansion of CD3+ T responder cells with α CD3/ α CD28 Fab fragments that were reversibly immobilized on beads coated with the streptavidin mutein Strep-tactin®.

5 [00117] 300.000 CD3+CD62L-responder T cells (Tresp, isolated by serial magnetic enrichment from a non-mobilized donor apheresis product) were labeled with 3 μ M CFSE and stimulated with 5 μ l of a 15 μ l preparation of Strep-tactin® beads (10 mg magnetic particles/ml, loaded with 35 μ g Strep-tactin®/mg beads) either loaded with 0.5 μ g α CD3 Fab fragment alone, 0.5 μ g α CD28 Fab fragment alone or a mixture of 0.5 μ g α CD3 Fab fragment
10 and 0.5 μ g α CD28 Fab.

 [00118] The α CD3 Fab fragment used was derived from the CD3 binding monoclonal antibody produced by the hybridoma cell line OKT3. The hybridoma cell line OKT3 and the OKT3 antibody are described in US Patent 4,361,549, the cell line has been deposited under accession number ATCC® CRL-8001™). The CD28 Fab used was derived
15 from the monoclonal anti-human CD28 antibody CD28.3 (Vanhove et al, BLOOD, 15 July 2003, Vol. 102, No. 2, pages 564-570). The nucleotide sequence of the variable domains of this antibody CD28.3 has been deposited in GenBank in the form of a synthetic single chain Fv construct anti-human CD28 antibody scFv28.3 under GenBank accession number AF451974.1).

20 [00119] Both Fab fragments were recombinantly produced in *E. coli* as described in International patent applications WO2013/011011 and WO 2013/124474 carrying as constant domains (CH1 and Ckappa) an IgG1 consensus sequence. The heavy chain of both Fab fragments was carboxy-terminally fused with a sequential arrangement of two streptavidin binding modules (SAWSHPQFEK(GGGS)₂GGSAWSHPQFEK, (SEQ ID NO: 07)), that is
25 commercially available as “Twin-Strep-tag® from IBA GmbH, Göttingen, Germany). The α CD3 Fab fragment was used as first agent with the streptavidin binding peptide serving as binding partner C 1 and the α CD28 Fab fragment was used as second agent with the streptavidin binding peptide serving as binding partner C2. The (tetrameric) streptavidin mutein “Strep-tactin® serves as multimerization reagent on which both Fab fragments were
30 reversibly immobilized.

 [00120] In the expansion experiment, Tresp cells stimulated with blank beads

(no Fab) served as negative control. Tresp cells were seeded in triplets in 48-well plates along with 300.000 CD3 cells autologous feeder cells (irradiated with 30Gy) in 3ml complete cell culture medium (RPMI (Gibco) supplemented with 10% (v/v) fetal calf serum, L-glutamine, b-mercapto ethanol, HEPES, penicillin, streptomycine and gentamycine) supplemented with 10U/ml interleukin 2 (IL-2). The cells were incubated at 37°C without media exchange and analyzed after 4 days by FACS analysis. FACS staining and analysis was done after 10min incubation with 100µM D-biotin. One representative plot for each condition is shown in **Fig. 4**. Plots show live CD3+ cells that were stained with propidium iodide (PI) for live/dead discrimination. **Fig. 4a** is a histogram showing size-distribution (forward scatter) of stimulated cells. **Fig. 4a** shows that a specific cell population of Tresp cells was stimulated and expanded (increase in size/number compared to the unstimulated “beads only” control) when incubated in the presence of beads on which a mixture of 0.5µg αCD3 Fab fragment and 0.5µg αCD28 Fab was immobilized, after being stimulated *in vitro* with αCD3/αCD28 Fab fragments that were reversibly immobilized on beads coated with the streptavidin mutein Strep-tactin®. **Fig. 4B** depicts histograms of the dilution of the proliferation dye CFSE representing the degree of proliferation according to the number of cells per cell division (indicated on top of **Fig. 4B**, 0 represents undivided cells; 5 represents cells that have gone through at least 5 divisions). It can be seen from **Fig. 4B** that the population of T cells stimulated with the beads on which a mixture of 0.5µg αCD3 Fab fragment and 0.5µg αCD28 Fab was immobilized have mostly gone through three cell divisions and represent a more uniform proliferation pattern than with a single stimulus alone (small number of cells within the undivided peak “0”). The increased absolute amount of proliferation (more cells have proliferated uniformly after 4d stimulation with αCD3 and αCD28 functionalized beads) is also represented by a more intense consumption of media as depicted by a indicator color change to yellow in **Fig. 4C**.

Example 2: Analysis of the differential intracellular calcium mobilization in Jurkat cells

[00121] Real-time low-cytometric analysis of the differential intracellular calcium mobilization induced in Jurkat cells that are either labeled with the αCD3 antibody clone OKT3 or with Fab fragments of OKT3 being multimerized with Strep-tactin® was examined here.

[00122] For this purpose, Jurkat cells were loaded with the calcium-sensitive dye Indo-1-AM and calcium release was triggered by injection of either αCD3 monoclonal antibody OKT3 (produced by the hybridoma cell line OKT3, see above, black squares) or αCD3 Fab fragments (derived from the parental cell line OKT3) that were multimerized by

reversible binding of its streptavidin binding peptide to soluble Strep-Tactin fluorescently conjugated with phycoerythrin. In the case of the intact multimeric OKT3 Fab-Strep-Tactin complexes, the calcium release was triggered over an identical time period as with the parental antibody clone (dark grey triangles). Activation of cells could be completely avoided by injection of D-biotin treated, pre-dissociated Fab-Strep-Tactin complexes (light grey circles) identical to injection of the PBS negative control (inverted white triangles). Application of ionomycin served as positive control for calcium influx. Time-resolved changes in intracellular Ca^{2+} concentration were monitored by flow-cytometry based on the change in FL6/FL7 ratio. It can be seen from **Fig. 5A** that both the parental antibody OKT3 as well as the multimerized monovalent Fab fragment of OKT3 effected calcium release, meaning that the multimerized monovalent Fab fragment of OKT3 is essentially as functional as the parental antibody. Notably, the multimeric OKT3 Fab fragment was not able to trigger calcium release if biotin was added to Strep-tactin on which the OKT3 Fab fragment was immobilized prior to the addition of the Streptactin-OKT3 Fab fragment. In this case, the biotin disrupted the reversible bond formed between Strep-tactin as multimerization agent and the OKT3 Fab fragment. The monovalent Fab fragment was therefore displaced from the multimerisation agent and after dissociation was not able to trigger calcium release by binding to CD3 of the Jurkat cells.

[00123] In the experiments shown in **Fig. 5B** indo-1-AM-labeled Jurkat cells were activated by OKT3 derived αCD3 Fab-Strep-Tactin-complexes as described in Fig. 5a. Injection of intact (upper graph) or pre-dissociated complexes (lower graph) served as positive or negative controls respectively. In addition, stimulation of cells with intact Fab-Strep Tactin-complexes followed by subsequent injection of D-biotin (near the peak activation at $t=140\text{s}$) resulted in abrupt disruption of αCD3 Fab-multimer signaling (middle graph). Injection of ionomycin into the pre-dissociated Fab complex group served as positive control. Data are representative of three different experiments. Importantly, **Fig. 5B** shows that the addition of D-biotin to the sample rapidly displaces the Fab fragment from the Strep-tactin multimerization agent, thereby effectively terminating the calcium release even under ongoing calcium stimulation and demonstrating that the dissociated OKT3 Fab fragment is not any longer biologically active. Likewise, the multimeric OKT3 Fab fragment was also not able to trigger calcium release when biotin was added to the Strep-tactin-OKT3 Fab fragment multimer prior to the addition of the Streptactin-OKT3 Fab sample to the Jurkat cells.

Example 3: Reversible staining of cells by CD3 Fab-multimers

[00124] This Example examines the reversible staining of cells by CD3 Fab-multimers. Freshly isolated PBMCs were stained with either the α CD3 monoclonal antibody clone OKT3 (left dot plot, parental clone for the Fab-multimers) or cognate phycoerythrin (PE)-labeled OKT3 Fab-multimers and analyzed either before (second left column) or after treatment with D-biotin (middle column). Remaining Fab monomers were then detected after subsequent washing steps using fresh PE-labeled Strep-Tactin® (second right column). Secondary Fab-multimer staining of reversibly stained cells served as control (right column). Only live CD3 cells which are negative in staining with propidium iodide (PI) for live/dead discrimination are shown in **Fig. 6**. Numbers in dot plots indicate the percentage of cells within gates. This experiment shows that the staining of CD3+ PBMCs with an anti-CD3 Fab fragment multimerized with Streptactin as multimerization reagent is fully reversible by addition of D-biotin and that the monovalent Fab fragment alone does not bind to the CD3 molecule present on PBMCs.

Example 4: Reversible isolation of cells by CD28 Fab-multimers

[00125] This Example shows the isolation of cells by reversible binding of anti-CD28 Fab fragments multimerized with *Strep*-Tactin® magnetic particles (the magnetic particles are available from IBA GmbH Göttingen, Germany). The Fab fragments derived from the antibody CD28.3 described in Example 1 above were used for this purpose. CD28+ cells were selected/isolated by Fab-multimer magnetic cell selection from freshly isolated PMBCs as essentially described in International Patent Application WO2013/011011. Before selection cells were control stained with either the cognate fluorescent α CD28-multimers (left dot plot) or with an antibody directed against the immunoglobulin kappa light chain (second left dot plot, α -Ig kappa mAb) as a control staining. After selection, CD28+ cells were treated with D-biotin and subsequently washed to remove magnetic beads and Fab-monomers. Liberated CD28+ cells were subsequently (re-) stained either with CD28 Fab-multimers (second right dot plot) or with the α -Igkappa mAb (right dot plot) to detect potentially remaining Fab-monomers. Only live (PI^{negative}) CD3+ cells are shown. Numbers in dot plots indicate the percentage of cells within gates. **Fig. 7** shows that CD28+ cells can be isolated from PMBC using such multimerized anti-CD28 Fab fragment and that all isolation reagents including the anti CD28 Fab-monomers can be removed after selection.

Example 5: Stimulation/expansion of CD3+ T responder cells with α CD3/ α CD28

Fab fragments that were reversibly immobilized on soluble Strep-tactin

[00126] In this example CD3⁺ T responder cells (isolated by magnetic selection from a sample of fresh PBMCs obtained from a Ficoll gradient) were expanded after *in vitro* stimulation with α CD3/ α CD28 Fab fragments that were reversibly immobilized on soluble oligomeric Strep-tactin® acting as a soluble multimerization reagent. The oligomeric Strep-tactin® was obtained by polymerizing Strep-tactin® with sulfo SMCC (sulfo succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, product # 22122 Thermo Scientific) and iminothiolan (product # 26101 Thermo Scientific) according to the protocol of the manufacturer (Thermo Scientific). The oligomeric streptavidin were separated from monomeric (unreacted) and dimeric streptavidin mutein by size exclusion chromatography and the so obtained fraction of the oligomeric streptavidin mutein ($n \geq 3$) was used as soluble multimerization reagent.

[00127] For the *in vitro* expansion, 300.000 CD3⁺ responder T cells (Tresp) were labeled with 2 μ M Carboxyfluorescein succinimidyl ester (CFSE) and stimulated with varying amounts of a preparation of soluble Strep-tactin® oligomers on which a combination of the above described α CD3 OKT3 Fab fragment and the α CD28 Fab fragment of the antibody 28.3 (both carrying the above-mentioned Twin-Strep-tag® as streptavidin binding peptide at the heavy chain) were immobilized. ("1x" corresponds to 3 μ g multimerized Streptactin functionalized with 0.5 μ g of the α CD3- and 0.5 μ g α CD28 monomeric Fab fragment, the numbers "0.5x", "2x" and "5x" indicate the respective n-fold amount of "1x"). Tresp cells either left unstimulated or were stimulated with blank Strep-tactin multimers (no Fab) served as negative controls. Tresp cells were seeded in duplicates in 48-well plates along with 300.000 CD3 negative autologous feeder cells (irradiated with 30Gy) in 1ml cell culture medium supplemented with 20U/ml IL-2. Cells were incubated at 37°C without media exchange and proliferation was analyzed according to CFSE dilution after 5 days by FACS analysis. **Fig. 8A** shows the increase in the size distribution of proliferating cells after 5 days in culture compared to the negative controls. **Fig. 8B** shows that CD3⁺ Tresp cells were properly stimulated and proliferated vigorously when incubated with soluble oligomeric Strep-tactin® (as compared to solid Streptactin magnetic particles in Fig.4) on which a mixture of α CD3 Fab and α CD28 Fab fragments were immobilized. The results in Fig. 8a and 8b indicate that under these *in vitro* conditions most of the CD3⁺ T responder cells divided (2 to 5 cell divisions) after engagement of the surface CD28 and TCR/CD3 complex with the α CD3 and α CD28 Fab fragments that were reversibly immobilized on soluble Strep-tactin® oligomers. After *in vitro*

expansion the soluble Fab-Strep-Tactin stimulation reagents were dissociated and removed after D-biotin treatment. The dissociation and removal of monomeric Fab fragments was flow-cytometrically analyzed by restaining cells with phycoerythrin label *Strep-Tactin*® (ST-PE). A representative histogram (dark grey histogram) is shown compared to the appropriate ST-PE only negative control (light gray histogram). It can be seen from **Fig. 8C** that both Fab fragments had completely dissociated and were entirely removed from the expanded cells. **Fig. 8D** shows the absolute number of live (trypan blue negative) cells after 5 days. The number was counted using a Neubauer counting chamber and plotted against the respective stimulation condition. Median cell numbers are shown in **Fig. 8D**; error bars indicate standard deviation (SD). **Fig. 8D** shows that all which mixtures of α CD3 Fab fragments and α CD28 Fab fragments that were immobilized on a soluble Strep-tactin multimerization reagent were equally effective in expanding the CD3⁺ cells and resulted in an approx. 4-fold increase of absolute cell numbers.

Example 6: Kinetics of proliferation of purified CD4⁺ and CD8⁺ T responder cells stimulated *in vitro* with reversible α CD3/ α CD28 Fab-Streptamer multimers without medium exchange

[00128] In this example the expansion kinetics of proliferation of purified CD4⁺ and CD8⁺ T responder cells (Tresp) that were stimulated *in vitro* with α CD3/ α CD28 Fab fragments that were reversibly immobilized soluble oligomeric streptavidin muteins were examined. For this purpose, soluble oligomeric Strep-tactin® mutein of two different sizes served as soluble multimerization reagent. The first kind of oligomeric Strep-tactin® was the fraction of the oligomeric streptavidin mutein ($n \geq 3$) obtained in Example 5 (also referred herein as “conventional Streptactin® backbone”, illustrated by the triangle symbol with the tip on top in Fig. 13). The second kind of this oligomeric streptavidin mutein used as soluble multimerization reagent was an oligomeric streptavidin mutein ($n \geq 3$) that was reacted with biotinylated human serum albumin (also referred herein as “large Streptactin® backbone”).

[00129] In this example 500.000 purified CD4⁺ or CD8⁺ responder T cells (Tresp) were separately stimulated with these two different Streptamer multimers as explained above, i.e. with either the Streptactin backbone of Example 5 (using a solution with a concentration of 1mg oligomeric streptavidin mutein/ml) or with the large Streptactin backbones (0.1mg/ml). 3 μ l of the both different backbones were either loaded with a combination of 0.5 μ g of the α CD3 and 0.5 μ g α CD28 Fab used in the earlier Examples that carried a streptavidin binding

peptide SAWSHPQFEK(GGGS)₂GGSAWSHPQFEK (SEQ ID NO: 07) at the C-terminus of the heavy chain of the Fab fragment. In addition, 4.5µl of the conventional Streptactin backbone was loaded with 0.5µg αCD3 Fab fragment, 0.5µg αCD8 Fab fragment (IBA GmbH Göttingen, that also carries at the C-terminus of the Fab fragment the streptavidin binding peptide SAWSHPQFEK(GGGS)₂GGSAWSHPQFEK (SEQ ID NO: 07) and 0.5µg αCD28 Fab fragment. Untreated (unstimulated) Tresp cells served as negative control and Tresp cells stimulated with commercially available Dynabeads (beads on which αCD3 and αCD28 monoclonal antibodies are irreversible immobilized) as positive control. Tresp cells were seeded in duplicates in 48-well plates in 1ml cell culture medium (RPMI 1640 (Gibco) supplemented with 10% (v/v fetal calf serum, 0.025% (w/v) L-glutamine, 0.025% (w/v) L-arginine, 0.1% (w/v) HEPES, 0.001% (w/v) gentamycine, 0.002% (w/v) streptomycine, 0.002% (w/v) peniciline) supplemented with 30U/ml IL-2. Cells were incubated at 37°C without media exchange and cell count was analyzed after 1, 3 and 6 days. In the experiments of **Fig. 13** the expansion was carried out without medium exchange. The results for the CD4+ T responder cells are shown in **Fig.13A**, the results for the CD8+ T responder cells are shown in **Fig. 13B**, with the graphs representing degree of proliferation according to the number of cells harvested per time point for CD4+ Tresp (**Fig. 13A**) and for CD8+ Tresp in **Fig.13B**.

[00130] As can be seen from **Fig. 13A** the “smaller” soluble multimerization reagent on which αCD3 and αCD28 Fab fragments were reversibly immobilized provided for the same amount of expansion of CD4+ T cells as Dynabeads (which are so far the standard reagent for the expansion of T cells), while the “larger” oligomeric soluble streptactin provided for even better expansion compared to Dynabead. This improvement might be caused by the soluble “larger oligomeric multimerization reagent” being able to bind to more T cells at the same time than the “smaller” soluble oligomer, thereby being able to stimulate more CD4+ T cells than the “smaller” oligomer.

[00131] As evident from **Fig. 13B**, using the soluble multimerization reagents of the present invention CD8+ T cells could be expanded within the first 3 days at least as efficiently as with Dynabeads. Notably, in this time period, the expansion experiment that used a soluble multimerization reagent that in addition to αCD3 and αCD28 Fab fragments (as first and second agent) carried reversibly immobilized thereon αCD8 Fab fragment, showed the best degree of expansion under these culturing conditions. This indicates that it is possible by using a stimulus that is specific for a particular sub-population of cells (here the αCD8 Fab fragment) to increase or modulate the selectivity of the expansion, thereby being able to obtain larger

amounts of a desired cell (sub)-population.

[00132] Thus, summarizing the above, Example 6 shows that the functionality of the soluble multimerization reagent used in the present invention in terms of triggering expansion of T cells is comparable to the current standard methodology of using Dynabeads for this purpose. However, since the stimulation can be controlled (and terminated, if wanted) by adding a competitor such as biotin in the case of a streptavidin based reversible interaction between the first and second agent and the multimerization reagent, the present invention provides a significant advantage over the Dynabeads technology since the expansion conditions can be optimized (it would for example be possible to stop the stimulation in the experiment of **Fig.13B** after 3 days). In addition, since the soluble multimerization reagent can be easily removed from the reaction (for example, by immobilizing the reagent on a biotinylated column after the expansion reaction), the expansion method of the invention can be carried out and automated in closed systems that are, for example, needed for GMP production of cells for therapeutic purposes, without having to deal with the removal of beads such as Dynabeads.

Example 7: Kinetics of proliferation of purified CD4+ and CD8+ T responder cells stimulated *in vitro* with reversible α CD3/ α CD28 Fab-Streptamer multimers with medium exchange

[00133] Also in this example the expansion kinetics of proliferation of purified CD4+ and CD8+ T responder cells (Tresp) that were stimulated *in vitro* with α CD3/ α CD28 Fab fragments that were reversibly immobilized on soluble oligomeric streptavidin muteins were examined. For this purpose, soluble oligomeric Strep-tactin® mutein of two different sizes served as soluble multimerization reagent. The first kind of oligomeric Strep-tactin® was the fraction of the oligomeric streptavidin mutein ($n \geq 3$) obtained in Example 5 (also referred herein as “conventional Streptactin® backbone”, illustrated by the triangle symbol with the tip down in Fig. 13). The second kind of this oligomeric streptavidin mutein used as soluble multimerization reagent was obtained by reacting the oligomeric Strep-tactin ($n \geq 3$) obtained in Example 5 with biotinylated human serum albumin. This soluble oligomeric multimerization reagent is also referred herein as “large Streptactin® backbone.”

[00134] In this example, 400.000 purified CD4+ or CD8+ responder T cells (Tresp)

were separately stimulated with these two different Streptamer multimers as explained above, i.e. with either the Streptactin backbone of Example 5 (1.0 mg/ml) or with the large Streptactin backbones (0.1mg/ml). 3 μ l of both the different backbones were either loaded with a combination of 0.5 μ g α CD3 and 0.5 μ g α CD28 Fab fragments described above. In addition, 4.5 μ l of the Streptactin backbone of Example 5 was loaded with 0.5 μ g α CD3, 0.5 μ g α CD8 Fab and 0.5 μ g α CD28 Fab fragment as described above. Untreated (unstimulated) Tresp cells served as negative control and Tresp cells stimulated with Dynabeads (on which α CD3 and α CD28 monoclonal antibodies are irreversible immobilized) as positive control. Tresp cells were seeded in duplicates in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2. Cells were incubated at 37°C with media exchange on day 3 and cell count was analyzed after 1, 3 and 6 days. The results for the CD4+ T responder cells are shown in **Fig.14A**, the results for the CD8+ T responder cells are shown in **Fig. 14B**, with the graphs representing degree of proliferation according to the number of cells harvested per time point for CD4+ Tresp (**Fig. 14A**) and for CD8+ Tresp in **Fig.14B**.

[00135] As can be seen from **Fig. 14A** the soluble multimerization reagents of the present invention on which α CD3 and α CD28 Fab fragments were reversibly immobilized provided for better expansion of CD4+ T cells than Dynabeads.

[00136] As evident from **Fig. 14B**, using the soluble multimerization reagents of the present invention CD8+ T cells could be expanded within the first 6 days at least as efficiently as with Dynabeads. Notably, in this time period, the expansion experiment that used the larger soluble multimerization reagent that carried α CD3 and α CD28 Fab fragments (as first and second agent) showed the best degree of expansion under these culturing conditions. This might again be caused by the soluble “larger oligomeric multimerization reagent” being able to bind to more T cells at the same time than the “smaller” soluble oligomer, thereby being able to stimulate more CD4+ T cells than the “smaller” oligomer.

Example 8: Expansion kinetics of purified CD4+ and CD8+ T cell cultures with or without medium exchange

[00137] In this Example the combined data from Examples 6 and 7 were normalized on input cell number for the “smaller” soluble multimerization reagent and positive and negative control. No normalization data was obtained on the “larger” multimerization reagent. As explained in Examples 6 and 7, 400.000 to 500.000 CD4+ or CD8+ responder T cells (Tresp) were stimulated with 3 μ l of a preparation of Streptactin multimers (1mg/ml; on which 0.5 μ g

α CD3 Fab fragment and 0.5 μ g α CD28 Fab fragment were immobilized. Untreated (unstimulated) Tresp cells served as negative control and Tresp cells stimulated with Dynabeads as positive control. Tresp cells were seeded in duplicates in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2. Tresp cells were seeded in duplicates in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2. Cells were incubated at 37°C with media exchange (straight lines in **Fig. 15**) or without media exchange (dashed lines in **Fig. 15**) on day 3 and cell count was analyzed after 1, 3 and 6 days. As evident from the normalized data of **Fig. 15A**, the “smaller” soluble multimerization reagent on which α CD3 and α CD28 Fab fragments were reversibly immobilized yielded an about 2.5 fold expansion of CD4⁺ T cells, while the expansion using Dynabeads yielded an about 1.8 fold expansion rate. Thus, the use of a soluble multimerization reagent of the invention even provides for an improvement in the expansion of CD4⁺ T cells over Dynabeads. Similarly, **Fig. 15B**, confirms that using the soluble multimerization reagents of the present invention CD8⁺ T cells could be expanded within the first 3 days at least as efficiently as with Dynabeads.

Example 9: Early cluster formation after activation of purified CD4⁺ and CD8⁺ T responder cells stimulated in vitro with reversible α CD3/ α CD28 Fab-Streptamer multimers

[00138] In this Example, 400.000 CD4⁺ or CD8⁺ responder T cells (Tresp) were stimulated with 3 μ l of a preparation of oligomeric Streptactin multimerization reagent (1mg/ml) loaded with a combination of 0.5 μ g α CD3- and 0.5 μ g α CD28 Fab. Untreated (unstimulated) Tresp cells served as negative control and Tresp cells stimulated with Dynabeads as positive control. Tresp cells were seeded in duplicates in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2. Cells were incubated at 37°C and microscopically analyzed after 1 and 2 days. Stimulation of CD4⁺ Tresp (**Fig. 16A**) and CD8⁺ Tresp (**Fig. 16B**) are shown for Dynabeads (middle row) and Streptamer multimers (lower row) respectively. The photographs represent degree of cluster formation: For better visibility exemplary clusters are indicated by circles for the stimulation with soluble streptavidin mutein oligomers in **Fig. 16A** and **Fig. 16B**. Clusters within the Dynabead stimulation are readily visibly by accumulation of dark stimulatory particles. As evident, both for CD4⁺ and CD8⁺ T cells early clusters formed when using the expansion method of the invention that employs a

soluble oligomeric multimerization reagent.

**Example 10: Expansion kinetics & phenotype of polyclonal
activated/expanded bulk CD3+ central memory T cells (Tcm)**

5 **[00139]** In this Example, 500.000 CD3+CD62L+CD45RA- responder Tcm cells (Tresp) were stimulated with 3µl of a preparation of the soluble oligomeric Streptactin of Example 5 (1mg/ml) that was either loaded with a combination of 0.5µg αCD3 and 0.5µg αCD28 Fab. Furthermore, 4.5µl of a preparation of Streptactin multimers loaded with 0.5µg αCD3, 0.5µg αCD8 Fab and 0.5µg αCD28 Fab was used as an additional stimulation condition. Untreated
10 (unstimulated) Tresp cells served as negative control and Tresp cells stimulated with Dynabeads (on which αCD3 and αCD28 monoclonal antibodies are irreversible immobilized) as positive control. Tresp cells were seeded in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2 only or 30U/ml IL-2 and 5ng/ml IL-15. Cells were incubated at 37°C with media exchange every 3 days and cell count was analyzed after 7 and 14 days.
15 Graphs represent degree of proliferation according to the number of cells harvested per time point, in **Fig. 17A** only IL-2 supplemented media and in **Fig.17B** IL-2 and IL-15 supplemented media. As can be seen from both Fig.17A and Fig. 17B, the soluble multimerization reagent that has reversibly bound thereon CD3 Fab fragment and αCD28 Fab fragment yields better cell expansion than the Dynabeads. As further shown by the flow-cytometric analysis of
20 CD62L and CD127 surface expression after 14 days of culture in variable cytokine milieus of **Fig. 17C**, the experimental approaches using soluble multimerization reagents of the present invention retain, under both conditions chosen here, a higher content of CD127-expressing long-lived memory T cells than expansion with Dynabeads. This illustrates a further advantage of the methods of the present invention.

25

**Example 11: Selective Antigen-specific expansion of Tcm responder cells out of bulk
CD3+ central memory T cells (kinetics & phenotype)**

30 **[00140]** In this Example, the kinetics and the phenotype of selective Antigen specific (Ag-specific) expansion out of purified CD3+CD62L+CD45RA- Tcm responder cells was examined.

[00141] In more detail, CD3+CD62L+CD45RA- Tcm responder cells were stimulated *in vitro* with both a peptide:MHC molecule complex (that acts as first agent that provides a primary activation signal to the cells) and an α CD28 Fab fragment (that acts as second reagent that stimulates an accessory molecule on the surface of the cells). Both the complex of antigen specific peptide with the MHC molecule and the α CD28 Fab fragment were reversibly immobilized on the soluble oligomeric streptavidin mutein (with $n \geq 3$) described in Example 5. The peptide that was used for the antigen specific expansion was the peptide CRVLCCYVL (SEQ ID NO: 06), amino acids 309–317 of the immediate-early 1 protein (described in Ameres et al, PLOS Pathogens, May 2013, vol. 9, issue 5, e1003383) representing an HLA-C7/IE-1 epitope that is specific for cytomegalovirus (CMV). The MHC I molecule that presents the peptide carries at the C-terminus of the α chain (heavy chain) the streptavidin binding peptide (SAWSHPQFEK(GGGS)₂GGSAWSHPQFEK, (SEQ ID NO: 07) that is commercially available as “Twin-Strep-tag®” from IBA GmbH, Göttingen, Germany).

[00142] For this purpose, 500.000 CD3+CD62L+CD45RA- responder Tcm cells (Tresp) were stimulated Ag-specifically using 3 μ l of a preparation of soluble oligomeric Streptactin multimerization reagent functionalized with 0.5 μ g of the peptide:MHC class I complexes equipped with the streptavidin binding peptide and with 0.5 μ g of the α CD28 Fab described above. As an alternative, 4.5 μ l of a of preparation of the Streptactin multimerization reagent were loaded with 0.5 μ g of these peptide:MHC class I complexes, 0.5 μ g CD8 α Fab and 0.5 μ g α CD28 Fab. For comparison, polyclonal stimulation was performed, using 3 μ l of a preparation of Streptactin multimerization reagent (1mg/ml) either loaded with a combination of 0.5 μ g α CD3 Fab and 0.5 μ g α CD28 Fab. Again as the alternative stimulation condition described above, 4.5 μ l of a preparation of Streptactin multimerization reagent reversibly loaded with 0.5 μ g α CD3 Fab, 0.5 μ g α CD8 Fab and 0.5 μ g α CD28 Fab was used. Untreated (unstimulated) Tresp cells served as negative control and Tresp cells stimulated polyclonal with Dynabeads (beads on which α CD3 and α CD28 monoclonal antibodies are irreversible immobilized) as positive control. Tresp cells were seeded in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2 and 5ng/ml IL-15. Cells were incubated at 37°C with media exchange every 3 days and cell count was analyzed after 7 and 14 days. The exemplary flow-cytometric analysis for the fraction of Ag-specific cells that was stimulated/expanded via the soluble strept-tactin oligomer on which the peptide:MHC-I complex for an HLA-C7/IE-1 epitope (for CMV) was immobilized (**Fig. 18A**) show that these antigen-specific T cells were specifically expanded. The graphs of **Fig. 18B** to **Fig. 18E** (that represent the degree of

expansion of distinct Ag-specificities according to the number of peptide:MHCI multimer-positive cells harvested per time point in analogy to the expansion experiment shown in **Fig.18A**) show that, the multimerization reagent that uses the respective complex of the Ag-specific peptide and MHC 1 molecule provided for the highest number of expanded cells (ranging from an twentyfold increase in the number of cells for the Ag-specific cells that recognize the pp65 epitope of CMV (amino acids 341-350 (QYDPVAALF, (SEQ ID NO: 08)) restricted by HLA-A2402) (see **Fig. 18B**) to an 98 fold increase in the number of Ag-specific cells that recognize the HLA-B7/IE-1₃₀₉₋₃₁₇ epitope (CRVLCCYVL (SEQ ID NO: 06)) of CMV (see **Fig. 18E**), thereby showing that the expansion method of the present invention is fully applicable to the expansion of Ag-specific cells. Finally, the exemplary flow-cytometric analysis of CD62L and CD127 surface expression after 14 days of culture for HLA-B7/Hexon5 epitope (for adenovirus) shown in **Fig. 18F** further confirms that experimental approaches using the soluble multimerization reagents of the present invention retain a higher content of CD127-expressing long-lived memory T cells in polyclonal and Ag-specific stimulatory conditions.

Example 12: Selective Ag-specific expansion kinetics & phenotype of bulk central memory T cells

[00143] This Example examines the kinetics of selective Ag-specific expansion out of purified CD3+CD62L+CD45RA-Tcm responder cells that were stimulated *in vitro* with a) antigen specific peptide MHC I complexes and b) α CD28 Fab fragments that were reversibly immobilized as first and second agent on soluble oligomeric streptavidin muteins.

[00144] For this purpose 500.000 CD3+CD62L+CD45RA- responder Tcm cells (Tresp) were stimulated Ag-specifically using 3 μ l of a preparation of Streptactin multimerization reagent functionalized with 0.5 μ g peptide:MHC class I complexes equipped with a streptavidin binding peptide (the specific peptide represents amino acids 114-124 (CPYSGTAYNSL, SEQ ID NO: 10) of the Hexon 5 protein of adenovirus) restricted by HLA-B07) and 0.5 μ g α CD28 Fab. As an alternative, 4.5 μ l of a preparation of Streptactin multimerization reagent loaded with 0.5 μ g this peptide:MHC class I complex, 0.5 μ g α CD8 Fab and 0.5 μ g α CD28 Fab. For comparison, polyclonal stimulation was performed, using 3 μ l of a preparation of Streptactin multimerization reagent (1mg/ml) either loaded with a combination of 0.5 μ g α CD3 Fab and 0.5 μ g α CD28 Fab. Again as the alternative stimulation

condition described above, 4.5µl of a preparation of Streptactin multimers loaded with 0.5µg αCD3 Fab, 0.5µg αCD8 Fab and 0.5µg αCD28 Fab was used. Untreated (unstimulated) Tresp cells served as negative control and Tresp cells stimulated polyclonal with Dynabeads as positive control. Tresp cells were seeded in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2 and 5ng/ml IL-15. Cells were incubated at 37°C with media exchange every 3 days and cell count was analyzed after 7 and 14 days. The pictures shown in **Fig. 19** represent degree of cluster formation on day 5, exemplary Ag-specific stimulation is illustrated for the HLA-B7/Hexon 5 epitope of adenovirus. As can be seen from **Fig. 19**, such adenovirus antigen specific cells could be specifically expanded from the original CD3+CD62L+CD45RA-Tcm responder population.

Example 13: Yield and phenotype of expanded CD8+ T cells – size variation of soluble multimerization reagent and addition of αCD8-Fab addition for stimulation

[00145] In this Example, the expansion of purified CD8+ T responder cells stimulated *in vitro* with αCD3/αCD28 Fab fragments that were reversibly immobilized soluble oligomeric streptavidin muteins were examined. In addition, the effect of adding αCD8-Fab to the multimerization reagent for increasing the specificity of the expansion for CD8+ T cells was examined.

[00146] For this purpose, 300.000 purified CD8+ responder T cells (Tresp) were separately stimulated with two different Streptactin based multimerization reagents, namely either the small oligomeric Streptactin multimerization reagent of Example 5 (1mg/ml) or the larger Streptactin oligomers described above (0.1mg/ml). 3µl of both different multimerization reagent (backbones) were either loaded with a combination of the 0.5µg αCD3 and 0.5µg αCD28 Fab fragments described above. In addition, 4.5µl of the smaller Streptactin multimerization reagent (backbone) was loaded with 0.5µg αCD3, 0.5µg αCD8 Fab and 0.5µg αCD28 Fab fragments described above. Furthermore 3µl of the “smaller” Streptactin multimerization reagent (backbone) only functionalized with 0.5µg αCD3 Fab fragment alone or 0.5µg αCD28 Fab fragment alone was used. Unstimulated Tresp cells served as negative control and Tresp stimulated with Dynabeads served as positive control. Tresp cells were seeded in duplicates in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2. Cells were incubated at 37°C with media exchange after 3 days and analyzed after 6 days. **Fig. 20A** depicts the degree of proliferation according to the number of cells harvested at

day 6 compared to the negative controls and normalized to the positive control. **Fig. 20A** shows that the expansion of the CD8⁺ T cells using the soluble multimerization reagents of the invention result in higher yields of the CD8⁺ T cells than expansion using dynabeads. The FACS analysis of CD8 surface expression (**Fig.20B**) and CD45RO surface expression (**Fig. 20C**) after cell culture shows that the same phenotype of CD8⁺ T cells were expanded by either the multimerization reagents of the invention or Dynabeads (the various stimulating conditions were compared using one-way ANOVA and no significant difference (n.s.) was detected). The improved yield of the CD8⁺ cells using the inventive expansion methods compared to the Dynabeads might be due to the fact that the soluble multimerization reagent can access their target receptors on the cell surface better than the antibodies that are immobilized on the Dynabeads. This improved yield might become very advantageous when expanding rare population of cells from an initial sample.

[00147] In addition, comparing the yield of expansion achieved with the multimerization agent on which both the 0.5 μ g α CD3 and 0.5 μ g α CD28 Fab fragments were jointly immobilized (second column from the left in **Fig. 20B**) to the yield using two multimerisation reagents which were functionalized only with the α CD3 Fab fragment alone or the α CD28 Fab fragment alone (third column from the left in **Fig. 20B**), it can be seen that both experiments had the same expansion efficiency. Thus, these experiments show that using one multimerization reagent on which both the first agent and the second agent are jointly immobilized is functionally equivalent to using for the expansion two separate multimerization reagents which are loaded with only the first agent and the second agent, respectively.

Example 14: Yield & phenotype of expanded CD8⁺ T cells – titration of separate soluble multimerization reagents with different ratios of α CD3- and α CD28 Fab fragment immobilized thereon

[00148] In this Example the yield and the phenotype of expanded CD8⁺ T responder cells (Tresp) that were stimulated *in vitro* with α CD3/ α CD28 Fab fragments that were reversibly immobilized in different amounts on soluble oligomeric streptavidin muteins were examined.

[00149] For this purpose 300.000 CD8⁺ responder T cells (Tresp) were stimulated with varying amounts of a mixture of preparations of the “small” oligomeric Streptactin

multimerization reagent (1mg/ml) functionalized with α CD3 Fab alone and α CD28 Fab alone („1x“ corresponds to 1.5 μ g Streptactin multimerization reagent functionalized with 0.5 μ g α CD3 alone and 1.5 μ g multimerized Streptactin functionalized with 0.5 μ g α CD28 Fab fragment alone), or 3 μ l of a preparation of the Streptactin multimerization reagent loaded with 0.5 μ g α CD3 and 0.5 μ g CD28 Fab, or 4.5 μ l of a preparation of the Streptactin multimerization reagent loaded with 0.5 μ g α CD3, 0.5 μ g strep-tagged α CD8 and 0.5 μ g α CD28 Fab. Untreated Tresp cells served as negative control and Tresp stimulated with Dynabeads as positive control. Tresp cells were seeded in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2. Cells were incubated at 37°C without media exchange and analyzed after 5 days. **Fig.21A** depicts the degree of proliferation according to the number of cells harvested at day 5 compared to the negative controls and normalized to the positive control. **Fig. 21A** shows that the expansion of the CD8+ T cells using the various soluble multimerization reagents of the invention result in higher yields of the CD8+ T cells than expansion using dynabeads (especially the cumulative total reagent amount of the 5x condition resulted in an optimal expansion of cells especially over time/increase in total cells by beginning cell division). The FACS analysis of CD8 surface expression (**Fig.21B**) and CD45RO surface expression (**Fig. 21C**) after cell culture shows that the same phenotype of CD8+ T cells were expanded by either the various multimerization reagents of the invention or by the commercially available Dynabeads.

Example 15: Activation of intracellular signaling cascades after Streptamer multimers stimulation of aCD19-CAR transduced Jurkat cells

[00150] In this Example the activation of intracellular signaling cascades of transduced Jurkat cells that have been modified to express a tumor-specific chimeric antigen receptor (CAR), namely here CD19 and that were stimulated using the oligomeric Strep-tactin® of Example 5 as soluble multimerization reagent was examined.

[00151] For this purpose, 300.000 Jurkat responder cells (Jresp) were stimulated with (A) varying amounts of a mixture of preparations of Streptactin multimerization reagent (1mg/ml) functionalized with α CD3 Fab and α CD28 Fab fragments described here („x1“ corresponds to 3 μ g Streptactin multimerization reagent functionalized with 0.5 μ g α CD3- and 0.5 μ g α CD28 Fab – this provides a “polyclonal Streptactin based multimerization reagent”), or

(B) 3µl of a preparation of Streptactin multimerization reagent functionalized with 0.5µg (x1) or 1µg (x2) of the extracellular domain (ECD) of CD19 (the natural ligand for the αCD19-CAR – this provides a “CAR-specific Streptactin based multimerization reagent”), or 3µl of a preparation of Streptactin multimerization reagent loaded with 0.5µg (x1) or 1µg (x2) αIgG recognizing the IgG4 spacer within the αCD19-CAR – this also provides a “CAR-specific Streptavidin mutein based multimerization reagent). ECD of CD19 equipped with a hexahistidine tag was obtained from Sino Biological/Life technologies (SEQ ID NO: 27) and was functionalized for binding to the streptavidin based multimerization reagent by mixing the ECD of CD19 with the adapter molecule His-STREPPER (IBA GmbH, Germany, Order number 2-0920-005) at a molecular ratio of 1:1 and incubating for 15 min at room temperature. The His-STREPPER adapter molecule contains a chelating portion that binds to the hexahistidine tag and a streptavidin binding peptide, thereby temporarily providing the target molecule, here the ECD of CD19 with a streptavidin binding peptide that can reversibly bind to a streptavidin mutein based multimerization reagent. Jresp stimulated with Dynabeads (beads having irreversibly immobilized thereon αCD3- and αCD28- monoclonal antibodies) or PMA and Ionomycin served as positive controls. Jresp cells were seeded in 1.5ml Eppendorf tubes in 200µl cell culture medium supplemented with 30U/ml IL-2. Cells were incubated at 37°C and put on ice and lysed after 0min to 20min of stimulation. Detection of phosphorylated ERK indicates active MAPK signaling, staining of the housekeeper β-Actin indicates loading of equal amounts of total protein per condition and time point. As can be seen from the comparison of **Fig. 22A** showing activation of the Jurkat cells via the “polyclonal Streptactin multimerization reagent” and **Fig. 22B** showing activation of the Jurkat cells via the two “CAR-specific Streptactin based multimerization reagents”, the Jurkat cells can be activated/expanded via the binding of the CD19 extracellular domain to the CD19 specific chimeric antigen receptor. Since genetic down-stream processing of T cells is almost exclusively performed on pre-selected cell populations, a generic activation via cross-linking of introduced CARs via the IgG4 spacer domain (this is conserved within various CARs with different specificities) broadens the applicability for reversible cell stimulation/expansion in these in vitro cell-processing situations.

[00152] Thus, this experiment shows that in principle any cell population that is activated by binding of an agent (ligand) that provides a primary activation signal to the cell population can be expanded using a first agent reversibly immobilized on a multimerization reagent as described here.

Example 16: Yield and subset composition of expanded CD3⁺ T cells with addition of α CD8-Fab for stimulation

[00153] The experiment shows the expansion of purified CD3⁺ T responder cells stimulated *in vitro* with α CD3/ α CD28 Fab fragments that were reversibly immobilized on the soluble oligomeric Strep-tactin® of Example 5 that served as a soluble multimerization reagent. In one experiment, in addition to α CD3/ α CD28 Fab fragments, also a α CD8 Fab fragment commercially available from IBA GmbH, Göttingen, Germany (catalogue number 6-8000-203) was immobilized on the soluble oligomer of the streptavidin mutein in order to test whether it is possible to preferentially stimulate a specific T cell subpopulation *in vitro* with the reversible α CD3/ α CD28 Fab-Streptamer multimers. In more detail, 500.000 purified CD3⁺ responder T cells (Tresp) were stimulated with 3 μ l of a preparation of oligomeric Streptavidin (1mg/ml) loaded with a combination of 0.5 μ g of the α CD3 and 0.5 μ g of the α CD28 Fab. As an alternative approach, 4.5 μ l of the Streptactin oligomer were loaded with 0.5 μ g α CD3, 0.5 μ g strep-tagged α CD8 Fab and 0.5 μ g strep-tagged α CD28 Fab. Unstimulated Tresp cells served as negative control and Tresp stimulated with Dynabeads (beads on which α CD3 and α CD28 monoclonal antibodies are irreversibly immobilized) served as positive control. As can be seen from **Fig. 23A**, the multimerization reagent that is reversibly loaded with the α CD3 Fab fragment, the α CD28 Fab fragment and also the α CD8 Fab fragment provided the highest number of expanded CD3⁺ T cells. With $1 \times 1 \times 10^6$ the number of expanded cells the yield was about 30 % higher than for expansion of these T cells using commercially available Dynabeads. In addition and more important, as shown in **Fig. 23B** with this multimerization reagent that carries the α CD3 Fab fragment, the α CD28 Fab fragment and the α CD8 Fab fragment, the amount of CD8⁺ T cells were the highest, compared to both the expansion with Dynabeads or a soluble multimerization reagent of the invention that carries only the α CD3 Fab fragment and the α CD28 Fab fragment as first and second agent as described herein. Thus, also this experiment shows the advantage of the present invention that in addition to a first agent that provides a primary activation signal to the desired cell population and optionally a second agent that provide a co-stimulatory signal, a further agent that is specific for the activation of the desired cell population can be immobilized on the multimerization reagent. Thus, by so doing, the present invention provides for the possibility to preferentially expand or selectively enrich any desired cell (sub)population from a sample that, for example,

comprises a variety of different subpopulations. .

Example 17: Parallel Antigen-specific expansion of Tcm responder cells out of a single pool

5 [00154] In this Example, the kinetics of parallel Antigen specific (Ag-specific) expansion out of a single pool of T responder cells stimulated *in vitro* with multiple reversible peptide:MHC/ α CD28 Fab-Streptamer multimers is examined.

10 [00155] 500.000 CD3+CD62L+CD45RA- responder Tcm cells (Tresp) are simultaneously stimulated for multiple Ag-specificities using for each specificity, 3 μ l of Streptactin multimers functionalized with 0.5 μ g of the respective peptide:MHC class I complexes that carries a streptavidin binding peptide and 0.5 μ g α CD28 Fab that also carries a streptavidin binding peptide. As an alternative approach, 4.5 μ l of Streptactin based multimerization reagent functionalized with 0.5 μ g peptide:MHC class I complexes carrying a streptavidin binding peptide, 0.5 μ g α CD8 Fab and 0.5 μ g α CD28 Fab as described here are
15 used for each specificity. For comparison, polyclonal stimulation is performed, using 3 μ l of a preparation of Streptactin based multimerization reagent (1mg/ml) either reversibly loaded with a combination of 0.5 μ g α CD3 Fab and 0.5 μ g α CD28 Fab. Again as the alternative stimulation condition described above, 4.5 μ l of a preparation of the Streptactin based multimerization reagent reversibly loaded with 0.5 μ g α CD3 Fab, 0.5 μ g α CD8 Fab and 0.5 μ g
20 α CD28 Fab (each of them carrying a streptavidin binding peptide can be used. Untreated (unstimulated) Tresp cells serve as negative control and Tresp cells stimulated polyclonal with Dynabeads (α CD3- and α CD28- mAb coated beads) as positive control. Tresp cells are seeded in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2 and 5ng/ml IL-
15. Cells are incubated at 37°C with media exchange every 3 days and cell count are analyzed
25 after 7 and 14 days.

Example 18: Preferential proliferation of CD8+ T cells among CD3+ T responder cells stimulated *in vitro* with streptavidin based multimerization reagents reversibly functionalized with α CD3/ α CD8/ α CD28 Fab fragments

30 [00156] 300.000 CD3+ responder T cells (Tresp) are stimulated with 3 μ l of a preparation of Streptactin multimerization (1mg/ml) or a preparation of a multimerization

reagent using the large Streptactin backbone (0.1mg/ml) either loaded with a combination of 0.5µg αCD3 and 0.5µg αCD28 Fab, or 4.5µl of a preparation of Streptactin based multimerization reagent loaded with 0.5µg αCD3, 0.5µg αCD8 Fab and 0.5µg αCD28 Fab, or 3µl of a mixture of preparations of Streptactin based multimerization reagent with 0.5µg αCD3 Fab alone and 0.5µg αCD28 Fab alone (each Fab fragment again carries a streptavidin binding peptide). Untreated Tresp cells serve as negative control and Tresp stimulated with Dynabeads (αCD3- and αCD28- mAb coated beads) as positive control. Tresp cells are seeded in duplicates in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2. Cells are incubated at 37°C with media exchange after 3 days and analyzed after 6 days.

10

Example 19: Preferential proliferation of CD8+ T cells among CD3+ T responder cells stimulated *in vitro* with streptavidin based multimerization reagents reversibly functionalized with αCD3 and αCD28 Fab fragments

[00157] 300.000 CD3+ responder T cells (Tresp) are stimulated with varying amounts of a mixture of preparations of Streptactin based multimerization reagent (1mg/ml) functionalized with αCD3 Fab fragment alone and αCD28 Fab fragment alone (1.5µg Streptactin based multimerization reagent functionalized with 0.5µg αCD3 Fab fragment alone and 1.5µg Streptactin based multimerization reagent functionalized with 0.5µg αCD28 Fab fragment alone), or varying amounts of a mixture of preparations of Streptactin based multimerization reagent functionalized with αCD3 Fab fragment and αCD28 Fab fragment with or without αCD8 Fab fragment (each Fab fragment again carries a streptavidin binding peptide) (3µg Streptactin based multimerization reagent functionalized with 0.5µg αCD3- and 0.5µg αCD28 Fab fragment – without αCD8 Fab fragment, or 4.5µl of a preparation of Streptactin multimerization reagent loaded with 0.5µg αCD3 Fab fragment, 0.5µg αCD8 Fab fragment and 0.5µg αCD28 Fab fragment, wherein Fab fragment again carries a streptavidin binding peptide). Untreated Tresp cells serve as negative control and Tresp stimulated with Dynabeads (αCD3- and αCD28- mAb coated beads) as positive control. Tresp cells are seeded in 48-well plates in 1ml cell culture medium supplemented with 30U/ml IL-2. Cells are incubated at 37°C with media exchange after 3 days and analyzed after 6 days.

[00158] The listing or discussion of a previously published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge.

[00159] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising”, “including,” containing”, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein
5 have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by exemplary embodiments and optional
10 features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.

[00160] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part
15 of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

[00161] Other embodiments are within the following claims. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art
20 will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

eolf-seql
SEQUENCE LISTING

<110> STAGE Cell Therapeutics GmbH

<120> METHODS, KITS AND APPARATUS FOR EXPANDING A POPULATION OF CELLS

<130> STA14985PCT

<150> US 61/980,506

<151> 2014-04-16

<160> 27

<170> PatentIn version 3.5

<210> 1

<211> 8

<212> PRT

<213> artificial

<220>

<223> Strep-tag

<400> 1

Trp Ser His Pro Gln Phe Glu Lys

1 5

<210> 2

<211> 4

<212> PRT

<213> artificial

<220>

<223> streptavidin mutein (analog) 1

<400> 2

Val Thr Ala Arg

1

<210> 3

<211> 4

<212> PRT

<213> artificial

<220>

<223> streptavidin mutein (analog) 2

<400> 3

eolf-seql

Ile Gly Ala Arg
1

<210> 4
<211> 28
<212> PRT
<213> artificial

<220>
<223> di-tag3

<400> 4

Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Ser Gly Gly Gly Ser
1 5 10 15

Gly Gly Gly Ser Trp Ser His Pro Gln Phe Glu Lys
20 25

<210> 5
<211> 24
<212> PRT
<213> artificial

<220>
<223> di-tag2

<400> 5

Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Ser Gly Gly Gly Ser
1 5 10 15

Trp Ser His Pro Gln Phe Glu Lys
20

<210> 6
<211> 9
<212> PRT
<213> artificial

<220>
<223> immediate-early 1 protein (amino acids 309-317)

<400> 6

Cys Arg Val Leu Cys Cys Tyr Val Leu

eolf-seql

1 5

<210> 7
 <211> 30
 <212> PRT
 <213> artificial

<220>
 <223> Twin-Strep-tag

<400> 7

Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Ser Gly Gly
 1 5 10 15

Gly Ser Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys
 20 25 30

<210> 8
 <211> 9
 <212> PRT
 <213> artificial

<220>
 <223> pp65 epitope of CMV (amino acids 341-350)

<400> 8

Gln Tyr Asp Pro Val Ala Ala Leu Phe
 1 5

<210> 9
 <211> 11
 <212> PRT
 <213> artificial

<220>
 <223> pp65 epitope of CMV (amino acids 265-274)

<400> 9

Arg Pro His Glu Arg Asn Gly Phe Thr Val Leu
 1 5 10

<210> 10
 <211> 11
 <212> PRT

eolf-seql

<213> artificial

<220>

<223> hexon 5 epitope of adenovirus (amino acids 114-124)

<400> 10

Lys	Pro	Tyr	Ser	Gly	Thr	Ala	Tyr	Asn	Ala	Leu
1				5					10	

<210> 11

<211> 9

<212> PRT

<213> artificial

<220>

<223> HA-tag

<400> 11

Tyr	Pro	Tyr	Asp	Val	Pro	Asp	Tyr	Ala
1				5				

<210> 12

<211> 11

<212> PRT

<213> artificial

<220>

<223> VSV-G-tag

<400> 12

Tyr	Thr	Asp	Ile	Glu	Met	Asn	Arg	Leu	Gly	Lys
1				5					10	

<210> 13

<211> 11

<212> PRT

<213> artificial

<220>

<223> HSV-tag

<400> 13

Gln	Pro	Glu	Leu	Ala	Pro	Glu	Asp	Pro	Glu	Asp
1				5					10	

eolf-seql

<210> 14
 <211> 10
 <212> PRT
 <213> artificial

<220>
 <223> T7 epitope

<400> 14

Ala Ser Met Thr Gly Gly Gln Gln Met Gly
 1 5 10

<210> 15
 <211> 10
 <212> PRT
 <213> artificial

<220>
 <223> myc epitope

<400> 15

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
 1 5 10

<210> 16
 <211> 14
 <212> PRT
 <213> artificial

<220>
 <223> V5-tag

<400> 16

Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr
 1 5 10

<210> 17
 <211> 119
 <212> PRT
 <213> mus musculus

<400> 17

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
 1 5 10 15

Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala His Phe Arg Gly Ser
50 55 60

eolf-seql

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Gly Met Glu Ala Glu
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Phe Thr
85 90 95

Phe Gly Ser Gly Thr Lys Leu Glu Ile Asn
100 105

<210> 19

<211> 116

<212> PRT

<213> mus musculus

<400> 19

Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Arg
1 5 10 15

Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Ile Ile His
20 25 30

Trp Ile Lys Leu Arg Ser Gly Gln Gly Leu Glu Trp Ile Gly Trp Phe
35 40 45

Tyr Pro Gly Ser Asn Asp Ile Gln Tyr Asn Ala Lys Phe Lys Gly Lys
50 55 60

Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Val Tyr Met Glu Leu
65 70 75 80

Thr Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Arg
85 90 95

Asp Asp Phe Ser Gly Tyr Asp Ala Leu Pro Tyr Trp Gly Gln Gly Thr
100 105 110

Met Val Thr Val
115

eolf-seql

<210> 20
 <211> 108
 <212> PRT
 <213> mus musculus

<400> 20

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly
 1 5 10 15

Glu Thr Val Thr Ile Thr Cys Arg Thr Asn Glu Asn Ile Tyr Ser Asn
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile
 35 40 45

Tyr Ala Ala Thr His Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Thr Ser Leu Gln Ser
 65 70 75 80

Glu Asp Phe Gly Asn Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Cys
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
 100 105

<210> 21
 <211> 314
 <212> PRT
 <213> artificial

<220>
 <223> HLA-A*2402

<400> 21

Met Gly Ser His Ser Met Arg Tyr Phe Ser Thr Ser Val Ser Arg Pro
 1 5 10 15

Gly Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr
 20 25 30

eolf-seql

Gln Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro
 35 40 45

Arg Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Glu Glu
 50 55 60

Thr Gly Lys Val Lys Ala His Ser Gln Thr Asp Arg Glu Asn Leu Arg
 65 70 75 80

Ile Ala Leu Arg Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu
 85 90 95

Gln Met Met Phe Gly Cys Asp Val Gly Ser Asp Gly Arg Phe Leu Arg
 100 105 110

Gly Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys
 115 120 125

Glu Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr
 130 135 140

Lys Arg Lys Trp Glu Ala Ala His Val Ala Glu Gln Gln Arg Ala Tyr
 145 150 155 160

Leu Glu Gly Thr Cys Val Asp Gly Leu Arg Arg Tyr Leu Glu Asn Gly
 165 170 175

Lys Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His
 180 185 190

His Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly
 195 200 205

Phe Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp
 210 215 220

Gln Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly
 225 230 235 240

eolf-seql

Thr Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln
 245 250 255

Arg Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr
 260 265 270

Leu Arg Trp Glu Pro Pro Pro Ser Gly Ser Ser Ala Trp Ser His Pro
 275 280 285

Gln Phe Glu Lys Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
 290 295 300

Ser Ala Trp Ser His Pro Gln Phe Glu Lys
 305 310

<210> 22
 <211> 314
 <212> PRT
 <213> artificial

<220>
 <223> HLA-B*0702

<400> 22

Met Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Val Ser Arg Pro
 1 5 10 15

Gly Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr
 20 25 30

Gln Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Glu Glu Pro
 35 40 45

Arg Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn
 50 55 60

Thr Gln Ile Tyr Lys Ala Gln Ala Gln Thr Asp Arg Glu Ser Leu Arg
 65 70 75 80

Asn Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu

eolf-seql
90

85

95

Gln Ser Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg
100 105 110

Gly His Asp Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn
115 120 125

Glu Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr
130 135 140

Gln Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Arg Arg Ala Tyr
145 150 155 160

Leu Glu Gly Glu Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly
165 170 175

Lys Asp Lys Leu Glu Arg Ala Asp Pro Pro Lys Thr His Val Thr His
180 185 190

His Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly
195 200 205

Phe Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp
210 215 220

Gln Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Arg
225 230 235 240

Thr Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln
245 250 255

Arg Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr
260 265 270

Leu Arg Trp Glu Pro Pro Pro Ser Gly Ser Ser Ala Trp Ser His Pro
275 280 285

Gln Phe Glu Lys Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

eolf-seql

290 295 300

Ser Ala Trp Ser His Pro Gln Phe Glu Lys
305 310

<210> 23
<211> 321
<212> PRT
<213> artificial

<220>
<223> HLA-C*0702

<400> 23

Met Ala Leu Thr Glu Thr Trp Ala Cys Ser His Ser Met Arg Tyr Phe
1 5 10 15

Asp Thr Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ser
20 25 30

Val Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala
35 40 45

Ala Ser Pro Arg Gly Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly
50 55 60

Pro Glu Tyr Trp Asp Arg Glu Thr Gln Lys Tyr Lys Arg Gln Ala Gln
65 70 75 80

Ala Asp Arg Val Ser Leu Arg Asn Leu Arg Gly Tyr Tyr Asn Gln Ser
85 90 95

Glu Asp Gly Ser His Thr Leu Gln Arg Met Ser Gly Cys Asp Leu Gly
100 105 110

Pro Asp Gly Arg Leu Leu Arg Gly Tyr Asp Gln Ser Ala Tyr Asp Gly
115 120 125

Lys Asp Tyr Ile Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala
130 135 140

eolf-seql

Asp Thr Ala Ala Gln Ile Thr Gln Arg Lys Leu Glu Ala Ala Arg Ala
 145 150 155 160

Ala Glu Gln Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu
 165 170 175

Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln Arg Ala Glu Pro
 180 185 190

Pro Lys Thr His Val Thr His His Pro Leu Ser Asp His Glu Ala Thr
 195 200 205

Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Thr Leu Thr
 210 215 220

Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val Glu
 225 230 235 240

Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val
 245 250 255

Val Pro Ser Gly Gln Glu Gln Arg Tyr Thr Cys His Met Gln His Glu
 260 265 270

Gly Leu Gln Glu Pro Leu Thr Leu Ser Trp Glu Pro Ser Ser Gln Pro
 275 280 285

Thr Ile Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly
 290 295 300

Ser Gly Gly Gly Ser Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu
 305 310 315 320

Lys

<210> 24
 <211> 100
 <212> PRT

eolf-seql

<213> homo sapiens

<400> 24

Met Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg His Pro Ala
 1 5 10 15

Glu Asn Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val Ser Gly Phe His
 20 25 30

Pro Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu Arg Ile Glu
 35 40 45

Lys Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp Ser Phe Tyr
 50 55 60

Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp Glu Tyr Ala
 65 70 75 80

Cys Arg Val Asn His Val Thr Leu Ser Gln Pro Lys Ile Val Lys Trp
 85 90 95

Asp Arg Asp Met
 100

<210> 25

<211> 118

<212> PRT

<213> mus musculus

<400> 25

Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
 1 5 10 15

Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Arg Thr Ser
 20 25 30

Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
 35 40 45

Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala

eolf-seql

50

55

60

Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser Asn Gln Val
 65 70 75 80

Phe Leu Lys Ile Ala Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95

Cys Ala Gln Ile Asn Pro Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ser
 115

<210> 26
 <211> 111
 <212> PRT
 <213> mus musculus

<400> 26

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Phe Asp
 20 25 30

Gly Asp Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45

Lys Leu Leu Ile Tyr Thr Thr Ser Asn Leu Glu Ser Gly Ile Pro Ala
 50 55 60

Arg Phe Ser Ala Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
 65 70 75 80

Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
 85 90 95

Glu Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105 110

eolf-seql

<210> 27
 <211> 283
 <212> PRT
 <213> artificial

<220>
 <223> human CD19 extracellular domain with His-Tag

<400> 27

Pro Glu Glu Pro Leu Val Val Lys Val Glu Glu Gly Asp Asn Ala Val
 1 5 10 15

Leu Gln Cys Leu Lys Gly Thr Ser Asp Gly Pro Thr Gln Gln Leu Thr
 20 25 30

Trp Ser Arg Glu Ser Pro Leu Lys Pro Phe Leu Lys Leu Ser Leu Gly
 35 40 45

Leu Pro Gly Leu Gly Ile His Met Arg Pro Leu Ala Ile Trp Leu Phe
 50 55 60

Ile Phe Asn Val Ser Gln Gln Met Gly Gly Phe Tyr Leu Cys Gln Pro
 65 70 75 80

Gly Pro Pro Ser Glu Lys Ala Trp Gln Pro Gly Trp Thr Val Asn Val
 85 90 95

Glu Gly Ser Gly Glu Leu Phe Arg Trp Asn Val Ser Asp Leu Gly Gly
 100 105 110

Leu Gly Cys Gly Leu Lys Asn Arg Ser Ser Glu Gly Pro Ser Ser Pro
 115 120 125

Ser Gly Lys Leu Met Ser Pro Lys Leu Tyr Val Trp Ala Lys Asp Arg
 130 135 140

Pro Glu Ile Trp Glu Gly Glu Pro Pro Cys Leu Pro Pro Arg Asp Ser
 145 150 155 160

eolf-seql

Leu Asn Gln Ser Leu Ser Gln Asp Leu Thr Met Ala Pro Gly Ser Thr
 165 170 175

Leu Trp Leu Ser Cys Gly Val Pro Pro Asp Ser Val Ser Arg Gly Pro
 180 185 190

Leu Ser Trp Thr His Val His Pro Lys Gly Pro Lys Ser Leu Leu Ser
 195 200 205

Leu Glu Leu Lys Asp Asp Arg Pro Ala Arg Asp Met Trp Val Met Glu
 210 215 220

Thr Gly Leu Leu Leu Pro Arg Ala Thr Ala Gln Asp Ala Gly Lys Tyr
 225 230 235 240

Tyr Cys His Arg Gly Asn Leu Thr Met Ser Phe His Leu Glu Ile Thr
 245 250 255

Ala Arg Pro Val Leu Trp His Trp Leu Leu Arg Thr Gly Gly Trp Lys
 260 265 270

Ala His His His His His His His His His His
 275 280

What is claimed is:**Claims**

1. An *in vitro*-method of expanding a population of cells, comprising contacting a sample comprising a population of cells with a multimerization reagent,
5 wherein the multimerization reagent has reversibly immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells;
wherein the multimerisation reagent comprises at least one binding site Z1 for the reversible binding of the first agent,
wherein the first agent comprises at least one binding partner C1, wherein the binding partner
10 C1 is able of reversibly binding to the binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1, and
wherein the first agent binds to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells and thereby activating the cells.
15
2. The method of claim 1, wherein the multimerization agent has reversibly immobilized thereon (bound thereto) a second agent that stimulates an accessory molecule on the surface of the cells,
wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is
20 able of being reversibly bound to a binding site Z2 of the multimerization reagent, wherein the second agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C2 and the binding site Z2,
wherein the second agent binds to the accessory molecule on the surface on the surface of the cells, thereby stimulating the activated cells.
25
3. The method of claim 1 or 2, wherein the population of cells is a lymphocyte population.
4. The method of claim 3, wherein the lymphocyte population is B cell population, a T
30 cell population, a natural killer cell population or a mixture thereof.

5. The method of claim 4, wherein the T-cell population is an antigen-specific T cell population, a T helper cell population, a cytotoxic T cell, a memory T cell, a regulatory T cell, or a natural killer T cell population.

6. The method of claim 5, wherein the first agent comprises a MHC I:peptide complex or wherein the first agent stimulates a TCR/CD3 complex-associated signal in the T cells.

7. The method of claim 6, wherein the first agent is a binding reagent that specifically binds CD3.

8. The method of claim 6 or 7, wherein the accessory molecule on the T cell is CD28 or CD137.

9. The method of claim 8, wherein the second agent that binds the accessory molecule is a binding reagent that specifically binds CD28 or CD137 or wherein the second agent is a mixture of two different kinds of binding reagents that both specifically bind CD28 or CD137.

10. The method of any of claims 7 to 9, wherein said first agent that specifically binds CD3 is selected from the group consisting of an anti-CD3-antibody, a divalent antibody fragment of an anti-CD3 antibody, a monovalent antibody fragment of an anti-CD3-antibody, and a proteinaceous CD3 binding molecule with antibody-like binding properties, and/or wherein the second agent that specifically binds CD28 is selected from the group consisting of an anti-CD28-antibody, a divalent antibody fragment of an anti-CD28 antibody, a monovalent antibody fragment of an anti-CD28-antibody, a proteinaceous CD28 binding molecule with antibody-like binding properties, an anti-CD137-antibody, a divalent antibody fragment of an anti-CD137 antibody, a monovalent antibody fragment of an anti-CD137-antibody, a proteinaceous CD137 binding molecule with antibody-like binding properties, 4-1BB ligand, and any mixture thereof.

11. The method of claim 10, wherein the divalent antibody fragment is an (Fab)₂'-fragment, or a divalent single-chain Fv fragment.

12. The method of claim 10, wherein the monovalent antibody fragment is selected from the group consisting of a Fab fragment, a Fv fragment, and a single-chain Fv fragment (scFv).

13. The method of claim 10, wherein the proteinaceous CD3, CD28 or CD137 binding molecule with antibody-like binding properties is selected from the group of an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, a protein based on the ankyrin scaffold, a protein based on the crystalline scaffold, an adnectin, and an avimer.

14. The method of claim 4, wherein the cell population is a B cell population and the first agent is a binding reagent that specifically binds CD40 or CD137.

15. The method of claim 14, wherein the first binding reagent that specifically binds CD40 or CD137 is selected from the group consisting of an anti-CD40-antibody, a divalent antibody fragment of an anti-CD40 antibody, a monovalent antibody fragment of an anti-CD40-antibody, and a proteinaceous CD40 binding molecule with antibody-like binding properties or an anti-CD137-antibody, a divalent antibody fragment of an anti-CD137 antibody, a monovalent antibody fragment of an anti-CD137-antibody, a proteinaceous CD137 binding molecule with antibody-like binding properties, and CD40 ligand (CD154).

16. The method of claim 15, wherein the divalent antibody fragment is an (Fab)₂'-fragment, or a divalent single-chain Fv fragment.

17. The method of claim 15, wherein the monovalent antibody fragment is selected from the group consisting of a Fab fragment, a Fv fragment, and a single-chain Fv fragment (scFv).

18. The method of claim 15, wherein the proteinaceous CD40 binding molecule or the proteinaceous CD137 binding molecule with antibody-like binding properties is selected from the group of an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, a protein based on the ankyrin scaffold, a protein based on the crystalline scaffold, an adnectin, and an avimer.

19. The method of any of claims 3 and 14 to 18, wherein the accessory molecule on the B cell is CD40.

20. The method of claim 19, wherein the second agent is CD40 ligand (CD154) or CD137.

21. The method of any of claims 2 to 20, wherein the binding sites Z1 and Z2 of the
5 multimerization reagent are identical.

22. The method of claim 21, wherein a single multimerisation reagent is used.

23. The method of any of claims 1 to 22, wherein the multimerization reagent is
10 immobilized on a solid surface.

24. The method of claim 23, wherein the solid surface is selected from the group consisting
of a magnetic bead, a polymeric bead, a cell culture plate, a microtiter plate, a membrane, a
hollow fiber and combinations thereof.

25. The method of claim 24, wherein the multimerization reagent is selected from the
group consisting of streptavidin, avidin, an analog of streptavidin that reversibly binds biotin,
an analog of avidin that reversibly binds biotin, a reagent that comprises at least two chelating
groups K, wherein the at least two chelating groups are capable of binding to a transition metal
20 ion, thereby rendering moiety A capable of binding to an oligohistidine affinity tag,
multimeric glutathione-S-transferase, multimeric calmodulin and a biotinylated carrier protein.

26. The method of any of claims 1 to 22, wherein the multimerization reagent is in a
soluble form.

27. The method of claim 26, wherein the multimerization reagent comprises an oligomer or
a polymer of streptavidin, an oligomer or a polymer of avidin, an oligomer or a polymer of an
analog of streptavidin that reversibly binds biotin, an oligomer or a polymer of an analog
avidin that reversibly bind biotin, a reagent that comprises at least two chelating groups K,
30 wherein the at least two chelating groups are capable of binding to a transition metal ion,
thereby rendering the reagent capable of binding to an oligohistidine affinity tag, multimeric
glutathione-S-transferase, multimeric calmodulin and a biotinylated carrier protein.

28. The method of claim 27, wherein the streptavidin, avidin, or the streptavidin analog or the avidin analog that reversibly binds to biotin is crosslinked by a polysaccharide or wherein the cross-linked oligomers or polymers of streptavidin, avidin or of ab analog of streptavidin or avidin that reversibly binds biotin is obtained by crosslinking via a bifunctional linker.

5

29. The method of claim 27 or 28, wherein the cross-linked oligomers or polymers of streptavidin, avidin, or of the analog of streptavidin or avidin that reversibly binds biotin comprise three or more streptavidin monomers.

10 30. The method of any of claims 1 to 29, wherein

(a) said binding partner C1 and C2 comprises independently from each other biotin and said multimerization reagent comprises a streptavidin analog or an avidin analog that reversibly binds to biotin,

15 (b) said binding partner C1 and C2 comprises independently from each other a biotin analog that reversibly binds to streptavidin or avidin and said multimerisation reagent comprises streptavidin, or avidin, or a streptavidin analog, or an avidin analog that reversibly binds to said biotin analog, or

20 (c) said binding partner C1 and C2 comprises independently from each other a streptavidin or avidin binding peptide and said multimerization reagent comprises streptavidin, or avidin, or a streptavidin analog, or an avidin analog that reversibly binds to said streptavidin or avidin binding peptide.

31. The method of claim 30, wherein said binding partner C1 and C2 comprises independently from each other the streptavidin-binding peptide Trp-Ser-His-Pro-Gln-Phe-Glu-Lys and said multimerization reagent comprises a streptavidin analog that comprises the amino acid sequence Val⁴⁴-Thr⁴⁵-Ala⁴⁶-Arg⁴⁷ at sequence positions 44 to 47 of wild type streptavidin or a streptavidin analog that comprises the amino acid sequence Ile⁴⁴-Gly⁴⁵-Ala⁴⁶-Arg⁴⁷ at sequence positions 44 to 47 of wild type streptavidin.

25

32. The method of any one of claims 1 to 31, wherein the binding between said binding partner C1 and the binding partner C2, respectively, and said binding sites Z1 and Z2, respectively of said multimerization reagent occurs in the presence of a divalent cation.

5 33. The method of claim 32,

wherein said binding partner C1 and the binding partner C2 comprises independently from each other a calmodulin binding peptide and the said multimerization reagent comprises calmodulin, or wherein said binding partner C comprises a FLAG peptide and said multimerization reagent comprises an antibody binding the FLAG peptide, or

10 wherein said first binding C comprises an oligohistidine tag and said multimerization reagent comprises an antibody binding the oligohistidine tag.

The method of claim 11 or 12, wherein the binding between said binding partner C and said binding sites Z of said multimerization reagent is disrupted by metal ion chelation.

15 34. The method of claim 33, wherein the metal chelation is accomplished by addition of EDTA or EGTA.

35. The method of any of claims 2 to 30, wherein the binding partners C1 and C2 are different.

20

36. The method of any of claims 2 to 30, wherein the binding partners C1 and C2 are identical.

37. The method of any of the foregoing claims, further comprising disrupting the binding
25 between said binding partner C1 of the first agent and/or said binding partner C2 of the second agent and said binding sites Z1 and/or Z2 of said multimerization reagent.

38. The method of claim 37, wherein disrupting the binding between said binding partner C1 of the first agent and/or said binding partner C2 of the second agent and said binding sites
30 Z1 and/or Z2 of said multimerization reagent causes termination of the stimulation of the cells.

39. The method of any of claims 1 to 38, wherein the dissociation constant (K_d) for the reversible binding between said binding site Z1 and said binding partner C1 and/or for the reversible binding between said binding site Z2 and said binding partner C2 is in the range of 10^{-2} M to 10^{-13} M.

5

40. The method of any of claims 1 to 39, wherein said reversible bond between said binding partner C1 of the first agent and/or said binding partner C2 of the second agent and said binding sites Z1 and /or binding sites Z2 of said multimerization reagent is disrupted by contacting said population of cells with a free first binding partner C1 or an analog of said first
10 binding partner C1 capable of disrupting the bond between the first binding partner C1 and the binding site Z1 and/or a free partner of said second binding partner C2 or an analog of said second binding partner C2, capable of disrupting the bond between the second binding partner C2 and the binding site Z2.

15 41. The method of claim 40, wherein the first free partner and/or the second free partner is a compound which is not detrimental to the cells.

42. The method of any of claims 25 to 41, wherein the reversible bond is disrupted by contacting the cells with biotin or a biotin analog, when

20 (a) said binding partner C1 and C2 comprises independently from each other biotin and said multimerization reagent comprises a streptavidin analog or an avidin analog that reversibly binds to biotin,

(b) said binding partner C1 and C2 comprises independently from each other a biotin analog that reversibly binds to streptavidin or avidin and said multimerisation reagent comprises
25 streptavidin, or avidin, or a streptavidin analog, or an avidin analog that reversibly binds to said biotin analog, or

(c) said binding partner C1 and C2 comprises independently from each other a streptavidin or avidin binding peptide and said multimerization reagent comprises streptavidin, or avidin, or a streptavidin analog, or an avidin analog that reversibly binds to said streptavidin or avidin
30 binding peptide.

43. The method of any of claims 25 to 39, wherein the reversible bond is disrupted by contacting the cells with a metal chelator, when the binding between said binding partner C1 and the binding partner C2, respectively, and said binding sites Z1 and Z2, respectively of said multimerization reagent occurs in the presence of a divalent cation.

5

44. An *in vitro*-method of expanding a population of cells, comprising contacting a sample comprising a population of cells with a multimerization reagent, wherein the multimerization reagent is in a soluble form and has immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells;

10 wherein the multimerisation reagent comprises at least one binding site Z1 for the binding of the first agent,

wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of binding to the binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the bond formed between the binding partner

15 C1 and the binding site Z1, and

wherein the first agent binds to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells and thereby activating the cells.

45. The method of claim 44, wherein the multimerization agent has immobilized thereon (bound thereto) a second agent that stimulates an accessory molecule on the surface of the

20

wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is able of being bound to a binding site Z2 of the multimerization reagent, wherein the second agent is bound to the multimerization reagent via the bond formed between the binding partner

25

C2 and the binding site Z2, wherein the second agent binds to the accessory molecule on the surface on the surface of the cells, thereby stimulating the activated cells.

46. The method of claim 44 or 45, wherein the bond formed between the binding partner C1 and the binding site Z1 is irreversible and/or the bond formed between the binding partner C2 and the binding site Z2 is irreversible.

30

47. The method of claim 44 or 45, wherein the bond formed between the binding partner C1 and the binding site Z1 is reversible and/or the bond formed between the binding partner C2 and the binding site Z2 is reversible.

5 48. The method of claims 47, wherein the dissociation constant (K_d) for the reversible binding between said binding site Z1 and said binding partner C1 and/or for the reversible binding between said binding site Z2 and said binding partner C2 is in the range of 10^{-2} M to 10^{-13} M.

10 49. The method of any of claim 44 to 48, wherein the population of cells is a lymphocyte population.

50. The method of claim 49, wherein the lymphocyte population is B cell population, a T cell population or a natural killer cell population.

15

51. The method of claim 50, wherein the T-cell population is an antigen-specific T cell population, a T-helper cell population, a cytotoxic T-cell, a memory T-cell, a regulatory T-cell or a natural killer T cell.

20 52. The method of claim 51, wherein the first agent comprises an MHC I: peptide complex or wherein the first agent stimulates a TCR/CD3 complex-associated signal in the T cells.

53. The method of claim 52, wherein the first agent is a binding reagent that specifically binds CD3.

25

54. The method of claim 52 or 53, wherein the accessory molecule on the T cell is CD28.

55. The method of claim 54, wherein the second agent that binds the accessory molecule is a binding reagent that specifically binds CD28.

30

56. The method of any of claims 53 to 55, wherein said first binding reagent that specifically binds CD3 is selected from the group consisting of an anti-CD3-antibody, a divalent antibody fragment of an anti-CD3 antibody, a monovalent

antibody fragment of an anti-CD3-antibody, and a proteinaceous CD3 binding molecule with antibody-like binding properties and/or, wherein

the second agent that specifically binds CD28 is selected from the group consisting of an anti-CD28-antibody, a divalent antibody fragment of an anti-CD28 antibody, a monovalent
5 antibody fragment of an anti-CD28-antibody, and a proteinaceous CD28 binding molecule with antibody-like binding properties.

57. The method of claim 56, wherein the divalent antibody fragment is an (Fab)₂'-fragment, or a divalent single-chain Fv fragment.

10

58. The method of claim 56, wherein the monovalent antibody fragment is selected from the group consisting of a Fab fragment, a Fv fragment, and a single-chain Fv fragment (scFv).

59. The method of claim 58, wherein the proteinaceous CD3 or CD28 binding molecule
15 with antibody-like binding properties is selected from the group of an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, a protein based on the ankyrin scaffold, a protein based on the crystalline scaffold, an adnectin, and an avimer.

60. The method of claim 50, wherein the first agent is a binding reagent that specifically
20 binds CD40 or CD137.

61. The method of claim 60, wherein the first binding reagent that specifically binds CD40 or CD137 is selected from the group consisting of an anti-CD40-antibody, a divalent antibody fragment of an anti-CD40 antibody, a monovalent antibody fragment of an anti-CD40-
25 antibody, and a proteinaceous CD40 binding molecule with antibody-like binding properties or an anti-CD137-antibody, a divalent antibody fragment of an anti-CD137 antibody, a monovalent antibody fragment of an anti-CD137-antibody, and a proteinaceous CD137 binding molecule with antibody-like binding properties.

30 62. The method of claim 61, wherein the divalent antibody fragment is an (Fab)₂'-fragment, or a divalent single-chain Fv fragment.

63. The method of claim 61, wherein the monovalent antibody fragment is selected from the group consisting of a Fab fragment, a Fv fragment, and a single-chain Fv fragment (scFv).

64. The method of claim 61, wherein the proteinaceous CD40 binding molecule or proteinaceous CD137 binding molecule with antibody-like binding properties is selected from the group of an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, a protein based on the ankyrin scaffold, a protein based on the crystalline scaffold, an adnectin, and an avimer.

65. The method of any of claims 50 and 60 to 64, wherein the accessory molecule on the B cell is CD40.

66. The method of claim 65, wherein the second agent is CD40 ligand (CD154) or CD137.

67. A reagent kit for expanding a population of cells, the kit comprising
 (i) a multimerization reagent,
 wherein the multimerisation reagent comprises at least one binding site Z for the reversible binding of a first agent,
 (ii) a first agent that binds to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells and thereby activating the cells,
 wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to a binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1, and
 (iii) a second agent that stimulates an accessory molecule on the surface of the cells,
 wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is able of reversibly binding to a binding site Z2 of the multimerization reagent, wherein the second agent is bound to the multimerization reagent via the bond formed between the binding partner C2 and the binding site Z2,
 wherein the second agent binds to the accessory molecule on the surface on the surface of the cells, thereby stimulating the activated cells.

68. A reagent kit for expanding a population of cells, the kit comprising

(i) a multimerization reagent,

wherein the multimerisation reagent is in soluble form and comprises at least one binding site Z for the reversible binding of a first agent,

(ii) a first agent that binds to a receptor molecule on the surface of the cells, thereby providing a primary activation signal to the cells and thereby activating the cells,

wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of binding to a binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1.

10

69. The reagent kit of claim 68, further comprising

(iii) a second agent that stimulates an accessory molecule on the surface of the cells,

wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is able of binding to a binding site Z2 of the multimerization reagent, wherein the second agent is

15 bound to the multimerization reagent via the bond formed between the binding partner C2 and the binding site Z2.

70. The kit of any of claims 67 to 69, wherein the population of cells is a lymphocyte population.

20

71. The kit of claim 70, wherein the lymphocyte population is B cell population, a T cell population or a natural killer cell population.

72. The kit of claim 71, wherein the T-cell population is an antigen-specific T cell

25 population, a T-helper cell population, a cytotoxic T-cell, a memory T-cell, a regulatory T-cell or a natural killer T cell.

73. The kit of any of claims 67 to 72, wherein the first agent comprises an MHC I : peptide complex or wherein the first agent stimulates a TCR/CD3 complex-associated signal in the T cells.

30

74. The kit of claim 73, wherein the first agent is a binding reagent that specifically binds CD3.

75. The kit of any of claim 72 to 74, wherein the accessory molecule on the T cell is CD28.

76. The kit of claim 75, wherein the second agent that binds the accessory molecule is a
5 binding reagent that specifically binds CD28.

77. The kit of any of claims 74 to 76, wherein
said first binding reagent that specifically binds CD3 is selected from the group consisting of
an anti-CD3-antibody, a divalent antibody fragment of an anti-CD3 antibody, a monovalent
10 antibody fragment of an anti-CD3-antibody, and a proteinaceous CD3 binding molecule with
antibody-like binding properties and/or, wherein
the second agent that specifically binds CD28 is selected from the group consisting of an anti-
CD28-antibody, a divalent antibody fragment of an anti-CD28 antibody, a monovalent
antibody fragment of an anti-CD28-antibody, and a proteinaceous CD28 binding molecule
15 with antibody-like binding properties.

78. The kit of claim 67, wherein the multimerization agent is immobilized on a solid
surface.

20 79. The kit of claim 78, wherein the solid surface is selected from the group consisting of a
magnetic bead, a polymeric bead, a cell culture plate, a microtiter plate, a membrane, a hollow
fiber and combinations thereof.

80. The kit of claim 79, wherein the multimerization reagent is the multimerization reagent
25 is selected from the group consisting of streptavidin, avidin, an analog of streptavidin that
reversibly binds biotin, an analog of avidin that reversibly binds biotin, a reagent that
comprises at least two chelating groups K, wherein the at least two chelating groups are
capable of binding to a transition metal ion, thereby rendering moiety A capable of binding to
an oligohistidine affinity tag, multimeric glutathione-S-transferase, multimeric calmodulin
30 and a biotinylated carrier protein.

81. The kit of claim 67, wherein the multimerization reagent is in a soluble form.

82. The kit of any of claims 68 to 78 or claim 81, wherein the multimerization reagent is selected from the group consisting of streptavidin, avidin, an analog of streptavidin that reversibly binds biotin, an analog of avidin that reversibly binds biotin, a reagent that comprises at least two chelating groups K, wherein the at least two chelating groups are capable of binding to a transition metal ion, thereby rendering the reagent capable of binding to an oligohistidine affinity tag, multimeric glutathione-S-transferase, multimeric calmodulin and a biotinylated carrier protein.

83. The kit of claim 82, wherein the streptavidin, avidin, or the streptavidin analog or the avidin analog that reversibly binds to biotin is crosslinked by a polysaccharide or wherein the cross-linked oligomers or polymers of streptavidin, avidin or of an analog of streptavidin or avidin that reversibly binds biotin is obtained by crosslinking via a bifunctional linker.

84. An *in vitro*-method of serially expanding a population of lymphocytes, wherein the population of lymphocytes comprises T cells, the method comprising contacting a sample comprising the T cell comprising population of lymphocytes with a multimerization reagent, wherein the multimerization reagent is in a soluble form and has reversibly immobilized thereon (i) a first agent that provides a primary activation signal to the T cells and (ii) a second agent which stimulates an accessory molecule on the surface of the T cells, wherein the multimerisation reagent comprises at least one binding site Z1 for the reversible binding of the first agent, wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to the binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1, wherein the multimerisation reagent comprises at least one binding site Z2 for the reversible binding of the second agent, wherein the second agent comprises at least one binding partner C2, wherein the binding partner C2 is able of reversibly binding to the binding site Z2 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C2 and the binding site Z2,

wherein the first agent binds to a receptor molecule on the surface of the T cells, thereby providing a primary activation signal to the cells and thereby activating the T cells, wherein the second agent binds to the accessory molecule on the surface of the T cells, thereby stimulating the activated cells, the first agent and the second agent thereby together inducing the T cells to expand.

85. The method of claim 84, wherein contacting the sample comprising the T cell comprising population of lymphocytes with the multimerization reagent results having immobilized thereon the first and second agent results in specific binding of T cells to the multimerisation reagent.

86. The method of claim 84 or 85, further comprising separating the T cells bound to the multimerisation agent from unbound cells of the lymphocyte population.

87. The method of any of claims 84 to 86, wherein contacting the sample comprising the T cell comprising population of lymphocytes with the multimerization reagent results having immobilized thereon the first and second agent is carried out in a bioreactor such as a culture plate, a hollow-fiber bioreactor or a plastic bag bioreactor.

88. The method of any of claims 84 to 88, further comprising contacting the population of lymphocytes (reaction mixture containing the T cells bound to the multimerization reagent via the first agent and the second agent) with (i) a free first binding partner C1 or an analogue thereof capable of disrupting the bond between the first binding partner C1 and the binding site Z1 and (ii) a free second binding partner C2 or an analogue thereof, capable of disrupting the bond between the second binding partner C2 and the binding site Z2, wherein said reversible bond between said binding partner C1 of the first agent and said binding sites Z1 as well as the reversible bond between said binding partner C2 of the second agent and said binding site Z2 of said multimerization reagent is disrupted, thereby releasing, the T cells, from the soluble multimerization reagent, and from the first agent and the second agent and stopping the expansion of the T cells.

89. The method of claim 88, comprising collecting an eluate containing the released T cells, the soluble multimerization reagent, the first agent and/or the second agent, the free

binding partner C1 or the analogue thereof and the free binding partner C2 or the analogue thereof.

90. The method of any of claims 84 to 89, wherein the binding sites Z1 and Z2 of the
5 multimerization reagent are identical.

91. The method of claim 90, wherein a single multimerisation reagent is used.

92. The method of any of claims 89 to 91, further comprising exposing the eluate to
10 chromatography on a suitable stationary phase, the stationary phase being a gel filtration matrix and/or affinity chromatography matrix, wherein the gel filtration and/or affinity chromatography matrix comprises an affinity reagent, wherein the affinity reagent comprises a binding site Z1 and/or Z2 specifically binding to the binding partner C1 and/or C2 comprised in the first agent or the second agent, thereby immobilizing the first agent, the second agent,
15 the first binding partner C1 or the analogue thereof and/or the free second binding partner C2 or the analogue thereof on the stationary phase.

93. The method of any of claim 88 to 92, wherein the stationary phase is fluidly connected to the bioreactor.

20

94. The method of claim 93, wherein the T cells are separated from the soluble multimerization reagent.

95. The method of claim 93, wherein the mixture comprising the T cells and the
25 multimerization reagent are exposed to chromatography on a suitable stationary phase, the stationary phase being a gel filtration matrix and/or affinity chromatography matrix, wherein the gel filtration and/or affinity chromatography matrix comprises an affinity reagent, wherein the affinity reagent comprises a binding partner D that (specifically) binds to the binding site Z1 of the multimerization reagent, thereby immobilizing the multimerization reagent on the
30 stationary phase.

96. The method of any of claims 84 to 95, wherein the first agent stimulates a TCR/CD3 complex-associated signal in the T cells.

97. The method of claim 96, wherein the first agent is a binding reagent that specifically binds CD3.

5 98. The method of any of claims 84 to 97, wherein the accessory molecule on the T cell is CD28.

99. The method of claim 98, wherein the second agent that binds the accessory molecule is a binding reagent that specifically binds CD28.

10

100. The method of any of claims 97 to 99, wherein
said first agent that specifically binds CD3 is selected from the group consisting of an anti-
CD3-antibody, a divalent antibody fragment of an anti-CD3 antibody, a monovalent antibody
fragment of an anti-CD3-antibody, and a proteinaceous CD3 binding molecule with antibody-
like binding properties and/or wherein

15

the second agent that specifically binds CD28 is selected from the group consisting of an anti-
CD28-antibody, a divalent antibody fragment of an anti-CD28 antibody, a monovalent
antibody fragment of an anti-CD28-antibody, and a proteinaceous CD28 binding molecule
with antibody-like binding properties.

20

101. The method of claim 100, wherein the divalent antibody fragment is an (Fab)₂'-
fragment, or a divalent single-chain Fv fragment.

25

102. The method of claim 101, wherein the monovalent antibody fragment is selected from
the group consisting of a Fab fragment, a Fv fragment, and a single-chain Fv fragment (scFv).

30

103. The method of any of claims 84 to 102, wherein the multimerization reagent comprises an
oligomer or a polymer of streptavidin, an oligomer or a polymer of avidin, an oligomer or a
polymer of an analog of streptavidin that reversibly binds biotin, an oligomer or a polymer of
an analog avidin that reversibly bind biotin.

104. The method of claim 103, wherein the streptavidin, avidin, or the streptavidin analog or
the avidin analog that reversibly binds to biotin is crosslinked by a polysaccharide or wherein

the cross-linked oligomers or polymers of streptavidin, avidin or of an analog of streptavidin or avidin that reversibly binds biotin is obtained by crosslinking via a bifunctional linker.

105. The method of claim 103 or 104, wherein the cross-linked oligomers or polymers of streptavidin, avidin, or of the analog of streptavidin or avidin that reversibly binds biotin comprise three or more streptavidin monomers.

106. The method of any of claims 84 to 105, wherein

(a) said binding partner C1 and C2 comprises independently from each other biotin and said multimerization reagent comprises a streptavidin analog or an avidin analog that reversibly binds to biotin,

(b) said binding partner C1 and C2 comprises independently from each other a biotin analog that reversibly binds to streptavidin or avidin and said multimerisation reagent comprises streptavidin, or avidin, or a streptavidin analog, or an avidin analog that reversibly binds to said biotin analog, or

(c) said binding partner C1 and C2 comprises independently from each other a streptavidin or avidin binding peptide and said multimerization reagent comprises streptavidin, or avidin, or a streptavidin analog, or an avidin analog that reversibly binds to said streptavidin or avidin binding peptide.

107. The method of claim 106, wherein said binding partner C comprises the streptavidin-binding peptide Trp-Ser-His-Pro-Gln-Phe-Glu-Lys and said multimerization reagent comprises a streptavidin analog that comprises the amino acid sequence Val⁴⁴-Thr⁴⁵-Ala⁴⁶-Arg⁴⁷ at sequence positions 44 to 47 of wild type streptavidin or a streptavidin analog comprising the amino acid sequence Ile⁴⁴-Gly⁴⁵-Ala⁴⁶-Arg⁴⁷ at sequence positions 44 to 47 of wild type streptavidin.

108. The method of any of claims 84 to 107, wherein the dissociation constant (K_d) for the reversible binding between said binding site Z1 and said binding partner C1 and/or for the reversible binding between said binding site Z2 and said binding partner C2 is in the range of 10^{-2} M to 10^{-13} M.

109. The method of any of claims 89 to 108 wherein the first free partner and/or the second free partner is a compound which is not detrimental to the cells.

110. The method of claim 109, wherein the reversible bond is disrupted by contacting the
5 cells with biotin or a biotin analog.

111. The method of any of claims 92 to 110, wherein a T cell receptor or a chimeric antigen receptor is introduced into the T cells either after expansion or during expansion.

10 112. The method of claim 111, wherein the T cells are stimulated with a third agent that binds to the introduced T cell receptor or the chimeric antigen receptor.

113. The method of any of claims 84 to 112, wherein the population of lymphocytes that comprises T cells is a population of peripheral blood mononucleated cells (PBMC) or a
15 population of enriched or purified T cells.

114. An arrangement of a bioreactor and a (first) stationary phase for chromatography, wherein the bioreactor is suitable for the expansion of cells, wherein the (first) stationary phase is suitable for cell separation and removal of reagents,
20 the stationary phase being a gel filtration matrix and/or affinity chromatography matrix, wherein the gel filtration and/or affinity chromatography matrix comprises an affinity reagent, wherein the affinity reagent comprises a binding site Z1 specifically binding to a binding partner C1 comprised in a first agent and/or the affinity reagent comprises a binding site Z2 specifically binding to a binding partner C2 comprised in a second agent, thereby being
25 suitable of immobilizing on the stationary phase the first agent and/or the second agent, the first binding partner C1 and/or the free second binding partner C2, wherein the bioreactor and the stationary phase are fluidly connected.

115. The arrangement of claim 114, wherein the first stationary phase is either comprised in
30 a chromatography column or is a planar stationary phase.

116. The arrangement of claim 115, further comprising a second stationary phase, the second stationary phase being fluidly connected to the first stationary phase.

117. The arrangement of claim 116, wherein the secondary stationary phase is a gel filtration matrix and/or affinity chromatography matrix, wherein the gel filtration and/or affinity chromatography matrix comprises an affinity reagent, wherein the affinity reagent
5 comprises a binding partner D that (specifically) binds to the binding site Z1 of the multimerization reagent, thereby being suitable of immobilizing the multimerization reagent on the stationary phase.

118. The arrangement of claim 117, wherein the second stationary phase and the bioreactor
10 are fluidly connected to each other.

119. An apparatus for purification and expansion of target cells, the apparatus comprising at least one arrangement of a bioreactor and of at least one stationary phase for chromatography as defined in claims 114 to 118.

120. The apparatus of claim 119, comprising a sample inlet being fluidly connected to the bioreactor of the arrangement of a bioreactor and the at least one stationary phase for chromatography.

121. The apparatus of any of claims 119 or 120, comprising a sample outlet for purified and expanded target cells, the sample outlet being fluidly connected to the stationary phase of the arrangement of a bioreactor and the at least one stationary phase for chromatography.

122. The apparatus of any of claims 119 to 121, wherein the apparatus is a functionally closed
25 system.

123. A multimerization reagent capable of expanding a population of cells,
wherein the multimerisation reagent is in soluble form and comprises at least one binding site Z1 for the reversible binding of a first agent that provides a primary activation signal to the
30 cells,
wherein the multimerization reagent has reversibly immobilized thereon (bound thereto) said first agent that provides a primary activation signal to the cells;

wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to the at least one binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1.

5

124. The multimerization reagent of claim 123,

wherein the multimerization reagent further comprises at least one binding site Z2 for the reversible binding of a second agent that stimulates an accessory molecule on the surface of the cells,

10 wherein the multimerization reagent has reversibly immobilized thereon (bound thereto) said second agent that stimulates an accessory molecule on the surface of the cells,

wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is able of binding to the at least one binding site Z2 of the multimerization reagent, wherein the second agent is bound to the multimerization reagent via the bond formed between the binding

15 partner C2 and the binding site Z2.

125. The multimerization reagent of claim 123 or 124, wherein the multimerization reagent is capable of expanding a lymphocyte population.

20 126. The multimerization reagent if claim 125, wherein the lymphocyte population to be expanded is a B cell population, a T cell population, or a natural killer cell population.

127. The multimerization reagent of claim 126, wherein the T-cell population is an antigen-specific T cell population, a T helper cell population, a cytotoxic T cell, a memory T cell, a
25 regulatory T cell, or a natural killer T cell population.

128. The multimerization reagent of claim 127, wherein the first agent comprises an MHC I : peptide complex or stimulates a TCR/CD3 complex-associated signal in the T cells.

30 129. The multimerization reagent of claim 128, wherein the first agent is a binding reagent that specifically binds CD3.

130. The multimerization reagent of any of claims 124 to 129, wherein the second agent that binds the accessory molecule is a binding reagent that specifically binds CD28 or CD137.

131. The multimerization reagent of any of claims 128 to 130, wherein

5 said first agent that specifically binds CD3 is selected from the group consisting of an anti-CD3-antibody, a divalent antibody fragment of an anti-CD3 antibody, a monovalent antibody fragment of an anti-CD3-antibody, and a proteinaceous CD3 binding molecule with antibody-like binding properties, and wherein
the second agent that specifically binds CD28 or CD137 is selected from the group consisting
10 of an anti-CD28-antibody, a divalent antibody fragment of an anti-CD28 antibody, a monovalent antibody fragment of an anti-CD28-antibody, a proteinaceous CD28 binding molecule with antibody-like binding properties, an anti-CD137-antibody, a divalent antibody fragment of an anti-CD137 antibody, a monovalent antibody fragment of an anti-CD137-antibody, a proteinaceous CD137 binding molecule with antibody-like binding properties, 4-
15 1BB ligand, and any mixture thereof.

132. The multimerization reagent of claim 131, wherein the divalent antibody fragment is an (Fab)₂'-fragment, or a divalent single-chain Fv fragment.

20 133. The multimerization reagent of claim 131, wherein the monovalent antibody fragment is selected from the group consisting of a Fab fragment, a Fv fragment, and a single-chain Fv fragment (scFv).

134. The multimerization reagent of claim 133, wherein the proteinaceous CD3, CD28 or
25 CD137 binding molecule with antibody-like binding properties is selected from the group of an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, a protein based on the ankyrin scaffold, a protein based on the crystalline scaffold, an adnectin, and an avimer.

135. The multimerization reagent of claim 126, wherein the first agent is a binding reagent
30 that specifically binds CD40 or CD137 and wherein the cell population is a B cell population.

136. The multimerization reagent of claim 135, wherein the first binding reagent that specifically binds CD40 or CD137 is selected from the group consisting of an anti-CD40-

antibody, a divalent antibody fragment of an anti-CD40 antibody, a monovalent antibody fragment of an anti-CD40-antibody, and a proteinaceous CD40 binding molecule with antibody-like binding properties or an anti-CD137-antibody, a divalent antibody fragment of an anti-CD137 antibody, a monovalent antibody fragment of an anti-CD137-antibody, a proteinaceous CD137 binding molecule with antibody-like binding properties, and CD40 ligand (CD154).

137. The multimerization reagent of claim 136, wherein the divalent antibody fragment is an (Fab)₂'-fragment, or a divalent single-chain Fv fragment.

138. The multimerization reagent of claim 136, wherein the monovalent antibody fragment is selected from the group consisting of a Fab fragment, a Fv fragment, and a single-chain Fv fragment (scFv).

139. The multimerization reagent of claim 136, wherein the proteinaceous CD40 binding molecule or the proteinaceous CD137 binding molecule with antibody-like binding properties is selected from the group of an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, a protein based on the ankyrin scaffold, a protein based on the crystalline scaffold, an adnectin, and an avimer.

140. The multimerization reagent of claims 126, wherein the accessory molecule on the B cell is CD40 or CD137 or a mixture thereof.

141. The multimerization reagent of claim 140, wherein the second agent is CD40 ligand (CD154), CD137 or a mixture thereof and the cell population is a B cell population.

142. The multimerization reagent of any of claims 124 to 141, wherein the binding sites Z1 and Z2 of the multimerization reagent are identical.

143. The multimerization reagent of any of claim 124 to 142, wherein the multimerization reagent comprises an oligomer or a polymer of streptavidin, an oligomer or a polymer of avidin, an oligomer or a polymer of an analog of streptavidin that reversibly binds biotin, an oligomer or a polymer of an analog avidin that reversibly bind biotin, a reagent that comprises

at least two chelating groups K, wherein the at least two chelating groups are capable of binding to a transition metal ion, thereby rendering the reagent capable of binding to an oligohistidine affinity tag, multimeric glutathione-S-transferase, multimeric calmodulin and a biotinylated carrier protein.

5

144. The multimerization reagent of claim 143, wherein the streptavidin, avidin, or the streptavidin analog or the avidin analog that reversibly binds to biotin is crosslinked by a polysaccharide or wherein the cross-linked oligomers or polymers of streptavidin, avidin or of an analog of streptavidin or avidin that reversibly binds biotin is obtained by crosslinking via a bifunctional linker.

10

145. The multimerization reagent of claim 143 or 144, wherein the cross-linked oligomers or polymers of streptavidin, avidin, or of the analog of streptavidin or avidin that reversibly binds biotin comprise three or more streptavidin monomers.

15

146. The multimerization reagent of any of claims 123 to 145, wherein

(a) said binding partner C1 and C2 comprises independently from each other biotin and said multimerization reagent comprises a streptavidin analog or an avidin analog that reversibly binds to biotin,

20 (b) said binding partner C1 and C2 comprises independently from each other a biotin analog that reversibly binds to streptavidin or avidin and said multimerisation reagent comprises streptavidin, or avidin, or a streptavidin analog, or an avidin analog that reversibly binds to said biotin analog, or

25 (c) said binding partner C1 and C2 comprises independently from each other a streptavidin or avidin binding peptide and said multimerization reagent comprises streptavidin, or avidin, or a streptavidin analog, or an avidin analog that reversibly binds to said streptavidin or avidin binding peptide.

30 147. The multimerization reagent of claim 146, wherein said binding partner C1 and C2 comprises independently from each other the streptavidin-binding peptide Trp-Ser-His-Pro-Gln-Phe-Glu-Lys and said multimerization reagent comprises a streptavidin analog that comprises the amino acid sequence Val⁴⁴-Thr⁴⁵-Ala⁴⁶-Arg⁴⁷ at sequence positions 44 to 47 of

wild type streptavidin or a streptavidin analog that comprises the amino acid sequence Ile⁴⁴-Gly⁴⁵-Ala⁴⁶-Arg⁴⁷ at sequence positions 44 to 47 of wild type streptavidin.

148. A composition capable of expanding a population of cells comprising

5 (i) a first multimerization reagent,

wherein the first multimerisation reagent is in soluble form and comprises at least one binding site Z1 for the reversible binding of a first agent that provides a primary activation signal to the cells,

10 wherein the first multimerization reagent has reversibly immobilized thereon (bound thereto) said first agent that provides a primary activation signal to the cells;

wherein the first agent comprises at least one binding partner C1, wherein the binding partner C1 is able of reversibly binding to the at least one binding site Z1 of the multimerization reagent, wherein the first agent is bound to the multimerization reagent via the reversible bond formed between the binding partner C1 and the binding site Z1, and

15 (ii) a second multimerization reagent,

wherein the second multimerization reagent is in soluble form and comprises at least one binding site Z2 for the reversible binding of a second agent that stimulates an accessory molecule on the surface of the cells,

20 wherein the multimerization reagent has reversibly immobilized thereon (bound thereto) said second agent that stimulates an accessory molecule on the surface of the cells,

wherein the second agent comprises a binding partner C2, wherein the binding partner C2 is able of binding to the at least one binding site Z2 of the multimerization reagent, wherein the second agent is bound to the multimerization reagent via the bond formed between the binding partner C2 and the binding site Z2.

25